<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library</title> <meta content="Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus - Hemmingsen, B - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003054.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus" name="citation_title"/> <meta content="Bianca Hemmingsen" name="citation_author"/> <meta content="Herlev University Hospital" name="citation_author_institution"/> <meta content="biancahemmingsen@hotmail.com" name="citation_author_email"/> <meta content="Gabriel Gimenez‐Perez" name="citation_author"/> <meta content="Hospital General de Granollers and School of Medicine and Health Sciences. Universitat Internacional de Catalunya (UIC)" name="citation_author_institution"/> <meta content="Didac Mauricio" name="citation_author"/> <meta content="Hospital Universitari Germans Trias i Pujol ‐ CIBERDEM" name="citation_author_institution"/> <meta content="Marta Roqué i Figuls" name="citation_author"/> <meta content="CIBER Epidemiología y Salud Pública (CIBERESP)" name="citation_author_institution"/> <meta content="Maria‐Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Bernd Richter" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD003054.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/12/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003054.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Diet; *Exercise; Cause of Death; Combined Modality Therapy [methods]; Diabetes Complications [prevention &amp; control]; Diabetes Mellitus, Type 2 [complications, epidemiology, *prevention &amp; control]; Diet, Diabetic; Fasting [blood]; Glucose Tolerance Test; Incidence; Randomized Controlled Trials as Topic; Risk" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003054.pub4&amp;doi=10.1002/14651858.CD003054.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="Oy81c7tH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003054\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003054\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","pl","fr","zh_HANS","fa","pt","ja","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003054.pub4",title:"Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus",firstPublishedDate:"Dec 4, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003054.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003054.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003054.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003054.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003054.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003054.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003054.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003054.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003054.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003054.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>36478 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003054.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0191"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0078"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-sec-0185"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/appendices#CD003054-sec-0196"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/table_n/CD003054StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/table_n/CD003054StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bianca Hemmingsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0003">Gabriel Gimenez‐Perez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0004">Didac Mauricio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0005">Marta Roqué i Figuls</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0006">Maria‐Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information#CD003054-cr-0007">Bernd Richter</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information/en#CD003054-sec-0218">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 December 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003054.pub4">https://doi.org/10.1002/14651858.CD003054.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003054-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003054-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003054-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003054-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003054-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003054-abs-0014">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003054-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003054-abs-0001" lang="en"> <section id="CD003054-sec-0001"> <h3 class="title" id="CD003054-sec-0001">Background</h3> <p>The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether diet, physical activity or both can prevent or delay T2DM and its associated complications in at‐risk people is unknown. </p> </section> <section id="CD003054-sec-0002"> <h3 class="title" id="CD003054-sec-0002">Objectives</h3> <p>To assess the effects of diet, physical activity or both on the prevention or delay of T2DM and its associated complications in people at increased risk of developing T2DM. </p> </section> <section id="CD003054-sec-0003"> <h3 class="title" id="CD003054-sec-0003">Search methods</h3> <p>This is an update of the Cochrane Review published in 2008. We searched the CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, ICTRP Search Portal and reference lists of systematic reviews, articles and health technology assessment reports. The date of the last search of all databases was January 2017. We continuously used a MEDLINE email alert service to identify newly published studies using the same search strategy as described for MEDLINE up to September 2017. </p> </section> <section id="CD003054-sec-0004"> <h3 class="title" id="CD003054-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) with a duration of two years or more.</p> </section> <section id="CD003054-sec-0005"> <h3 class="title" id="CD003054-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology for data collection and analysis. We assessed the overall quality of the evidence using GRADE. </p> </section> <section id="CD003054-sec-0006"> <h3 class="title" id="CD003054-sec-0006">Main results</h3> <p>We included 12 RCTs randomising 5238 people. One trial contributed 41% of all participants. The duration of the interventions varied from two to six years. We judged none of the included trials at low risk of bias for all 'Risk of bias' domains. </p> <p>Eleven trials compared diet plus physical activity with standard or no treatment. Nine RCTs included participants with impaired glucose tolerance (IGT), one RCT included participants with IGT, impaired fasting blood glucose (IFG) or both, and one RCT included people with fasting glucose levels between 5.3 to 6.9 mmol/L. A total of 12 deaths occurred in 2049 participants in the diet plus physical activity groups compared with 10 in 2050 participants in the comparator groups (RR 1.12, 95% CI 0.50 to 2.50; 95% prediction interval 0.44 to 2.88; 4099 participants, 10 trials; very low‐quality evidence). The definition of T2DM incidence varied among the included trials. Altogether 315 of 2122 diet plus physical activity participants (14.8%) developed T2DM compared with 614 of 2389 comparator participants (25.7%) (RR 0.57, 95% CI 0.50 to 0.64; 95% prediction interval 0.50 to 0.65; 4511 participants, 11 trials; moderate‐quality evidence). Two trials reported serious adverse events. In one trial no adverse events occurred. In the other trial one of 51 diet plus physical activity participants compared with none of 51 comparator participants experienced a serious adverse event (low‐quality evidence). Cardiovascular mortality was rarely reported (four of 1626 diet plus physical activity participants and four of 1637 comparator participants (the RR ranged between 0.94 and 3.16; 3263 participants, 7 trials; very low‐quality evidence). Only one trial reported that no non‐fatal myocardial infarction or non‐fatal stroke had occurred (low‐quality evidence). Two trials reported that none of the participants had experienced hypoglycaemia. One trial investigated health‐related quality of life in 2144 participants and noted that a minimal important difference between intervention groups was not reached (very low‐quality evidence). Three trials evaluated costs of the interventions in 2755 participants. The largest trial of these reported an analysis of costs from the health system perspective and society perspective reflecting USD 31,500 and USD 51,600 per quality‐adjusted life year (QALY) with diet plus physical activity, respectively (low‐quality evidence). There were no data on blindness or end‐stage renal disease. </p> <p>One trial compared a diet‐only intervention with a physical‐activity intervention or standard treatment. The participants had IGT. Three of 130 participants in the diet group compared with none of the 141 participants in the physical activity group died (very low‐quality evidence). None of the participants died because of cardiovascular disease (very low‐quality evidence). Altogether 57 of 130 diet participants (43.8%) compared with 58 of 141 physical activity participants (41.1%) group developed T2DM (very low‐quality evidence). No adverse events were recorded (very low‐quality evidence). There were no data on non‐fatal myocardial infarction, non‐fatal stroke, blindness, end‐stage renal disease, health‐related quality of life or socioeconomic effects. </p> <p>Two trials compared physical activity with standard treatment in 397 participants. One trial included participants with IGT, the other trial included participants with IGT, IFG or both. One trial reported that none of the 141 physical activity participants compared with three of 133 control participants died. The other trial reported that three of 84 physical activity participants and one of 39 control participants died (very low‐quality evidence). In one trial T2DM developed in 58 of 141 physical activity participants (41.1%) compared with 90 of 133 control participants (67.7%). In the other trial 10 of 84 physical activity participants (11.9%) compared with seven of 39 control participants (18%) developed T2DM (very low‐quality evidence). Serious adverse events were rarely reported (one trial noted no events, one trial described events in three of 66 physical activity participants compared with one of 39 control participants ‐ very low‐quality evidence). Only one trial reported on cardiovascular mortality (none of 274 participants died ‐ very low‐quality evidence). Non‐fatal myocardial infarction or stroke were rarely observed in the one trial randomising 123 participants (very low‐quality evidence). One trial reported that none of the participants in the trial experienced hypoglycaemia. One trial investigating health‐related quality of life in 123 participants showed no substantial differences between intervention groups (very low‐quality evidence). There were no data on blindness or socioeconomic effects. </p> </section> <section id="CD003054-sec-0007"> <h3 class="title" id="CD003054-sec-0007">Authors' conclusions</h3> <p>There is no firm evidence that diet alone or physical activity alone compared to standard treatment influences the risk of T2DM and especially its associated complications in people at increased risk of developing T2DM. However, diet plus physical activity reduces or delays the incidence of T2DM in people with IGT. Data are lacking for the effect of diet plus physical activity for people with intermediate hyperglycaemia defined by other glycaemic variables. Most RCTs did not investigate patient‐important outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003054-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003054-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003054-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003054-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003054-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003054-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003054-abs-0016">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003054-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003054-abs-0007">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003054-abs-0015">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003054-abs-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003054-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003054-abs-0004" lang="en"> <h3>Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk </h3> <p><b>Review question</b> </p> <p>Are diet or physical activity, or both able to prevent or delay the development of type 2 diabetes and its associated complications in at‐risk people? </p> <p><b>Background</b> </p> <p>People with moderately elevated blood glucose (often referred to as 'prediabetes') are said to be at an increased risk of developing type 2 diabetes. It is currently recommended that all people with increased risk of developing type 2 diabetes should adjust their eating habits and physical activity levels. We wanted to find out whether these changes in diet, physical activity or both could prevent or delay type 2 diabetes in people at increased risk. We also wanted to know the effects on patient‐important outcomes, such as complications of diabetes (e.g. kidney and eye disease, heart attack, stroke), death from any cause, health‐related quality of life (a measure of a person’s satisfaction with their life and health) and side‐effects. </p> <p><b>Study characteristics</b> </p> <p>Participants had to have blood glucose levels higher than considered normal, but below the glucose levels that are used to diagnose type 2 diabetes mellitus. We found 12 randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with 5238 participants. The duration of the treatments varied from two years to six years. Most trials included people defined as being at increased risk of type 2 diabetes based on glucose levels measured two hours after ingestion of 75 g of glucose (i.e. 'impaired glucose tolerance' (IGT) after an oral glucose tolerance test). </p> <p>This evidence is up to date as of January 2017. We used a MEDLINE email alert service to identify newly published studies up to September 2017. </p> <p><b>Key results</b> </p> <p>One study compared diet only with physical activity only. Fifty‐seven of 130 participants (44%) in the diet‐only group compared with 58 of 141 participants (41%) in the physical activity‐only group developed type 2 diabetes. Two studies compared physical activity with standard treatment; in one study 58 of 141 participants (41%) in the physical activity group compared with 90 of 133 participants (68%) in the control group developed type 2 diabetes; in the other study 10 of 84 participants (12%) in the physical activity group compared with seven out of 39 participants (18%) in the control group developed type 2 diabetes. Eleven studies compared diet plus physical activity with standard or no treatment. Diet plus physical activity decreased the risk of developing type 2 diabetes, which occurred in 315 of 2122 participants (15%) in the diet plus physical activity group compared with 614 of 2389 participants (26%) in the standard treatment group. </p> <p>We detected neither an advantage nor a disadvantage of diet, physical activity or both with regard to heart attacks or strokes. Our included studies did not report on complications of diabetes such as kidney or eye disease. The effects on health‐related quality of life were inconclusive. Very few participants died in the course of the studies and side‐effects were also rare. Future long‐term studies should investigate more patient‐important outcomes like complications of diabetes, because we do not know for sure whether ’prediabetes’ is just a condition arbitrarily defined by a laboratory measurement or is, in fact, a real risk factor for type 2 diabetes mellitus and whether treatment of this condition translates into better patient‐important outcomes. </p> <p><b>Quality of the evidence</b> </p> <p>All included trials had deficiencies in the way that they were conducted or how key items were reported. For diet plus physical activity compared with standard treatment, we found rather good evidence that the development of new type 2 diabetes was reduced or delayed. For the other comparisons the number of participants was small, resulting in a high risk of random errors (play of chance). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003054-sec-0191" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003054-sec-0191"></div> <h3 class="title" id="CD003054-sec-0192">Implications for practice</h3> <section id="CD003054-sec-0192"> <p>There is moderate‐quality evidence that diet plus physical activity reduces or delays the risk of type 2 diabetes mellitus in people with impaired glucose tolerance. Whether there is the same intervention effect in people with increased risk defined by other glycaemic variables, such as impaired fasting glucose or elevated glycosylated haemoglobin A1c (HbA1c) levels, needs to be clarified. There is no clear evidence whether diet alone or physical activity alone influences the risk of type 2 diabetes mellitus. Data on patient‐important outcomes such as mortality, macrovascular and microvascular diabetic complications and health‐related quality of life are sparse. </p> </section> <h3 class="title" id="CD003054-sec-0193">Implications for research</h3> <section id="CD003054-sec-0193"> <p>It remains to be clarified whether the reduction in the incidence of type 2 diabetes mellitus with diet plus physical activity in people with impaired glucose tolerance could decrease the long‐term risk of complications associated with type 2 diabetes mellitus. Future trials should also investigate the effect of diet plus physical activity in people with impaired fasting glucose or moderately elevated HbA1c and focus on patient‐important outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003054-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003054-sec-0043"></div> <div class="table" id="CD003054-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Diet plus physical activity versus standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diet plus physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> diet plus physical activity </p> <p><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diet plus physical activity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: up to 6 years (mean duration 3.6 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (2 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (0.50 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4099 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged from 0.44 to 2.88</p> <p>TSA showed that 0.61% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Diagnostic criteria:</p> <p> <ul id="CD003054-list-0001"> <li> <p>3 trials applied the WHO 1985 criteria (FPG ≥ 7.8 mmol/L or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). </p> </li> <li> <p>3 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). </p> </li> <li> <p>1 trial with ADA 1997 criteria (FPG ≥ 7.0 mmol/L or 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT (i.e. identical to WHO 1999 criteria) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </li> <li> <p>1 trial with FPG &gt; 7.0 mmol/L (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>), 1 trial with FGP &gt; 7.8 mmol/L (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>), 1 trial with 2‐hour PG ≥ 11.1 mmol/L after a 75 g OGTT (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </li> <li> <p>4 trials also relied on T2DM reported by physicians or the use of glucose‐lowering drugs (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </li> </ul> </p> <p>Follow‐up: up to 6 years (mean duration 3.8 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> (129 to 164) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.50 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4511 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged from 0.50 to 0.65</p> <p>TSA showed firm evidence for a 10% RRR in favour of diet plus physical activity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: up to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 1/51 participants in the diet plus physical activity group compared with 0/51 participants in the standard treatment group experienced a SAE (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) </p> <p>1 trial reported that no adverse occurred (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>In 4 other trials it was clearly described that SAE data had been collected but data were not presented (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: up to 6 years (mean duration 3.1 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.24 to 3.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3263 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA showed that 0.13% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b><br/> Follow‐up: 3.11 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants experienced a non‐fatal myocardial infarction or non‐fatal stroke (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Description: SF‐36 to evaluate the SF‐6D, PCS and MCS</p> <p>MID was defined as difference in scores between groups of at least 3%</p> <p>Follow‐up: 3.2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐6D and PCS improved in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>), MID was not achieved </p> <p>MCS improved in the placebo group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>), MID was not achieved </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b><br/> Description: direct medical costs of the interventions </p> <p>Follow‐up: up to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean direct medical costs of the intervention ranged across control groups from<br/> USD 61 to USD 184 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean direct medical costs in the intervention groups ranged across diet plus physical activity group from USD 225 to USD 3625 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported on the health system/society perspective: USD 31,500/USD 51,600 per QALY with diet plus physical activity (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>) </p> <p>1 trial reported total extra 3‐year mean costs for the diet plus physical activity group of GBP 1126, with GBP 615 being dietitian costs, and more outpatient visits in the intervention group than in the control group costing GBP 327 more (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>1 trial reported direct medical costs for each participant in the diet plus physical activity group of USD 850 compared with USD 142 in the control group; direct costs of care outside the trial were USD 5177 for the diet plus physical activity group compared with USD 7454 for the control group (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>) </p> <p>1 trial reported direct medical costs of interventions over the 3‐year trial period of USD 61 per participant in the control group compared with USD 225 in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADA:</b> American Diabetes Association; <b>CI:</b> confidence interval; <b>DPP:</b> Diabetes Prevention Program; <b>FGL:</b> fasting glucose levels; <b>FPG:</b> fasting plasma glucose; <b>MCS:</b> mental component summaries; <b>MID:</b> minimal important difference; <b>OGTT:</b> oral glucose tolerance test; <b>PCS:</b> physical component summaries;<b>PG:</b> plasma glucose; <b>QUALY:</b> quality‐adjusted life years; <b>RR:</b> risk ratio; <b>RRR:</b> relative risk reduction; <b>SAE:</b> serious adverse event; <b>SF‐36:</b> 36‐Item Short‐Form; <b>SF‐6D:</b> health utility index (SF‐6D); <b>T2DM:</b> type 2 diabetes mellitus; <b>TSA:</b> trial sequential analysis; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of bias including possible publication and other bias, inconsistency and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>b</sup>Downgraded by one level because of other bias (early termination of three trials due to benefit providing the majority of data) ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>c</sup>Downgraded by two levels because of reporting bias and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>d</sup>Downgraded by two levels because of serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>e</sup>Downgraded by three levels because of serious risk of bias (performance bias, detection bias, other bias) and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>f</sup>Downgraded by two levels because of risk of bias (trial stopped early for benefit providing the majority of data) and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003054-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diet versus physical activity or standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diet versus physical activity or standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> dietary intervention </p> <p><b>Comparison:</b> physical activity or standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Physical activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diet or standard treatment</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/130 participants died in the diet group vs 0/141 participants in the physical activity group </p> <p>3/133 participants died in the standard treatment group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Definition: WHO 1985 criteria</p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/130 participants developed T2DM in the diet group vs 58/141 participants in the physical activity group </p> <p>90/133 participants developed T2DM in the standard treatment group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (serious) adverse events occurred in any group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants in any group died of cardiovascular reasons</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of reporting and other bias and serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0211">Appendix 15</a> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003054-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Physical activity versus standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> physical activity </p> <p><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Physical activity</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 0/141 participants in the physical activity group compared with 3/133 participants in the standard treatment group died (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>) </p> <p>1 trial reported that 3/84 participants in the physical activity group and 1/39 participants in the standard treatment group died (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Definition:</p> <p> <ul id="CD003054-list-0002"> <li> <p>1 trial: FPG ≥ 7.8 mmol/L or a 2‐hour plasma glucose ≥ 11.1 mmol/L after a 75 g OGTT (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </li> <li> <p>1 trial FPG &gt; 6.9 mmol/L and/or 2‐hour plasma glucose concentration &gt; 12.1 mmol/L (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) </p> </li> </ul> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 58/141 participants in the physical activity group compared with 90/133 participants in the standard treatment group developed T2DM (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>) </p> <p>1 trial reported that 10/84 participants in the physical activity group compared with 7/39 participants in the standard treatment group developed T2DM (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no (serious) adverse events occurred (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>1 trial reported that 3/66 participants in the physical activity group compared with 1/39 participants in the standard treatment group experienced a serious adverse event (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants in any group died of cardiovascular reasons</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b><br/> Description: non‐fatal myocardial infarction/stroke </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 0/66 participants in the physical activity group compared with 3/31 participants in the standard treatment group experienced a non‐fatal myocardial infarction (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> <p>1 trial reported that 1/66 participants in the physical activity group compared with 1/31 participants in the standard treatment group experienced a non‐fatal stroke (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Definition: measured by two questions (grading total physical and mental health from 1 to 7; grading general health from 1 (best) to 5 (very bad)) </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27%, 43% and 29% of participants in the physical activity group experienced worse, unchanged and better health‐related quality of life, respectively (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> <p>35%, 43% and 22% in the standard treatment group experienced worse, unchanged and better health‐related quality of life, respectively (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FPG:</b> fasting plasma glucose; <b>OGTT:</b> oral glucose tolerance test; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of reporting and other bias and serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0212">Appendix 16</a> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003054-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003054-sec-0044"></div> <section id="CD003054-sec-0045"> <h3 class="title" id="CD003054-sec-0045">Description of the condition</h3> <p>'Prediabetes', 'borderline diabetes', the 'prediabetic stage', 'high risk of diabetes' or 'intermediate hyperglycaemia' (<a href="./references#CD003054-bbs2-0144" title="World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf2006; Vol. (accessed 17 March 2017). ">WHO/IDF 2006</a>) are often characterised by various measurements of elevated blood glucose concentrations (such as isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT), isolated elevated glycosylated haemoglobin A1c (HbA1c) or combinations thereof). These elevated blood glucose levels indicating hyperglycaemia are considered too high to be normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). Therefore, because of the continuous spectrum from the normal to the diabetic stage, a sound evidence base is needed to define thresholds for conditions of 'sub‐diabetes'. It is obvious that the different terms used to describe various stages of hyperglycaemia might induce different emotional reactions. For example, the term 'prediabetes' may imply (at least for the lay person) that diabetes is unavoidable whereas (high) risk of diabetes has the positive connotation that the disease may be avoided altogether. We will use all of the above‐mentioned terms throughout this systematic review, however a we will focus on 'prediabetes' because many people associate this label with dire consequences ‐ despite the disputable construct of intermediate health states termed prediseases (<a href="./references#CD003054-bbs2-0136" title="VieraAJ . Predisease: when does it make sense?. Epidemiologic Reviews2011;33:122‐34. ">Viera 2011</a>). On the other side, any diagnosis of 'prediabetes' might be an opportunity to review, for example, eating habits and physical activity levels, thus enabling affected individuals to actively change their way of life. </p> <p>The most commonly used criteria to define people with a high risk of developing T2DM were established by the American Diabetes Association (ADA) and the World Health Organization (WHO). The first glycaemic measurement used to define the prediabetic stage by the US National Diabetes Data Group was IGT (<a href="./references#CD003054-bbs2-0122" title="National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes1979;28:1039‐57. ">NDDG 1979</a>). IGT is based on the measurement of plasma glucose two hours after ingestion of 75 g glucose. The prediabetic range is defined as a plasma glucose level between 7.8 to 11.1 mmol/L (140 to 200 mg/dL) two hours after the glucose load. Studies have indicated that IGT is caused by insulin resistance and defective insulin secretion (<a href="./references#CD003054-bbs2-0062" title="Abdul‐GhaniMA , JenkinsonCP , RichardsonDK , TripathyD , DeFronzoRA . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes2006;55(5):1430‐5. [PUBMED: 16644701] ">Abdul‐Ghani 2006</a>). In 1997 the ADA and later on the WHO introduced the IFG concept to define 'prediabetes' (<a href="./references#CD003054-bbs2-0063" title="American Diabetes Association. Report on the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(Suppl 1):S5‐20. ">ADA 1997</a>; <a href="./references#CD003054-bbs2-0143" title="World Health Organization. Part 1: diagnosis and classification of diabetes mellitus. Report of a World Health Organization Consultation. Geneva: World Health Organization, 1999:1‐59. ">WHO 1999</a>). The initial definition of IFG was 6.1 to 6.9 mmol/L (110 to 125 mg/dL). Later on, the ADA reduced the lower threshold for defining IFG to 5.6 mmol/L (100 mg/dL) (<a href="./references#CD003054-bbs2-0064" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow‐up report on the diagnosis of diabetes mellitus. Diabetes Care2003;26(11):3160‐7. ">ADA 2003</a>). However, this lower cut‐off point for IFG to define 'prediabetes' was not endorsed by the WHO (<a href="./references#CD003054-bbs2-0144" title="World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf2006; Vol. (accessed 17 March 2017). ">WHO/IDF 2006</a>). IFG seems to be associated with ß‐cell dysfunction (impaired insulin secretion) and an increase of the hepatic glucose output (<a href="./references#CD003054-bbs2-0082" title="DeFronzoRA , FerranniniE , SimonsonDC . Fasting hyperglycemia in non‐insulin‐dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism: Clinical and Experimental1989;38(4):387‐95. [PUBMED: 2657323] ">DeFronzo 1989</a>). More recently, HbA1c has been introduced for identifying people with a high risk of developing T2DM. In 2009, the International Expert Committee (IEC) suggested the HbA1c to identify people with a high risk of T2DM. People with HbA1c measurements between 6.0% to 6.4% fulfilled this criterion (<a href="./references#CD003054-bbs2-0106" title="International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care2009;32(7):1327‐34. [PUBMED: 19502545] ">IEC 2009</a>). Shortly after, the ADA redefined this HbA1c level as 5.7% to 6.4% to identify people with a high risk of developing T2DM (<a href="./references#CD003054-bbs2-0067" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>). Unlike IFG and IGT, HbA1c reflects longer‐term glycaemic control, that is, how the blood glucose levels have been during the previous two to three months (<a href="./references#CD003054-bbs2-0107" title="InzucchiSE . Clinical practice. Diagnosis of diabetes. New England Journal of Medicine2012;367(6):542‐50. [PUBMED: 22873534] ">Inzucchi 2012</a>). </p> <p>In 2010, the International Diabetes Federation (IDF) estimated the prevalence of IGT to be 343 million, and this number is predicted to increase to 471 million by 2035 (<a href="./references#CD003054-bbs2-0105" title="International Diabetes Federation (IDF). IDF Diabetes Atlas. 6th Edition. Brussels: International Diabetes Federation, 2013. ">IDF 2013</a>). Studies have shown poor correlations between HbA1c and IFG/IGT (<a href="./references#CD003054-bbs2-0091" title="GosmanovAR , WanJ . Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. The American Journal of the Medical Sciences2014;348(3):191‐4. [PUBMED: 24556928] ">Gosmanov 2014</a>; <a href="./references#CD003054-bbs2-0132" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>). Moreover, the various glycaemic tests do not seem to identify the same people (<a href="./references#CD003054-bbs2-0091" title="GosmanovAR , WanJ . Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. The American Journal of the Medical Sciences2014;348(3):191‐4. [PUBMED: 24556928] ">Gosmanov 2014</a>; <a href="./references#CD003054-bbs2-0132" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>). The risk of progression from 'prediabetes' to T2DM depends on the diagnostic criteria used to identify 'prediabetes'. Some people diagnosed with 'prediabetes' will never develop T2DM, and some will return to normoglycaemia. IGT is often accepted as the best glycaemic variable for 'prediabetes' to predict progression to T2DM. However, studies indicate that less than half of the people defined as prediabetic by means of IGT will develop T2DM in the following 10 years. IFG and HbA1c are both thought to predict a different risk spectrum for developing T2DM (<a href="./references#CD003054-bbs2-0080" title="ChengC , KushnerH , FalknerBE . The utility of fasting glucose for detection of prediabetes. Metabolism: Clinical and Experimental2006;55(4):434‐8. [PUBMED: 16546472] ">Cheng 2006</a>; <a href="./references#CD003054-bbs2-0121" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>). Most importantly, 'prediabetes' is commonly an asymptomatic condition, and naturally often remains 'undiagnosed' (<a href="./references#CD003054-bbs2-0079" title="Centers for Disease Control and Prevention (CDC). www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html(accessed October 2015). ">CDC 2015</a>). Consequently, 'prediabetes' may exist before the diagnosis of T2DM is established. </p> <p>Currently, ADA recommends reduced calorie intake and increased physical activity for people with increased risk of T2DM (<a href="./references#CD003054-bbs2-0069" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2017. Diabetes Care2017;40:(Suppl 1). ">ADA 2017</a>). It is still not clarified if any particular intervention, especially glucose‐lowering drugs, should be recommended for people with 'prediabetes' (<a href="./references#CD003054-bbs2-0151" title="YudkinJS , MontoriVM . The epidemic of pre‐diabetes: the medicine and the politics. BMJ2014;349:g4485. ">Yudkin 2014</a>). Trials have indicated that the progression from 'prediabetes' to T2DM is reduced, or maybe just delayed with 'lifestyle' interventions (increased physical activity, dietary changes or both) (<a href="./references#CD003054-bbs2-0083" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. [PUBMED: 11832527] ">Diabetes Prevention Program 2002</a>; <a href="./references#CD003054-bbs2-0084" title="Diabetes Prevention Program Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9702):1677‐86. [DOI: 10.1016/S0140‐6736(09)61457‐4; PUBMED: 19878986] ">Diabetes Prevention Program FU 2009</a>; <a href="./references#CD003054-bbs2-0086" title="TuomilehtoJ , LindstromJ , ErikssonJG , ValleTT , HamalainenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. [PUBMED: 11333990] ">Finnish Diabetes Prevention Study Group 2001</a>). A recent meta‐analysis of 22 studies with behaviour‐changing interventions in people at high risk of T2DM concluded that the effect of lifestyle interventions on longer‐term diabetes prevention had not been clarified (<a href="./references#CD003054-bbs2-0085" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>). </p> <p>The prescription of pharmacological glucose‐lowering interventions for the prevention of T2DM is not generally accepted among international diabetes associations and clinicians. Several groups of pharmacological glucose‐lowering interventions have been investigated in people with 'prediabetes'. Some findings indicate that the progression from 'prediabetes' to T2DM is reduced or maybe just delayed (<a href="./references#CD003054-bbs2-0083" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. [PUBMED: 11832527] ">Diabetes Prevention Program 2002</a>; <a href="./references#CD003054-bbs2-0084" title="Diabetes Prevention Program Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9702):1677‐86. [DOI: 10.1016/S0140‐6736(09)61457‐4; PUBMED: 19878986] ">Diabetes Prevention Program FU 2009</a>). However, the ADA recommends metformin for people with 'prediabetes' and a body mass index more than 35 kg/m², aged less than 60 years, and women with prior gestational diabetes mellitus (<a href="./references#CD003054-bbs2-0068" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2015. Diabetes Care2015;38(Suppl 1):S1‐93. [PUBMED: 24357209] ">ADA 2015</a>). </p> </section> <section id="CD003054-sec-0046"> <h3 class="title" id="CD003054-sec-0046">Description of the intervention</h3> <p>Interventional as well as observational studies have shown a reduction in the incidence of T2DM with reduced calorie intake and increased physical activity in people at risk of T2DM (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0093" title="HelmrichSP , RaglandDR , LeungRW , PaffenbargerRSJr . Physical activity and reduced occurrence of non‐insulin‐dependent diabetes mellitus. New England Journal of Medicine1991;325:147‐52. ">Helmrich 1991</a>; <a href="./references#CD003054-bbs2-0133" title="SmithAD , CrippaA , WoodcockJ , BrageS . Physical activity and incident type 2 diabetes mellitus: a systematic review and dose‐response meta‐analysis of prospective cohort studies. Diabetologia2016;59(12):2527‐45. [PUBMED: 27747395] ">Smith 2016</a>). It has been shown that diet plus physical activity reduces cardiovascular risk factors, thereby indicating a potential beneficial effect on mortality and cardiovascular outcomes (<a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>). </p> <p>Diet plus physical activity is recommended as an initial intervention not only for people with intermediate hyperglycaemia but also for people with T2DM (<a href="./references#CD003054-bbs2-0069" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2017. Diabetes Care2017;40:(Suppl 1). ">ADA 2017</a>). However, one large‐scale, randomised, controlled trial in people overweight or obese people with T2DM did not show a substantial effect on mortality and cardiovascular outcomes with intensive diet plus physical activity compared with control after 9.6 years (<a href="./references#CD003054-bbs2-0111" title="Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine2013;369(2):145‐54. [DOI: 10.1056/NEJMoa1212914] ">Look AHEAD 2013</a>). </p> <p>Nutritional advice usually consists of caloric restriction in overweight people, low total fat content (especially saturated fat) and high (predominantly unrefined) carbohydrate content. Physical activity advice usually consists of an intervention programme. </p> <p><b>Adverse effects of the intervention</b> </p> <p>Physical activity or diet interventions are not generally considered to be associated with any serious adverse event. However, physical activity may cause traumatic injuries of variable severity depending on the type and intensity of physical activity. Additionally, exercising may produce adverse effects on the cardiovascular system in those people with insufficient training or unfavourable cardiovascular fitness (even cardiovascular events and death may potentially occur while exercising). Also, the implementation of dietary measures may produce several deficiencies in nutritional status if restrictive low‐calorie diets are used. Further, dieting may reduce quality of life of people under this treatment. Unfortunately, very little information on these issues is available from randomised controlled trials. </p> </section> <section id="CD003054-sec-0047"> <h3 class="title" id="CD003054-sec-0047">How the intervention might work</h3> <p>There are prospective cohort studies that have shown that increased physical activity, independent of other risk factors, has a protective effect against the development of T2DM (<a href="./references#CD003054-bbs2-0093" title="HelmrichSP , RaglandDR , LeungRW , PaffenbargerRSJr . Physical activity and reduced occurrence of non‐insulin‐dependent diabetes mellitus. New England Journal of Medicine1991;325:147‐52. ">Helmrich 1991</a>; <a href="./references#CD003054-bbs2-0115" title="MansonJE , NathanDM , KrolewskiAS , StampferMJ , WillettWC , HennekensCH . A prospective study of exercise and incidence of diabetes among U.S. male physicians. JAMA1992;268(1):63‐7. ">Manson 1992</a>). These epidemiological prospective studies demonstrated that various levels of regular physical activity once to several times a week were associated with a decreased incidence of the disease at long‐term follow‐up (14 years and five years respectively) (<a href="./references#CD003054-bbs2-0093" title="HelmrichSP , RaglandDR , LeungRW , PaffenbargerRSJr . Physical activity and reduced occurrence of non‐insulin‐dependent diabetes mellitus. New England Journal of Medicine1991;325:147‐52. ">Helmrich 1991</a>; <a href="./references#CD003054-bbs2-0115" title="MansonJE , NathanDM , KrolewskiAS , StampferMJ , WillettWC , HennekensCH . A prospective study of exercise and incidence of diabetes among U.S. male physicians. JAMA1992;268(1):63‐7. ">Manson 1992</a>). </p> <p>Three large clinical trials in people with IGT have shown a relative risk reduction of about 50% in the progression to T2DM with restricted diet and increased physical activity (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). However, whether and how diet, physical activity or both influence the risk of complications associated with T2DM is still not clarified. </p> </section> <section id="CD003054-sec-0048"> <h3 class="title" id="CD003054-sec-0048">Why it is important to do this review</h3> <p>There has been an increased focus on the prevention or delay of T2DM with non‐pharmacological interventions and glucose‐lowering medications. Recently, several systematic reviews and health technology assessment reports have been performed in people with elevated risk of T2DM (<a href="./references#CD003054-bbs2-0070" title="AguiarEJ , MorganPJ , CollinsCE , PlotnikoffRC , CallisterR . Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta‐analysis. The International Journal of Behavioral Nutrition and Physical Activity2014;11:2. [PUBMED: 24423095] ">Aguiar 2014</a>; <a href="./references#CD003054-bbs2-0071" title="AliMK , Echouffo‐TcheuguiJ , WilliamsonDF . How effective were lifestyle interventions in real‐world settings that were modelled on the Diabetes Prevention Program?. Health Affairs (Project Hope)2012;31(1):67‐75. [PUBMED: 22232096] ">Ali 2012</a>; <a href="./references#CD003054-bbs2-0072" title="AshraNB , SpongR , CarterP , DaviesMJ , DunkleyA , GilliesC , et al. A systematic review and meta‐analysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. www.gov.uk/government/uploads/system/uploads/attachment_data/file/456147/PHE_Evidence_Review_of_diabetes_prevention_programmes‐_FINAL.pdf (accessed 17 March 2017). ">Ashra 2015</a>; <a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>; <a href="./references#CD003054-bbs2-0078" title="Cardona‐MorrellM , RychetnikL , MorrellSL , EspinelPT , BaumanA . Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta‐analysis. BMC Public Health2010;10:653. [PUBMED: 21029469] ">Cardona‐Morrell 2010</a>; <a href="./references#CD003054-bbs2-0085" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>; <a href="./references#CD003054-bbs2-0087" title="GillettM , RoyleP , SnaithA , ScotlandG , PoobalanA , ImamuraM , et al. Non‐pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2012;16(33):1‐236, iii‐iv. [PUBMED: 22935084] ">Gillett 2012</a>; <a href="./references#CD003054-bbs2-0088" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. [MEDLINE: 17237299] ">Gillies 2007</a>; <a href="./references#CD003054-bbs2-0089" title="GlechnerA , HarreiterJ , GartlehnerG , RohlederS , KautzkyA , TuomilehtoJ , et al. Sex‐specific differences in diabetes prevention: a systematic review and meta‐analysis. Diabetologia2015;58(2):242‐54. [PUBMED: 25465437] ">Glechner 2015</a>; <a href="./references#CD003054-bbs2-0090" title="GongQH , KangJF , YingYY , LiH , ZhangXH , WuYH , et al. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta‐analysis of the effects on glycemic control. Internal Medicine (Tokyo, Japan)2015;54(3):303‐10. [PUBMED: 25748739] ">Gong 2015</a>; <a href="./references#CD003054-bbs2-0101" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD003054-bbs2-0103" title="Institute for Clinical and Economic Review. Diabetes prevention programs: effectiveness and value. Final Evidence Report and Meeting SummaryJuly 2016. ">ICER 2016</a>; <a href="./references#CD003054-bbs2-0118" title="MerlottiC , MorabitoA , CerianiV , PontiroliAE . Prevention of type 2 diabetes in obese at‐risk subjects: a systematic review and meta‐analysis. Acta Diabetologica2014;51(5):853‐63. [PUBMED: 25085464] ">Merlotti 2014a</a>; <a href="./references#CD003054-bbs2-0119" title="MerlottiC , MorabitoA , PontiroliAE . Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies. Diabetes, Obesity &amp; Metabolism2014;16(8):719‐27. [PUBMED: 24476122] ">Merlotti 2014b</a>; <a href="./references#CD003054-bbs2-0120" title="ModestiPA , GalantiG , Cala'P , CalabreseM . Lifestyle interventions in preventing new type 2 diabetes in Asian populations. Internal and Emergency Medicine2016;11(3):375‐84. [PUBMED: 26475162] ">Modesti 2016</a>; <a href="./references#CD003054-bbs2-0123" title="SLNorris , XZhang , AAvenell , EGregg , CHSchmid , LauJ . Long‐term non‐pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews2005;Issue 2:CD005270. [DOI: 10.1002/14651858.CD005270] ">Norris 2005</a>; <a href="./references#CD003054-bbs2-0128" title="SantaguidaPL , BalionC , HuntD , MorrisonK , GersteinH , RainaP , et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary)2005;128:1‐11. [PUBMED: 16194123] ">Santaguida 2005</a>; <a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>; <a href="./references#CD003054-bbs2-0131" title="SelphS , DanaT , BougatsosC , BlazinaI , PatelH , ChouR . Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews2015; Vol. Report no.:13‐05190‐EF‐1. [PUBMED: 25973510] ">Selph 2015</a>; <a href="./references#CD003054-bbs2-0135" title="StevensJW , KhuntiK , HarveyR , JohnsonM , PrestonL , WoodsHB , et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta‐analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice2015;107(3):320‐31. [PUBMED: 25638454] ">Stevens 2015</a>; <a href="./references#CD003054-bbs2-0148" title="YamaokaK , TangoT . Efficacy of lifestyle education to prevent type 2 diabetes. A meta‐analysis of randomized controlled trials. Diabetes Care2005;28:2780‐6. ">Yamaoka 2005</a>; <a href="./references#CD003054-bbs2-0149" title="YatesT , KhuntiK , BullF , GorelyT , DaviesMJ . The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia2007;50(6):1116‐26. [PUBMED: 17415549] ">Yates 2007</a>; <a href="./references#CD003054-bbs2-0150" title="YoonU , KwokLL , MagkidisA . Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism: Clinical and Experimental2013;62(2):303‐14. [PUBMED: 22959500] ">Yoon 2013</a>; <a href="./references#CD003054-bbs2-0152" title="YuenA , SugengY , WeilandTJ , JelinekGA . Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health2010;34(2):172‐8. [PUBMED: 23331362] ">Yuen 2010</a>; <a href="./references#CD003054-bbs2-0153" title="ZhangX , ImperatoreG , ThomasW , ChengYJ , LobeloF , NorrisK , et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2017;123:149‐64. [PUBMED: 28024276] ">Zhang 2017</a>; <a href="./references#CD003054-bbs2-0154" title="ZhengL , WuJ , WangG , PersuitteG , MaY , ZouL , et al. Comparison of control fasting plasma glucose of exercise‐only versus exercise‐diet among a pre‐diabetic population: a meta‐analysis. European Journal of Clinical Nutrition2016;70(4):424‐30. [PUBMED: 26330149] ">Zheng 2016</a>). </p> <p>Sixteen of these systematic reviews included exclusively people with intermediate hyperglycaemia (<a href="./references#CD003054-bbs2-0070" title="AguiarEJ , MorganPJ , CollinsCE , PlotnikoffRC , CallisterR . Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta‐analysis. The International Journal of Behavioral Nutrition and Physical Activity2014;11:2. [PUBMED: 24423095] ">Aguiar 2014</a>; <a href="./references#CD003054-bbs2-0087" title="GillettM , RoyleP , SnaithA , ScotlandG , PoobalanA , ImamuraM , et al. Non‐pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2012;16(33):1‐236, iii‐iv. [PUBMED: 22935084] ">Gillett 2012</a>; <a href="./references#CD003054-bbs2-0088" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. [MEDLINE: 17237299] ">Gillies 2007</a>; <a href="./references#CD003054-bbs2-0089" title="GlechnerA , HarreiterJ , GartlehnerG , RohlederS , KautzkyA , TuomilehtoJ , et al. Sex‐specific differences in diabetes prevention: a systematic review and meta‐analysis. Diabetologia2015;58(2):242‐54. [PUBMED: 25465437] ">Glechner 2015</a>; <a href="./references#CD003054-bbs2-0090" title="GongQH , KangJF , YingYY , LiH , ZhangXH , WuYH , et al. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta‐analysis of the effects on glycemic control. Internal Medicine (Tokyo, Japan)2015;54(3):303‐10. [PUBMED: 25748739] ">Gong 2015</a>; <a href="./references#CD003054-bbs2-0101" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD003054-bbs2-0103" title="Institute for Clinical and Economic Review. Diabetes prevention programs: effectiveness and value. Final Evidence Report and Meeting SummaryJuly 2016. ">ICER 2016</a>; <a href="./references#CD003054-bbs2-0123" title="SLNorris , XZhang , AAvenell , EGregg , CHSchmid , LauJ . Long‐term non‐pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews2005;Issue 2:CD005270. [DOI: 10.1002/14651858.CD005270] ">Norris 2005</a>; <a href="./references#CD003054-bbs2-0128" title="SantaguidaPL , BalionC , HuntD , MorrisonK , GersteinH , RainaP , et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary)2005;128:1‐11. [PUBMED: 16194123] ">Santaguida 2005</a>; <a href="./references#CD003054-bbs2-0131" title="SelphS , DanaT , BougatsosC , BlazinaI , PatelH , ChouR . Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews2015; Vol. Report no.:13‐05190‐EF‐1. [PUBMED: 25973510] ">Selph 2015</a>; <a href="./references#CD003054-bbs2-0135" title="StevensJW , KhuntiK , HarveyR , JohnsonM , PrestonL , WoodsHB , et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta‐analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice2015;107(3):320‐31. [PUBMED: 25638454] ">Stevens 2015</a>; <a href="./references#CD003054-bbs2-0148" title="YamaokaK , TangoT . Efficacy of lifestyle education to prevent type 2 diabetes. A meta‐analysis of randomized controlled trials. Diabetes Care2005;28:2780‐6. ">Yamaoka 2005</a>; <a href="./references#CD003054-bbs2-0149" title="YatesT , KhuntiK , BullF , GorelyT , DaviesMJ . The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia2007;50(6):1116‐26. [PUBMED: 17415549] ">Yates 2007</a>; <a href="./references#CD003054-bbs2-0150" title="YoonU , KwokLL , MagkidisA . Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism: Clinical and Experimental2013;62(2):303‐14. [PUBMED: 22959500] ">Yoon 2013</a>; <a href="./references#CD003054-bbs2-0152" title="YuenA , SugengY , WeilandTJ , JelinekGA . Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health2010;34(2):172‐8. [PUBMED: 23331362] ">Yuen 2010</a>; <a href="./references#CD003054-bbs2-0154" title="ZhengL , WuJ , WangG , PersuitteG , MaY , ZouL , et al. Comparison of control fasting plasma glucose of exercise‐only versus exercise‐diet among a pre‐diabetic population: a meta‐analysis. European Journal of Clinical Nutrition2016;70(4):424‐30. [PUBMED: 26330149] ">Zheng 2016</a>); 10 systematic reviews included people with an increased risk of T2DM defined by additional variables with intermediate hyperglycaemia being one risk factor only (e.g. obesity, metabolic risk factors, family history of diabetes etc) (<a href="./references#CD003054-bbs2-0071" title="AliMK , Echouffo‐TcheuguiJ , WilliamsonDF . How effective were lifestyle interventions in real‐world settings that were modelled on the Diabetes Prevention Program?. Health Affairs (Project Hope)2012;31(1):67‐75. [PUBMED: 22232096] ">Ali 2012</a>; <a href="./references#CD003054-bbs2-0072" title="AshraNB , SpongR , CarterP , DaviesMJ , DunkleyA , GilliesC , et al. A systematic review and meta‐analysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. www.gov.uk/government/uploads/system/uploads/attachment_data/file/456147/PHE_Evidence_Review_of_diabetes_prevention_programmes‐_FINAL.pdf (accessed 17 March 2017). ">Ashra 2015</a>; <a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>; <a href="./references#CD003054-bbs2-0078" title="Cardona‐MorrellM , RychetnikL , MorrellSL , EspinelPT , BaumanA . Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta‐analysis. BMC Public Health2010;10:653. [PUBMED: 21029469] ">Cardona‐Morrell 2010</a>; <a href="./references#CD003054-bbs2-0085" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>; <a href="./references#CD003054-bbs2-0118" title="MerlottiC , MorabitoA , CerianiV , PontiroliAE . Prevention of type 2 diabetes in obese at‐risk subjects: a systematic review and meta‐analysis. Acta Diabetologica2014;51(5):853‐63. [PUBMED: 25085464] ">Merlotti 2014a</a>; <a href="./references#CD003054-bbs2-0119" title="MerlottiC , MorabitoA , PontiroliAE . Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies. Diabetes, Obesity &amp; Metabolism2014;16(8):719‐27. [PUBMED: 24476122] ">Merlotti 2014b</a>; <a href="./references#CD003054-bbs2-0120" title="ModestiPA , GalantiG , Cala'P , CalabreseM . Lifestyle interventions in preventing new type 2 diabetes in Asian populations. Internal and Emergency Medicine2016;11(3):375‐84. [PUBMED: 26475162] ">Modesti 2016</a>; <a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>; <a href="./references#CD003054-bbs2-0153" title="ZhangX , ImperatoreG , ThomasW , ChengYJ , LobeloF , NorrisK , et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2017;123:149‐64. [PUBMED: 28024276] ">Zhang 2017</a>). </p> <p>This review is an update of the Cochrane Review published in 2008 (<a href="./references#CD003054-bbs2-0155" title="OrozcoLJ , BuchleitnerAM , Gimenez‐PerezG , RoqueI Figuls M , RichterB , MauricioD . Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD003054.pub3; PUBMED: 18646086] ">Orozco 2008</a>). In this update we have implemented new methodology and changed the priority of outcomes, focusing on patient‐important outcome measures. Also, we have only included trials where intermediate hyperglycaemia was measured at baseline as an indicator of increased risk for the development of T2DM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003054-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003054-sec-0049"></div> <p>To assess the effects of diet, physical activity or both for the prevention or delay of T2DM and its associated complications in people at increased risk of developing T2DM. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003054-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003054-sec-0050"></div> <section id="CD003054-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003054-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled clinical trials (RCTs).</p> </section> <section id="CD003054-sec-0053"> <h4 class="title">Types of participants</h4> <p>Nondiabetic individuals at increased risk of developing T2DM, that is, diagnosed with intermediate hyperglycaemia or 'prediabetes'. </p> <p><b>Diagnostic criteria for 'prediabetes'</b> </p> <p>To be consistent with changes in the classification of and diagnostic criteria for 'prediabetes' (impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c)) over the years, the diagnosis had to be established using the standard criteria valid at the time of the trial commencing (for example <a href="./references#CD003054-bbs2-0063" title="American Diabetes Association. Report on the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(Suppl 1):S5‐20. ">ADA 1997</a>; <a href="./references#CD003054-bbs2-0067" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>; <a href="./references#CD003054-bbs2-0122" title="National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes1979;28:1039‐57. ">NDDG 1979</a>; <a href="./references#CD003054-bbs2-0143" title="World Health Organization. Part 1: diagnosis and classification of diabetes mellitus. Report of a World Health Organization Consultation. Geneva: World Health Organization, 1999:1‐59. ">WHO 1999</a>). Ideally, the diagnostic criteria should have been described. If necessary, we used the trial authors' definition of 'prediabetes' but contacted trial authors for additional information. Differences of glycaemic measurements used to define 'prediabetes' may introduce substantial heterogeneity. We therefore planned to subject diagnostic criteria to a subgroup analysis. </p> </section> <section id="CD003054-sec-0054"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of intervention versus comparator.</p> <p><b>Intervention</b> </p> <p> <ul id="CD003054-list-0003"> <li> <p>Diet</p> </li> <li> <p>Physical activity</p> </li> <li> <p>Diet plus physical activity</p> </li> </ul> </p> <p><b>Comparator</b> </p> <p> <ul id="CD003054-list-0004"> <li> <p>Standard treatment</p> </li> <li> <p>No intervention</p> </li> </ul> </p> <p><b>Comparison of interventions</b> </p> <p> <ul id="CD003054-list-0005"> <li> <p>Diet versus physical activity</p> </li> </ul> </p> <p>Other concomitant interventions had to be the same in the intervention and comparator groups to establish fair comparisons. </p> <p><b>Minimum duration of intervention</b> </p> <p>We included trials with a minimum duration of intervention of two years.</p> <p><b>Summary of exclusion criteria</b> </p> <p>We excluded the following.</p> <p> <ul id="CD003054-list-0006"> <li> <p>Trials where the intervention or comparator group comprised the administration of any pharmacological agent. </p> </li> <li> <p>People diagnosed with 'metabolic syndrome' because this is a special cohort of doubtful clinical usefulness and uncertain distinct disease entity (a composite of risk indicators such as elevated blood lipids, insulin resistance, obesity, high blood pressure). </p> </li> <li> <p>Trials applying diet advice through single‐food or supplement dietary changes (e.g. zinc supplement). </p> </li> <li> <p>Trials with identical diet or physical activity interventions, or both, applied with different approaches (e.g. same advice applied by means of individual or group sessions). </p> </li> </ul> </p> <p>We did not exclude trials because one or several of our primary or secondary outcome measures were not reported in the publication. In case none of our primary or secondary outcomes were reported, we included the trial and contacted the corresponding author for supplementary data. If no additional data were available we planned to provide some basic information in a supplementary table. </p> </section> <section id="CD003054-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD003054-sec-0056"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003054-list-0007"> <li> <p>All‐cause mortality</p> </li> <li> <p>Incidence of T2DM</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </section> <section id="CD003054-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003054-list-0008"> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Non‐fatal stroke</p> </li> <li> <p>Amputation of lower extremity</p> </li> <li> <p>Blindness or severe vision loss</p> </li> <li> <p>End‐stage renal disease</p> </li> <li> <p>Non‐serious adverse events</p> </li> <li> <p>Hypoglycaemia</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Time to progression to T2DM</p> </li> <li> <p>Measures of blood glucose control</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> <p><b>Method of outcome measurement</b> </p> <p> <ul id="CD003054-list-0009"> <li> <p>All‐cause mortality: defined as death from any cause</p> </li> <li> <p>Incidence of T2DM and time to progression to T2DM: defined according to diagnostic criteria valid at the time the diagnosis was established, using the standard criteria valid at the time of the trial commencing (e.g. <a href="./references#CD003054-bbs2-0066" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2008. Diabetes Care2008;31(Suppl 1):S12‐54. [PUBMED: 18165335] ">ADA 2008</a>; <a href="./references#CD003054-bbs2-0142" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15:539‐53. ">WHO 1998</a>). If necessary, we used the trial authors' definition of T2DM. </p> </li> <li> <p>Serious adverse events: defined according to the International Conference on Harmonization Guidelines as any event that led to death, that was life‐threatening, required in‐patient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability, and any important medical event that may have had jeopardised the participant or required intervention to prevent it (<a href="./references#CD003054-bbs2-0104" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR &amp; ICH Guidelines. PA 19063‐2043. USA: Barnett International/PAREXEL, 1997. ">ICH 1997</a>) or as reported in trials. </p> </li> <li> <p>Cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, amputation of lower extremity, blindness or severe vision loss, hypoglycaemia (mild, moderate, severe/serious): defined as reported in trials. </p> </li> <li> <p>End‐stage renal disease: defined as dialysis, renal transplantation or death due to renal disease. </p> </li> <li> <p>Non‐serious adverse events: defined as number of participants with any untoward medical occurrence not necessarily having a causal relationship with the intervention. </p> </li> <li> <p>Health‐related quality of life: defined as mental and physical health‐related quality of life, separate and combined, evaluated by a validated instrument such as Short‐Form 36. </p> </li> <li> <p>Measures of blood glucose control: fasting blood glucose, blood glucose two hours after ingestion of 75 g glucose and HbA1c measurements. </p> </li> <li> <p>Socioeconomic effects: for example costs of the intervention, absence from work, medication consumption. </p> </li> </ul> </p> <p><b>Timing of outcome measurement</b> </p> <p> <ul id="CD003054-list-0010"> <li> <p>Measured at the end of the intervention and the end of follow‐up: all‐cause mortality, cardiovascular mortality, blindness or severe vision loss, hypoglycaemia (mild, moderate, severe/serious), end‐stage renal disease, non‐serious adverse events; health‐related quality of life, measures of blood glucose control, socioeconomic effects </p> </li> <li> <p>Measured at the end of the intervention and the longest reported end of follow‐up: incidence of T2DM </p> </li> <li> <p>Measured at any time of the intervention and during follow‐up: serious adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD003054-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003054-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We based this review update on different search techniques.</p> <p>First, we extracted the included trials of two systematic reviews targeting people at increased risk for T2DM. The first review was funded by the Agency for Healthcare Research and Quality (AHRQ) and evaluated lifestyle interventions (<a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>). The second review was funded by the Centers for Disease Control and Prevention Community Preventive Services Task Force and evaluated combined diet and physical activity programs (<a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>). Both of these reviews included extensive and highly sensitive search strategies conducted in several databases up to June 2013 (<a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>) and up to February 2015 (<a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>). In addition to evaluating these two systematic reviews, we checked the reference lists of a further 28 systematic reviews and extracted 145 potentially relevant trials in total. This snowballing search technique is reflected in the upper right part of the trial flow diagram. </p> <p>Second, we identified further trials using a revised search strategy from 2014 to the specified date. We did not place restrictions on the language of publication, and searched the following literature databases. </p> <p> <ul id="CD003054-list-0011"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via Cochrane Register of Studies Online (CRSO) (searched 17 January 2017). </p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)) (from 1946 to present, searched 17 January 2017). </p> </li> <li> <p>Embase Ovid (from 1974 to 2017 Week 3, searched 17 January 2017)</p> </li> </ul> </p> <p>Additionally we searched the following trials registers from inception to the specified date. </p> <p> <ul id="CD003054-list-0012"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched 17 January 2017). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) searched 17 January 2017) </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD003054-sec-0197">Appendix 1</a>. We continuously applied an email alert service for MEDLINE via OvidSP to identify newly published trials using the search strategy detailed in <a href="./appendices#CD003054-sec-0197">Appendix 1</a> up to September 2017. </p> </section> <section id="CD003054-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved, included trials, (systematic) reviews, meta‐analyses and health technology assessment reports. </p> </section> </section> <section id="CD003054-sec-0061"> <h3 class="title" id="CD003054-sec-0061">Data collection and analysis</h3> <section id="CD003054-sec-0062"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BH and BR) independently scanned the abstract or title, or both, of every record we retrieved, to determine which trials should be assessed further. We investigated the full‐text articles of all potentially relevant articles. We resolved discrepancies through consensus or by recourse to a third review author (MM). We prepared a flow diagram of the number of trials identified and excluded at each stage in accordance with the PRISMA flow diagram of trial selection (<a href="./references#CD003054-bbs2-0110" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>; <a href="#CD003054-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD003054-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram" data-id="CD003054-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> </div> </section> <section id="CD003054-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled the inclusion criteria, two review authors (BH and GG) independently extracted outcome data and assessed the risk of bias. One review author (BH) extracted key characteristics of participants and interventions and another (GG) checked them. We reported data on efficacy outcomes and adverse events using standard data extraction sheets from Cochrane Metabolic and Endocrine Disorders. We resolved any disagreements by discussion or, if required, by consultation with a third review author (BR) (for details, see <a href="./references#CD003054-sec-0225" title="">Characteristics of included studies</a>; <a href="#CD003054-tbl-0004">Table 1</a>; <a href="./appendices#CD003054-sec-0198">Appendix 2</a>; <a href="./appendices#CD003054-sec-0199">Appendix 3</a>; <a href="./appendices#CD003054-sec-0200">Appendix 4</a>; <a href="./appendices#CD003054-sec-0201">Appendix 5</a>; <a href="./appendices#CD003054-sec-0202">Appendix 6</a>; <a href="./appendices#CD003054-sec-0203">Appendix 7</a>; <a href="./appendices#CD003054-sec-0204">Appendix 8</a>; <a href="./appendices#CD003054-sec-0205">Appendix 9</a>; <a href="./appendices#CD003054-sec-0206">Appendix 10</a>; <a href="./appendices#CD003054-sec-0207">Appendix 11</a>; <a href="./appendices#CD003054-sec-0208">Appendix 12</a>; <a href="./appendices#CD003054-sec-0209">Appendix 13</a>; <a href="./appendices#CD003054-sec-0210">Appendix 14</a>; <a href="./appendices#CD003054-sec-0211">Appendix 15</a>: <a href="./appendices#CD003054-sec-0212">Appendix 16</a>; <a href="./appendices#CD003054-sec-0213">Appendix 17</a>; <a href="./appendices#CD003054-sec-0214">Appendix 18</a>; <a href="./appendices#CD003054-sec-0215">Appendix 19</a>). </p> <div class="table" id="CD003054-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial (design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a><b><sup>a</sup> </b> </p> <p><b>(cluster‐RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1: diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>"Power calculations were done for the original 6‐year intervention trial. For the present study we estimated minimal detectable differences. With an α of 0·05, we estimated that there was an 80% chance of detecting a 43% reduction in all‐cause mortality and a 63% reduction in cardiovascular disease mortality when comparing the control group with the combined lifestyle intervention groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>110,660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>6 years (23 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 2: physical activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 3: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] "><b>DPP 2002</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The principal analyses of primary and secondary outcomes will employ the "intent‐to‐treat" approach ... The intent‐to‐treat analyses will include all randomized participants with all participants included in their randomly assigned treatment group; treatment group assignment will not be altered based on the participant’s adherence to the assigned treatment regimen. All statistical tests will be two‐sided. The overall significance level of the primary outcome will be α = 0.05. However, because interim analyses will be conducted throughout the DPP, the significance levels used in the interim and final analyses of the primary outcome will be adjusted to account for the multiplicity of interim analyses" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153,183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2.8 years (15 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: placebo + standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a><b><sup>d</sup> </b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The DPS is designed to be large enough to detect a 35% reduction in diabetes incidence with an intensive diet and exercise intervention with 80% power (beta = 20%) at the two‐tailed 5% significance level (alpha = 5%) ..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Median 4 years (10.6 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] "><b>EDIPS 2009</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"EDIPS‐Newcastle was designed to contribute to the European study. We aimed for a sample size of 100 participants (50 in each arm), contributing to a planned total of 750 participants across Europe" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3.11 years (3.11 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] "><b>Hellgren 2016</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] "><b>HELP PD 2011</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Based on a longitudinal correlation of r = 0.20, this sample was projected to provide 94% power to detect a net intervention effect of 3.5 mg/dL (two‐sided alpha of 0.05) and 86% power to detect an effect size of 3 mg/dL. These estimates include allowance for a 5% loss to follow‐up rate every 6 months" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] "><b>IDPP 2006</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"It was assumed that the cumulative incidence of diabetes in 3 years would be approximately 30% in the control group and that there would be a 50% reduction with the intervention methods. The sample size required in each of the four subgroups was 134 with a type 1 error of 5%, 80% power, and allowing for a dropout rate of 10%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] "><b>JDPP 2013</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"According to prospective studies on the Japanese population, the yearly incidence of diabetes among subjects with IGT varies between 1 and 5% ... Therefore, it was assumed that the 6‐year cumulative incidence of diabetes would be 30% in the control group. The present study was designed to detect a 50% reduction in the incidence by the intervention. Thus the sample size required was 313 with a type 1 error of 5%, with 80% power (beta = 20%) at the two‐tailed 5% significance level, and allowing for a withdrawal rate of 30%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. "><b>Kosaka 2005</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> <p>(Number of randomised participants was calculated based on the following information: "The rate of drop‐out during the 1‐year observation was 5.6% in the control group and 4.7% in the intensive intervention group, respectively") </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. "><b>Oldroyd 2005</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"We calculated that a sample size of 100 individuals (50 in each arm) was necessary to detect a 0.6 mmol/l difference in mean fasting plasma glucose and a 20% difference in the proportion with glucose intolerance, both with 90% power at the 5% significance level" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: no intervention</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] "><b>PODOSA 2014</b> </a> </p> <p><b>(cluster‐RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"When the protocol was amended in 2009, we knew that the number of families with more than one person recruited with impaired fasting glucose or impaired glucose tolerance was small, so the new power calculation did not take clustering into account. A sample of 150 people assessed at 3 years gave 86% power to detect a mean difference in weight of 2.5 kg between the two groups, assuming an SD of 5 kg with a two‐sided 5% significance level." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] "><b>SLIM 2003</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"It was calculated that, based on the results of the Finnish Diabetes Prevention Study (DPS), 50–60 subjects per group would be sufficient to detect a 1.0 mmol/l difference in 2‐h glucose concentration between groups ..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4.1 years (range 3 to 6 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2136</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>3091</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>5238<sup>l</sup> </i> </b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>"‐" denotes not reported</p> <p><sup>a</sup>Randomised numbers in each group not specified.<br/> <sup>b</sup>After 6 years of intervention, during the subsequent 17‐year follow‐up period after the intervention had stopped 6 participants were lost to follow‐up.<br/> <sup>c</sup>Of the 1082 participants assigned to placebo, 1052 were available for the DPPOS (see DPP 2002); of these 935 were enrolled in the DPPOS. Of the 1079 assigned to the behaviour changing intervention 1042 were available for the DPPOS; of these 915 were enrolled in the DPPOS.<br/> <sup>d</sup>Trial authors state that ITT analysis was performed but data are presented as a per‐protocol analysis.<br/> <sup>e</sup>Data for the end of intervention. Participants included in the extension period were 200 in the intervention group and 166 in the control group.<br/> <sup>f</sup>Number of analysed participants varied during the trial (intervention group: 39 at 1 year; 35 at 2 years; 27 at 3 years; 28 at 4 years; 21 at 5 years; control group: 43 at 1 year; 37 at 2 years; 33 at 3 years; 28 at 4 years; 21 at 5 years).<br/> <sup>g</sup>123 participants were eligible for the trial, 4 died and 10 developed T2DM and did not complete the final examination. One received a gastric bypass; 17 refused follow‐up. Not specified to which intervention groups these people were randomised.<br/> <sup>h</sup>Number of analysed participants varied during the trial (intervention group: 139 at 6 months, 135 at 12 months, 125 at 18 months and 127 at 24 months; control group: 141 at 6 months, 138 at 12 months, 132 at 18 months and 134 at 24 months).<br/> <sup>i</sup>Number of analysed participants varied during the trial (intervention group: 37 at 6 months, 32 at 12 months and 30 at 24 months; control group: 32 at 6 months, 30 at 12 months and 24 at 24 months).<br/> <sup>j</sup>78 families with 85 participants and 55 family volunteers were allocated to the intervention, 78 families with 86 participants and 69 family volunteers were allocated to the control.<br/> <sup>k</sup>Number of analysed participants varied during the trial (intervention group: 52 at 3 years, 51 at 4 years, 34 at 5 years and 35 (one that was missing at 6 years attended 6‐year follow‐up) at 6 years; control group: 54 at 3 years, 43 at 4 years, 29 at 5 years and 35 (6 that were missing at five years attended 6‐year follow‐up) at 6 years.<br/> <sup>l</sup>2 trials did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately. </p> <p>DPP: Diabetes Prevention Program; DPPOS: Diabetes Prevention Program Outcome Study; EDIPS: European Diabetes Prevention Study; HELP PD: Healthy Living Partnerships to Prevent Diabetes; IDPP: Indian Diabetes Prevention Programmes; ITT: intention‐to‐treat; JDPP: Japan Diabetes Prevention Program; PODOSA: Prevention of Diabetes and Obesity in South Asians; RCT: randomised controlled trial; SLIM: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht </p> </div> </div> <p>We provided information about potentially relevant ongoing trials, including trial identifier, in the '<a href="./references#CD003054-sec-0228" title="">Characteristics of ongoing studies</a>' table and in a joint appendix 'Matrix of study endpoints (publications and trial documents)' (<a href="./appendices#CD003054-sec-0202">Appendix 6</a>). For each included trial, we tried to retrieve the protocol and planned to report primary, secondary and other outcomes in comparison with data in publications in a joint appendix. If not available from the search of the databases, reference screening or Internet searches, we asked trial authors to provide a copy of the protocol. </p> <p>We emailed all authors of the included trials to enquire whether they would be willing to answer questions regarding their trials. We presented the results of this survey in <a href="./appendices#CD003054-sec-0209">Appendix 13</a>. We sought relevant missing information on the trial from the primary author(s) of the article, if possible. </p> <p><b>Dealing with duplicate and companion publications</b> </p> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised the information yield by collating all available data, and we used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial, and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. Furthermore, we also listed duplicate publications, companion documents, multiple reports of a trial, and trial documents of excluded trials (such as trials registry information) as secondary references under the study ID of the excluded trial. </p> <p><b>Data from clinical trials registers</b> </p> <p>If data from included trials were available as study results in clinical trials registers, such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trials register but no additional information (study results, publication or both) was available, we added this trial to the table '<a href="./references#CD003054-sec-0227" title="">Characteristics of studies awaiting classification</a>'. </p> </section> <section id="CD003054-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (BH and GG) independently assessed the risk of bias of each included trial. We resolved any disagreements by consensus, or by consultation with a third review author (BR). If adequate information was not available from the trial publication, trial protocol or both, we contacted trial authors for missing data on 'Risk of bias' items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD003054-bbs2-0100" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) and judged risk of bias criteria as either low, high, or unclear and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003054-bbs2-0100" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>) where any of the specified criteria for a judgement on low, unclear or high risk of bias justified the associated categorisation. </p> <p><b>Random sequence generation</b> </p> <p>Selection bias due to inadequate generation of a randomised sequence ‐ assessment at trial level </p> <p>We described for each included trial the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p> <ul id="CD003054-list-0013"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. Use of the minimisation technique will be considered as equivalent to being random. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the sequence generation process.</p> </li> <li> <p>High risk of bias: the sequence generation method was non‐random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; allocation by availability of the intervention). We excluded such trials. </p> </li> </ul> </p> <p><b>Allocation concealment</b> </p> <p>Selection bias due to inadequate concealment of allocations prior to assignment ‐ assessment at trial level </p> <p>We described for each included trial the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. </p> <p> <ul id="CD003054-list-0014"> <li> <p>Low risk of bias: central allocation (including telephone, interactive voice‐recorder, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the allocation concealment.</p> </li> <li> <p>High risk of bias: using an open random allocation schedule (e.g. a list of random numbers); using assignment envelopes without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure. We excluded such trials. </p> </li> </ul> </p> <p><b>Blinding of participants and study personnel</b> </p> <p>Performance bias due to knowledge of the allocated interventions by participants and personnel during the trial ‐ assessment at outcome level </p> <p>We evaluated the risk of performance bias separately for each outcome (<a href="./references#CD003054-bbs2-0102" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether outcomes were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD003054-list-0015"> <li> <p>Low risk of bias: blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; no blinding or incomplete blinding, but the review authors judged that the outcome was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to be influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> <p><b>Blinding of outcome assessment</b> </p> <p>Detection bias due to knowledge of the allocated interventions by outcome assessment ‐ assessment at outcome level </p> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD003054-bbs2-0102" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether outcomes were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD003054-list-0016"> <li> <p>Low risk of bias: blinding of outcome assessment ensured, and unlikely that the blinding could have been broken; no blinding of outcome assessment, but the review authors judged that the outcome measurement was not likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding. </p> </li> </ul> </p> <p><b>Incomplete outcome data</b> </p> <p>Attrition bias due to amount, nature or handling of incomplete outcome data ‐ assessment at outcome level </p> <p>We described for each included trial, and for each outcome, the completeness of data including attrition and exclusions from the analysis. We investigated whether attrition and exclusions were reported and the number included in the analysis at each stage (compared with the number of randomised participants per intervention/comparator groups), if reasons for attrition or exclusion were reported, and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome, such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms). </p> <p> <ul id="CD003054-list-0017"> <li> <p>Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data. </p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; ‘as‐treated’ or similar analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation. </p> </li> </ul> </p> <p><b>Selective reporting</b> </p> <p>Reporting bias due to selective outcome reporting ‐ assessment at trial level</p> <p>We assessed outcome reporting bias by integrating the results of <a href="./appendices#CD003054-sec-0202">Appendix 6</a>, 'Matrix of trial endpoints (publications and trial documents)' (<a href="./references#CD003054-bbs2-0116" title="MathieuS , BoutronI , MoherD , AltmanDG , RavaudP . Comparison of registered and published primary outcomes in randomized controlled trials. JAMA2009;302:977‐84. ">Mathieu 2009</a>), with those of <a href="./appendices#CD003054-sec-0203">Appendix 7</a> 'High risk of outcome reporting bias according to ORBIT classification' (<a href="./references#CD003054-bbs2-0108" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. [DOI: 10.1136/bmj.c365] ">Kirkham 2010</a>). This analysis formed the basis for the judgement of selective reporting. </p> <p> <ul id="CD003054-list-0018"> <li> <p>Low risk of bias: the trial protocol was available and all of the trial’s pre‐specified (primary and secondary) outcomes that were of interest in the review were reported in the pre‐specified way; the study protocol was not available but it was clear that the published reports included all expected outcomes (ORBIT classification). </p> </li> <li> <p>Unclear risk of bias: insufficient information about selective reporting.</p> </li> <li> <p>High risk of bias: not all of the trial’s pre‐specified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that had not been pre‐specified; one or more reported primary outcomes had not been pre‐specified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the trial report failed to include results for a key outcome that would be expected to have been reported for such a trial (ORBIT classification). </p> </li> </ul> </p> <p><b>Other bias</b> </p> <p>Bias due to problems not covered elsewhere ‐ assessment at trial level</p> <p>Other risk of bias reflects other circumstances that may threaten the validity of the trials, for example, funding bias and academic bias (<a href="./references#CD003054-bbs2-0112" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012;Issue 12:Art. No.: MR000033. DOI: 10.1002/14651858.MR000033.pub2. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>). </p> <p> <ul id="CD003054-list-0019"> <li> <p>Low risk of bias: the trial appeared to be free of other sources of bias.</p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias. </p> </li> <li> <p>High risk of bias: had a potential source of bias related to the specific trial design used; has been claimed to have been fraudulent; had some other serious problem. </p> </li> </ul> </p> <p>We presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.</p> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We considered the following self‐reported outcomes.</p> <p> <ul id="CD003054-list-0020"> <li> <p>Non‐serious adverse events</p> </li> <li> <p>Hypoglycaemia, if reported by participants</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Blood glucose control, if measured by trial participants</p> </li> </ul> </p> <p>We considered the following investigator‐assessed outcomes</p> <p> <ul id="CD003054-list-0021"> <li> <p>All‐cause mortality</p> </li> <li> <p>Incidence of T2DM</p> </li> <li> <p>Time to progression to T2DM</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction</p> </li> <li> <p>Non‐fatal stroke</p> </li> <li> <p>Amputation of lower extremity</p> </li> <li> <p>Blindness or severe vision loss</p> </li> <li> <p>End‐stage renal disease</p> </li> <li> <p>Hypoglycaemia, if measured by trial personnel</p> </li> <li> <p>Blood glucose control, if measured by trial personnel</p> </li> <li> <p>Socioeconomic effects.</p> </li> </ul> </p> <section id="CD003054-sec-0065"> <h5 class="title">Summary assessment of risk of bias</h5> <section id="CD003054-sec-0066"> <h6 class="title">Risk of bias for a trial across outcomes</h6> <p>Some risk of bias domains like selection bias (sequence generation and allocation sequence concealment) affected the risk of bias across all outcome measures in a trial. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. In case of high risk of selection bias, we excluded the trial. </p> </section> <section id="CD003054-sec-0067"> <h6 class="title">Risk of bias for an outcome within a trial and across domains</h6> <p>We assessed the risk of bias for an outcome measure including all of the entries relevant to that outcome, that is, both trial‐level entries and outcome‐specific entries. Low risk of bias was defined as low risk of bias for all key domains, unclear risk of bias as unclear risk of bias for one or more key domains and high risk of bias as high risk of bias for one or more key domains. </p> </section> <section id="CD003054-sec-0068"> <h6 class="title">Risk of bias for an outcome across trials and across domains</h6> <p>These were our main summary assessments that were be incorporated in our judgements about the quality of evidence in the 'Summary of finding' table(s). Low risk of bias was defined as most information coming from trials at low risk of bias, unclear risk of bias as most information coming from trials at low or unclear risk of bias and high risk of bias as a sufficient proportion of information coming from trials at high risk of bias. </p> </section> </section> </section> <section id="CD003054-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two trials were available for a comparison of a given outcome we expressed dichotomous data as risk ratio (RR) with 95% confidence intervals (CIs) and with trial sequential analysis (TSA)‐adjusted CIs if the diversity‐adjusted required information size was not reached. We planned to calculate time‐to‐event data as hazard ratio (HR) with 95% CI with the generic inverse variance method. We planned to use unadjusted HRs for preference, as adjustment could differ among the included trials.<br/> We expressed continuous data reported on the same scale as mean difference (MD) with 95% CIs and with TSA‐adjusted CIs if the diversity‐adjusted required information size was not reached. For trials addressing the same outcome but using different outcome measure scales we planned to use standardised mean differences (SMD) with 95% CI. For outcomes meta‐analysed as SMD and the generic inverse variance method, we are presently unable to conduct TSA and adjust the 95% CIs.<br/> The scales measuring health‐related quality of life (HRQoL) may go in different directions. In some scales, values increase with improved HRQoL, whereas in other scales, values decrease with improved HRQoL. To adjust for the different directions of the scales, we planned to multiply the scales that reported better HRQoL with decreasing values by ‐1. </p> </section> <section id="CD003054-sec-0070"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over trials, cluster‐randomised trials and multiple observations for the same outcome. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we either combined groups to create a single, pair‐wise comparison or appropriately reduced the sample size so that the same participants did not contribute multiply (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (<a href="./references#CD003054-bbs2-0081" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>We planned to reanalyse cluster‐randomised trials that did not appropriately adjust for potential clustering of participants within clusters in their analysis. The variance of the intervention effects would have been inflated by a design effect (DEFF). Calculation of a DEFF involves estimation of an intra‐cluster correlation (ICC). We planned to obtain estimates of ICCs through contact with trial authors, or by imputing them using estimates from other included studies that reported ICCs, or using external estimates from empirical research (e.g. <a href="./references#CD003054-bbs2-0074" title="BellML , McKenzieJE . Designing psycho‐oncology randomised trials and cluster randomised trials: variance components and intra‐cluster correlation of commonly used psychosocial measures. Psychooncology2013;22:1738‐47. ">Bell 2013</a>). We planned to examine the impact of clustering using sensitivity analyses. </p> </section> <section id="CD003054-sec-0071"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain missing data from trial authors and carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention‐to‐treat, and as‐treated and per‐protocol populations. </p> <p>We investigated attrition rates (e.g. dropouts, losses to follow‐up, withdrawals), and critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward). </p> <p>Where means and standard deviations (SDs) for outcomes were not reported and we could not get the information that we needed from trial authors, we imputed these values by assuming the SDs of the missing outcome to be the average of the SDs from those trials in which this information was reported. </p> <p>We planned to investigate the impact of imputation on meta‐analyses by performing sensitivity analyses. </p> </section> <section id="CD003054-sec-0072"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we planned not to report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we also considered the I² statistic (<a href="./references#CD003054-bbs2-0096" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327:557‐60. ">Higgins 2003</a>), which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD003054-bbs2-0081" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD003054-bbs2-0095" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539‐58. ">Higgins 2002</a>). </p> </section> <section id="CD003054-sec-0073"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more trials investigating a particular outcome, we used funnel plots to assess small‐trial effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials) and publication bias. We therefore interpreted results carefully (<a href="./references#CD003054-bbs2-0134" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). </p> </section> <section id="CD003054-sec-0074"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure an answer that would be clinically meaningful. Unless good evidence showed homogeneous effects across trials of different methodological quality, we primarily summarised low risk of bias data using a random‐effects model (<a href="./references#CD003054-bbs2-0147" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration to the whole distribution of effects and presented a 95% prediction interval (<a href="./references#CD003054-bbs2-0075" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta‐analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5‐18. ">Borenstein 2017a</a>; <a href="./references#CD003054-bbs2-0076" title="BorensteinM . Prediction intervals. www.meta‐analysis.com/prediction (accessed 3 July 2017). ">Borenstein 2017b</a>; <a href="./references#CD003054-bbs2-0097" title="HigginsJPT , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval needs at least three trials to be calculated and specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD003054-bbs2-0127" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). For rare events such as event rates below 1%, we planned to use the Peto's odds ratio method, provided that there was no substantial imbalance between intervention and comparator group sizes and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003054-bbs2-0081" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p><b>Trial sequential analyses</b> </p> <p>In a single trial, sparse data and interim analyses increase the risk of type I and type II errors. To avoid type I errors, group sequential monitoring boundaries are applied to decide whether a trial could be terminated early because of a sufficiently small P value, that is the cumulative Z‐curve crosses the monitoring boundaries (<a href="./references#CD003054-bbs2-0109" title="LanKKG , DeMetsDL . Discrete sequential boundaries for clinical trials. Biometrika1983;70:659‐63. ">Lan 1983</a>). Likewise, before reaching the planned sample size of a trial, the trial may be stopped due to futility if the cumulative Z‐score crosses the futility monitoring boundaries. Sequential monitoring boundaries for benefit, harm, or futility can be applied to meta‐analyses as well, called trial sequential monitoring boundaries (<a href="./references#CD003054-bbs2-0098" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21190240] ">Higgins 2010</a>; <a href="./references#CD003054-bbs2-0139" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). In TSA, the addition of each trial in a cumulative meta‐analysis is regarded as an interim meta‐analysis and helps to clarify if significance or futility is reached or whether additional trials are needed (<a href="./references#CD003054-bbs2-0139" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>TSA combines a calculation of the diversity‐adjusted required information size (cumulated meta‐analysis sample size to detect or reject a specific relative intervention effect) for meta‐analysis with the threshold of data associated with statistics. We planned to perform TSA on all outcomes included in the 'Summary of findings' table (<a href="./references#CD003054-bbs2-0077" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD003054-bbs2-0125" title="PogueJM , YusufS . Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials1997;18(6):580‐93; discussion 661‐6. [PUBMED: 9408720] ">Pogue 1997</a>; <a href="./references#CD003054-bbs2-0139" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>The idea in TSA is that if the cumulative Z‐curve crosses the boundary for benefit or harm before a diversity‐adjusted required information size is reached, a sufficient level of evidence for the anticipated intervention effect has been reached with the assumed type I error and no further trials may be needed. If the cumulative Z‐curve crosses the boundary for futility before a diversity‐adjusted required information size is reached, the assumed intervention effect can be rejected with the assumed type II error and no further trials may be needed. If the Z‐curve does not cross any boundary, then there is insufficient evidence to reach a conclusion. To construct the trial sequential monitoring boundaries, the required information size is needed and is calculated as the least number of participants needed in a well‐powered single trial and subsequently adjusted for diversity among the included trials in the meta‐analysis (<a href="./references#CD003054-bbs2-0077" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ Trial Sequential Analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [PUBMED: 18824466] ">Brok 2009</a>; <a href="./references#CD003054-bbs2-0139" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). We applied TSA as it decreases the risk of type I and II errors due to sparse data and multiple updating in a cumulative meta‐analysis, and it provides us with important information in order to estimate the risks of imprecision when the required information size is not reached. Additionally, TSA provides important information regarding the need for additional trials and the required information size of such trials (<a href="./references#CD003054-bbs2-0139" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial Sequential Analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>). </p> <p>We applied trial sequential monitoring boundaries according to an estimated clinically important effect. We based the required information size on an a priori effect corresponding to a 10% relative risk reduction (RRR) for beneficial effects of the interventions and a 30% relative risk increase for harmful effects of the interventions. </p> <p>For continuous outcomes we performed TSA with MDs, by using the trials applying the same scale to calculate the required sample size. For continuous outcomes, we tested the evidence for the achieved differences in the cumulative meta‐analyses. </p> <p>For adjustment of heterogeneity of the required information size we used the diversity (D²) estimated in the meta‐analyses of included trials. When diversity was zero in a meta‐analysis, we performed a sensitivity analysis using an assumed diversity of 20%. </p> </section> <section id="CD003054-sec-0075"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity and performed subgroup analyses to investigate interactions. </p> <p> <ul id="CD003054-list-0022"> <li> <p>Trials with a long duration (four years and longer) versus trials with a short duration (less than four years). </p> </li> <li> <p>Diagnostic 'prediabetes' criteria (IFG, IGT, HbA1c)</p> </li> <li> <p>Age, depending on data</p> </li> <li> <p>Sex</p> </li> <li> <p>Ethnicity, depending on data</p> </li> <li> <p>Comorbid conditions, such as hypertension or obesity</p> </li> <li> <p>Participants with previous gestational diabetes mellitus</p> </li> </ul> </p> </section> <section id="CD003054-sec-0076"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting the analysis to the following. </p> <p> <ul id="CD003054-list-0023"> <li> <p>Published trials.</p> </li> <li> <p>Taking into account risk of bias, as specified in the '<a href="#CD003054-sec-0064">Assessment of risk of bias in included studies</a>' section. </p> </li> <li> <p>Trials using the following filters: imputation, language of publication, source of funding (industry versus other), or country. </p> </li> </ul> </p> <p>We also planned to test the robustness of results by repeating the analysis using different measures of effect size (RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD003054-sec-0077"> <h5 class="title">Quality of evidence</h5> <p>We presented the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account issues relating not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results. Two review authors (BH and BR) rated the quality of evidence for each outcome. We presented a summary of the evidence in 'Summary of findings' tables ( <a href="./full#CD003054-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003054-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003054-tbl-0003">summary of findings Table 3</a>). These tables provide key information about the best estimate of the magnitude of the effect of interventions, in relative terms and as absolute differences, the numbers of participants and trials addressing each important outcome, and rate the overall confidence in effect estimates for each outcome. We created the ’Summary of findings’ tables on the basis of methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003054-bbs2-0130" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>) by means of the table editor in Review Manager 5 (<a href="./references#CD003054-bbs2-0126" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and included three appendices (<a href="./appendices#CD003054-sec-0210">Appendix 14</a>; <a href="./appendices#CD003054-sec-0211">Appendix 15</a>; <a href="./appendices#CD003054-sec-0212">Appendix 16</a>) providing checklists as guides to the consistency and reproducibility of GRADE assessments (<a href="./references#CD003054-bbs2-0117" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82. ">Meader 2014</a>) to help with the standardisation of the 'Summary of findings' tables. Alternatively, we would have used the GRADEproGDT software (<a href="./references#CD003054-bbs2-0092" title="McMaster University (developed by Evidence Prime). GRADEproGDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEproGDT 2015</a>) and would have presented evidence profile tables as an appendix. We presented results for the outcomes as described in the <a href="#CD003054-sec-0055">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' tables. We justified all decisions to downgrade the quality of the evidence using footnotes, and we made comments to aid the reader’s understanding of the review where necessary. </p> <p>We presented a 'Summary of findings' table to report the following outcomes, listed according to priority. </p> <p> <ul id="CD003054-list-0024"> <li> <p>All‐cause mortality</p> </li> <li> <p>Incidence of T2DM</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Cardiovascular mortality</p> </li> <li> <p>Non‐fatal myocardial infarction/stroke</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003054-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003054-sec-0078"></div> <section id="CD003054-sec-0079"> <h3 class="title">Description of studies</h3> <p>For a detailed description of studies, see the '<a href="./references#CD003054-sec-0225" title="">Characteristics of included studies</a>', '<a href="./references#CD003054-sec-0226" title="">Characteristics of excluded studies</a>', '<a href="./references#CD003054-sec-0227" title="">Characteristics of studies awaiting classification</a>' and '<a href="./references#CD003054-sec-0228" title="">Characteristics of ongoing studies</a>' sections. </p> <section id="CD003054-sec-0080"> <h4 class="title">Studies awaiting classification</h4> <p>We classified five trials in six references as studies awaiting classification (see '<a href="./references#CD003054-sec-0227" title="">Characteristics of studies awaiting classification</a>' table). </p> </section> <section id="CD003054-sec-0081"> <h4 class="title">Ongoing studies</h4> <p>We found three ongoing randomised controlled trials (RCTs) in nine references (<a href="./references#CD003054-bbs2-0059" title="NCT01530165. apps.who.int/trialsearch/Trial3.aspx?trialid=NCT01530165 (first received 4 April 2017). NCT01530165. clinicaltrials.gov/show/NCT01530165 (first received 3 April 2017). ">NCT01530165</a>; <a href="./references#CD003054-bbs2-0060" title="ACTRN12613000857707. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000857707 (first received 3 April 2017). NCT01777893. clinicaltrials.gov/ct2/show/NCT01777893 (first received 3 April 2017). FogelholmM , LarsenTM , Westerterp‐PlantengaM , MacDonaldI , MartínezAJ , Handjieva‐DarlenskaT , et al. PREVIEW‐Design, methods and baseline participant description of an international intervention to prevent type‐2 diabetes. Annals of Nutrition and Metabolism2015;67:414. RabenA , FogelholmM , LarsenTM , DrummensM , PoppittS , FormigueraJA , et al. PREVIEW: Prevention of diabetes through lifestyle intervention and population studies in Europe and a round the world. Over 2,000 volunteers randomized to the 3‐y RCT. Obesity Facts. Conference: 22nd Congress of the European Congress on Obesity, ECO 2015 Prague Czech Republic, 2015; Vol. 8, issue 0:126. ">PREVIEW</a>; <a href="./references#CD003054-bbs2-0061" title="ISRCTN83465245. www.isrctn.com/ISRCTN83465245 (first received 27 March 2017). MortonK , SuttonS , HardemanW , TroughtonJ , YatesT , GriffinS , et al. A text‐messaging and pedometer program to promote physical activity in people at high risk of type 2 diabetes: the development of the PROPELS follow‐on support program. JMIR mHealth and uHealth2015;3(4):e105. [PUBMED: 26678750] YatesT , GriffinS , BodicoatDH , BrierlyG , DallossoH , DaviesMJ , et al. Promotion of physical activity through structured education with differing levels of ongoing support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials2015;16:289. [PUBMED: 26130075] ">PROPELS</a>). We estimate the ongoing trials to include 23,808 participants. The definition of intermediate hyperglycaemia varied among the ongoing trials; one trial included participants with impaired glucose tolerance (IGT) (<a href="./references#CD003054-bbs2-0059" title="NCT01530165. apps.who.int/trialsearch/Trial3.aspx?trialid=NCT01530165 (first received 4 April 2017). NCT01530165. clinicaltrials.gov/show/NCT01530165 (first received 3 April 2017). ">NCT01530165</a>), one trial included participants with IGT, impaired fasting glucose (IFG) or both (<a href="./references#CD003054-bbs2-0060" title="ACTRN12613000857707. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000857707 (first received 3 April 2017). NCT01777893. clinicaltrials.gov/ct2/show/NCT01777893 (first received 3 April 2017). FogelholmM , LarsenTM , Westerterp‐PlantengaM , MacDonaldI , MartínezAJ , Handjieva‐DarlenskaT , et al. PREVIEW‐Design, methods and baseline participant description of an international intervention to prevent type‐2 diabetes. Annals of Nutrition and Metabolism2015;67:414. RabenA , FogelholmM , LarsenTM , DrummensM , PoppittS , FormigueraJA , et al. PREVIEW: Prevention of diabetes through lifestyle intervention and population studies in Europe and a round the world. Over 2,000 volunteers randomized to the 3‐y RCT. Obesity Facts. Conference: 22nd Congress of the European Congress on Obesity, ECO 2015 Prague Czech Republic, 2015; Vol. 8, issue 0:126. ">PREVIEW</a>), and one trial included participants with IFG or moderately elevated glycosylated haemoglobin A1c (HbA1c) (<a href="./references#CD003054-bbs2-0061" title="ISRCTN83465245. www.isrctn.com/ISRCTN83465245 (first received 27 March 2017). MortonK , SuttonS , HardemanW , TroughtonJ , YatesT , GriffinS , et al. A text‐messaging and pedometer program to promote physical activity in people at high risk of type 2 diabetes: the development of the PROPELS follow‐on support program. JMIR mHealth and uHealth2015;3(4):e105. [PUBMED: 26678750] YatesT , GriffinS , BodicoatDH , BrierlyG , DallossoH , DaviesMJ , et al. Promotion of physical activity through structured education with differing levels of ongoing support for people at high risk of type 2 diabetes (PROPELS): study protocol for a randomized controlled trial. Trials2015;16:289. [PUBMED: 26130075] ">PROPELS</a>). All the ongoing trials assessed one or more outcomes of interest for our review. Two of the ongoing trials' predefined outcomes stated that they would assess one of our primary outcomes (incidence of T2DM) (<a href="./references#CD003054-bbs2-0059" title="NCT01530165. apps.who.int/trialsearch/Trial3.aspx?trialid=NCT01530165 (first received 4 April 2017). NCT01530165. clinicaltrials.gov/show/NCT01530165 (first received 3 April 2017). ">NCT01530165</a>; <a href="./references#CD003054-bbs2-0060" title="ACTRN12613000857707. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12613000857707 (first received 3 April 2017). NCT01777893. clinicaltrials.gov/ct2/show/NCT01777893 (first received 3 April 2017). FogelholmM , LarsenTM , Westerterp‐PlantengaM , MacDonaldI , MartínezAJ , Handjieva‐DarlenskaT , et al. PREVIEW‐Design, methods and baseline participant description of an international intervention to prevent type‐2 diabetes. Annals of Nutrition and Metabolism2015;67:414. RabenA , FogelholmM , LarsenTM , DrummensM , PoppittS , FormigueraJA , et al. PREVIEW: Prevention of diabetes through lifestyle intervention and population studies in Europe and a round the world. Over 2,000 volunteers randomized to the 3‐y RCT. Obesity Facts. Conference: 22nd Congress of the European Congress on Obesity, ECO 2015 Prague Czech Republic, 2015; Vol. 8, issue 0:126. ">PREVIEW</a>). Future updates will include all ongoing trials, if possible. </p> </section> <section id="CD003054-sec-0082"> <h4 class="title">Results of the search</h4> <p>The original Cochrane Review published in 2008 included eight RCTs. In this update we excluded two of these trials as they did not have intermediate hyperglycaemia as an inclusion criterion (<a href="./references#CD003054-bbs2-0014" title="BoS , CicconeG , BaldiC , BeniniL , DusioF , ForastiereG , et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. Journal of General Internal Medicine2007;22(12):1695‐703. ">Bo 2007</a>; <a href="./references#CD003054-bbs2-0050" title="WingRR , VendittiE , JakicicJM , PolleyBA , LangW . Lifestyle intervention in overweight individual with a family history of diabetes. Diabetes Care1998;21:350‐9. ">Wing 1998</a>). Thus, six trials of the original review remained (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). The updated search of the databases identified 2072 records after duplicates were removed (<a href="#CD003054-fig-0001">Figure 1</a>). We excluded most of the references on the basis of their titles and abstracts because they clearly did not meet the inclusion criteria. We evaluated 181 references further. In this updated search we identified a total of 56 additional references for four of the already included trials of the 2008 review (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). After screening the full‐texts and evaluating the existing references from the 2008 review, 12 RCTs published in 127 records met our inclusion criteria. We excluded a total of 62 references from the updated search after full‐text evaluation. Therefore, in addition to the six included trials of the Cochrane Review published in 2008 we included six more trials (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>We continuously used a MEDLINE email alert service to identify newly published studies using the same search strategy as described for MEDLINE up to September 2017. </p> </section> <section id="CD003054-sec-0083"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included studies is presented elsewhere (see <a href="./references#CD003054-sec-0225" title="">Characteristics of included studies</a>; <a href="#CD003054-tbl-0004">Table 1</a> and <a href="./appendices#CD003054-sec-0198">Appendix 2</a>; <a href="./appendices#CD003054-sec-0199">Appendix 3</a>; <a href="./appendices#CD003054-sec-0200">Appendix 4</a>; <a href="./appendices#CD003054-sec-0201">Appendix 5</a>; <a href="./appendices#CD003054-sec-0202">Appendix 6</a>; <a href="./appendices#CD003054-sec-0203">Appendix 7</a>; <a href="./appendices#CD003054-sec-0204">Appendix 8</a>; <a href="./appendices#CD003054-sec-0205">Appendix 9</a>; <a href="./appendices#CD003054-sec-0206">Appendix 10</a>; <a href="./appendices#CD003054-sec-0207">Appendix 11</a>; <a href="./appendices#CD003054-sec-0208">Appendix 12</a>). The following is a succinct overview: </p> <section id="CD003054-sec-0084"> <h5 class="title">Source of data</h5> <p>We contacted all trial authors or investigators through email (see <a href="./appendices#CD003054-sec-0209">Appendix 13</a>). When important information was lacking on ongoing studies and excluded studies, we contacted investigators for clarification. </p> </section> <section id="CD003054-sec-0085"> <h5 class="title">Overview of trial populations</h5> <p>Ten trials reported the number of participants screened (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Two trials did not report the number of participants randomised to each intervention group upon trial initiation (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). A total of 5238 participants were randomised; 11 trials evaluated diet plus physical activity (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). The two trial randomising participants to physical activity only in one of their treatment arms did not report the number of participants randomised to the intervention groups (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>); the same was the case for the one trial arm randomising to diet only (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>Ten trials provided information about sample size and power calculations (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>The proportion of participants finishing the trial varied from 48% (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>) to 98% (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </section> <section id="CD003054-sec-0086"> <h5 class="title">Trial design</h5> <p>Ten included trials were parallel RCTs and two trials had a cluster‐randomised design (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). In Da Qing each clinic was randomised to carry out the intervention on each of the eligible participants attending the clinic (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). A total of 33 health care clinics were included (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). No intra‐cluster correlation (ICC) coefficient was reported. However, we estimated it to be 0.05. The design effect was therefore estimated to be 1+ (average cluster size ‐ 1) x 0.05 = 1 + ((530/33) ‐ 1) x 0.05 = 1.75. For dichotomous data, we divided both the number of participants experiencing an event as well as the number of participants by the design effect. For continuous data we only adjusted the sample size for the design effect. Means and standard deviations remained unchanged. In the <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a> trial participants constituted 156 family clusters that were randomised (78 families with 85 participants were allocated to the intervention group and 78 families with 86 participants were allocated to the control group). First degree relatives living in the same city were not randomised separately. The ICC coefficient was assumed to be zero. </p> <p>The number of participants varied from 78 (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>) to 2161 (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). One trial contributed 41% of the total number of all randomised participants (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). Four trials were multi‐centre trials (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>), four trials were single‐centre trials (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>), and four trials did not provide any centre description (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). All trials were performed in outpatient settings. </p> <p>None of the trials reported blinding of the participants and investigators. One trial had a run‐in period of three weeks where participants had to fill out a diary and take placebo pills (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The duration of the intervention in the included trials varied from two to six years. Three trials had an extended follow‐up period after the intervention period had stopped (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). The extended follow‐up period varied from 5 to 17 years. One trial based the sample size calculation on an anticipated incidence of T2DM during six years of follow‐up. Trial authors said that they had planned six years' follow‐up, but only reported three years of follow‐up (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). Another trial originally planned a follow‐up of three years, but was extended to six years in the course of the trial (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>Six trials were performed in European countries (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>); two trials in the USA (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>) and four trials in Asian countries (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). </p> <p>Two trials included one or more intervention arms with metformin (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). Results from these intervention arms will be reported elsewhere (<a href="./references#CD003054-bbs2-0114" title="LüQ , KeLQ , TongN , CaoL , WuT , ZhangJ . Metformin for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database of Systematic Reviews2010, Issue 6. [DOI: 10.1002/14651858.CD008558] ">Lü 2010</a>). One of the trials originally included a troglitazone arm, which was discontinued due to liver toxicity of the drug (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> <p>Three of the included trials stated that they had received grants from a pharmaceutical company (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). Eight trials reported non‐commercial funding (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial did not report the funding source (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). </p> <p>Three trials were terminated early due to beneficial effects in the intervention group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). </p> </section> <section id="CD003054-sec-0087"> <h5 class="title">Participants</h5> <p>Four trials included only Asian people (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>): two of these trials included Japanese people (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>), one trial included Asian Indians (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>) and one trial included Chinese people (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). One trial performed in the UK only included people of Indian or Pakistini origin (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Two trials included only white people (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Two trials included people with different ethnicity (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>): in one of the trials more than 50% of the included participants were white and about 20% African American (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>), the other trial reported about 75% were white and 25% African American (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). Three trials did not report the ethnicity of the participants (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>): two of the trials might have included mainly white participants as they were conducted in Sweden and Finland (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> <p>All trial authors provided information on gender. One trial included only men (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>), the remaining trials included both men and women. All trials except one had a balanced distribution of women and men in the intervention and comparator groups, this trial included 54% women in the intervention group compared with 31% in the comparator group (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). </p> <p>The age of the included participants varied from 45 to 63 years.</p> <p>All trials except one reported fasting glucose values at baseline (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). Mean fasting glucose values at baseline varied from 5.5 mmol/L to 6.2 mmol/L. Nine trials reported two‐hour glucose values after a glucose‐load at baseline and ranged from 8.2 mmol/L to 9.2 mmol/L (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Glycosylated haemoglobin A1c (HbA1c) values were reported at baseline in six trials and ranged from 5.7% to 6.2% (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial did not report any glycaemic baseline values (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> <p>All trials reported body mass index (BMI) at baseline. Three of the included trials required a minimum BMI for all eligible participants (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). In two trials the mean BMI at baseline was less than 25 kg/m<sup>2</sup> (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). Four trials had a mean BMI at baseline between 25 kg/m<sup>2</sup> to 30 kg/m<sup>2</sup> (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Six trials reported a mean BMI at baseline above 30 kg/m<sup>2</sup> (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). None of the trials had a mean BMI at baseline above 35 kg/m<sup>2</sup>. Most trials excluded participants with other endocrine conditions, hepatic or kidney disease. </p> <section id="CD003054-sec-0088"> <h6 class="title">Diagnosis of intermediate hyperglycaemia</h6> <p>The diagnosis applied in the included trials for identifying intermediate hyperglycaemia varied. Three trials applied the World Health Organization (WHO) 1985 diagnostic criteria for the definition of IGT (fasting plasma glucose (FPG) &lt; 7.8 mmol/L and two‐hour plasma glucose after oral glucose tolerance test (OGTT) between ≥ 7.8 mmol/L and &lt; 11.1 mmol/L) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). Three trials applied the WHO 1999 criteria for the definition of IGT (fasting plasma glucose (FPG) &lt; 7.0 mmol/L and two‐hour plasma glucose after OGTT between ≥ 7.8 mmol/L and &lt; 11.1 mmol/L) (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). For one of these trials it was stated that the diagnosis of IGT was based on the OGTT and trial authors did not clearly describe any measurement of FPG (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). In the main publication it was described that intermediate hyperglycaemia was defined according to the WHO 1999 criteria, but the reference for the diagnostic criteria was the WHO 1985 reference (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0141" title="World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. apps.who.int/iris/bitstream/10665/39592/1/WHO_TRS_727.pdf (accessed 30 November 2017). ">WHO 1985</a>). The investigators confirmed that the diagnosis of T2DM was established by FPG or two‐hour plasma glucose (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). Therefore, plasma glucose must have been measured (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). One trial applied the WHO 1999 criteria for the definition of IFG (FPG ≥ 6.1 and &lt; 7.8 mmol/L and two‐hour glucose &lt; 7.8 mmol/L) and/or IGT (FPG &lt; 7.0 mmol/L and two‐hour plasma glucose after OGTT between ≥ 7.8 mmol/L and &lt; 11.1 mmol/L) (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). One trial included people with IGT defined by FPG &lt; 7.8 mmol/L and two‐hour plasma glucose after 100 g OGTT between 8.9 mmol/L and 13.3 mmol/L, which roughly corresponds to 7.8 mmol/L to 11 mmol/L after a 75 g OGTT (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). Therefore, the criterion was almost identical to the WHO 1980 criteria for IGT (FPG &lt; 8.0 mmol/L and two‐hour plasma glucose after OGTT between ≥ 8.0 mmol/L and &lt; 11.0 mmol/L) (<a href="./references#CD003054-bbs2-0140" title="World Health Organization. WHO Expert Committee on diabetes mellitus. apps.who.int/iris/bitstream/10665/41399/1/WHO_TRS_646.pdf (accessed 30 November 2017). ">WHO 1980</a>). One trial included people with fasting glucose levels between 5.3 mmol/L and 6.9 mmol/L (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). This definition did not adhere to the definition by the WHO or American Diabetes Association (ADA), however, the definition was very close to the glycaemic levels recommended by ADA 2003 (FPG 5.6 mmol/L to 6.9 mmol/L) (<a href="./references#CD003054-bbs2-0064" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow‐up report on the diagnosis of diabetes mellitus. Diabetes Care2003;26(11):3160‐7. ">ADA 2003</a>). One trial applied the diagnostic criteria for impaired glucose defined by ADA 1997 (FPG 5.3 mmol/L to 6.9 mmol/L and two‐hour plasma glucose after OGTT between 7.8 and 11.0 mmol/L) (<a href="./references#CD003054-bbs2-0063" title="American Diabetes Association. Report on the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(Suppl 1):S5‐20. ">ADA 1997</a>) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). For the Native American Indian clinics FPG less then 6.9 mmol/L with no lower limit applied. Before June 1997, the criterion for FPG was 5.6 to 7.7 mmol/L, or less than 7.7 mmol/L in the Native American Indian clinics (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). A total of 54 participants (total in all three intervention groups) included in the Diabetes Prevention Program (DPP) had FPG above 7.0 mmol/L at baseline (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). Thirteen percent of the participants included in the DPP had HbA1c ≥ 6.5% at baseline (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). One trial defined IGT by FPG &lt; 7.8 mmol/L and two‐hour plasma glucose after OGTT between ≥ 7.8 mmol/L and &lt; 12.5 mmol/L (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). No medical associations recommend these limits to diagnose IGT (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Twenty‐two participants of the initially randomised 147 participants had a two‐hour glucose value above 11 mmol/L in this trial (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial defined IFG as FPG &gt; 6.0 mmol/L to &lt; 7.0 mmol/L with two‐hour plasma glucose after OGTT &lt; 8.9 mmol/L, while IGT was defined as two‐hour plasma glucose after OGTT between 8.8 mmol/L and &lt; 12.2 mmol/L, and fasting glucose &lt; 7.0 mmol/L (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> </section> <section id="CD003054-sec-0089"> <h5 class="title">Interventions</h5> <p>All the participants in the included trials were treatment‐naive with regard to pharmacological glucose‐lowering interventions. Two of the included trials had more than one intervention group of relevance for this review (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> initially analysed data from the two intervention groups separately. As the treatment effect was almost identical in both groups, they analysed the two groups together and thereafter designated them as the combined intervention group. Both the intervention arms in <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> had a more intense physical activity strategy than the comparator group. Diet advice was identical in both intervention groups and the comparator group. <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> had four intervention arms: physical activity only, diet only, physical activity plus diet and control group. We combined data for the physical activity only, diet only and physical activity plus diet group as one intervention group in the post‐intervention follow‐up period. </p> <p>Ten trials aimed for weight reduction for all participants allocated to the intervention groups or only for participants with a BMI above a certain limit (this BMI limit varied among the included trials) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Participants with BMI above 25 kg/m<sup>2</sup> allocated to the diet‐only group in <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> were encouraged to reduce their calorie intake, so they lost 0.5 kg to 1.0 kg per month until they achieved a BMI of 23 kg/m<sup>2</sup>. For the other intervention groups in <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>, the intervention intensity did not change according to BMI. Three trials aimed for a BMI less than 25 kg/m<sup>2</sup> in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). One trial advised participants with a BMI above 22 kg/m<sup>2</sup> allocated to the diet plus physical activity group to lose weight (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). One trial recommended a weight reduction of at least 7% in participants in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>); two trials recommended a weight loss of 5% to 7% (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>); one trial aimed at 5% weight reduction in obese or overweight participants allocated to diet plus physical activity (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). One trial recommended a weight loss goal of 2.5 kg more in the diet plus physical activity group compared with the control group (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>The physical activity interventions differed largely among the trials. Some trials did not aim for a certain amount of minutes of activity, but just an increase in existing physical activity levels for the participants in the intervention group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). Other trials recommended physical activity of different intensity with a minimum number of minutes per day or week (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Some defined physical activity levels in the intervention groups, which corresponded to the physical activity recommended in the control groups in other trials. Some trials promoted physical activity (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a><a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>) and others offered physical activity programmes (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Most programmes included walking and cycling. </p> <p>Only one trial focused exclusively on physical activity interventions for the prevention of T2DM (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> <p>The diet interventions were mainly based on caloric restriction, reduced fat intake and increased fibre intake (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>The number of contacts with the participants in the intervention groups ranged from 3 to 46 (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). The intervention was applied to the participants in groups or on an individual basis. Nine of the trials applied both individual and group sessions for the participants in the intervention group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>); three trials provided individual sessions only (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). In most of the trials the intervention facilitators were a physiotherapist, an exercise physiologist and a dietitian. </p> <p>In one of the included trials, the control group did not receive any intervention (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). In the remaining included trials, the control group received recommendations, advice or education on how to increase physical activity and reduce calorie intake. </p> <p>Three trials had an extended follow‐up period after the intervention period had stopped (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). In the <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> and <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a> follow‐up studies, the participants did not receive any kind of diet or physical activity advice from the investigators. In the <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> follow‐up study (Diabetes Prevention Program Outcome Study (DPPOS)) sessions on diet plus physical activity were offered to all participants every third month. The participants initially randomised to the DPP diet plus exercise group were also offered sessions in order to reinvigorate their self‐management behaviours for weight loss (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). In the <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> the participants were re‐examined after 20 years and 23 years of follow‐up. In the <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> and <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a> follow‐up studies the participants were examined yearly. </p> </section> <section id="CD003054-sec-0090"> <h5 class="title">Outcomes</h5> <p>All included trials reported one or more of the primary outcomes for this review. All included trials, except one (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>), explicitly specified the primary outcome. Nine trials predefined a primary outcome with interest for this review (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Six trials had registered a protocol in a trials register (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). One trial changed its primary outcome from incidence of T2DM to weight change during the trial in order to ensure statistical power (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Weight change had originally been defined as a secondary outcome. Reporting on adverse events, macrovascular and microvascular complications was sparse. </p> </section> </section> <section id="CD003054-sec-0091"> <h4 class="title">Excluded studies</h4> <p>We excluded 41 trials after full‐text evaluation (for details see <a href="./references#CD003054-sec-0226" title="">Characteristics of excluded studies</a>). We excluded 16 trials published in 26 references as the duration of the intervention was less than two years (<a href="./references#CD003054-bbs2-0015" title="Study protocol. clinicaltrials.gov/show/NCT01283308 (accessed 17 September 2017). WeberMB , RanjaniH , MeyersGC , MohanV , NarayanKM . A model of translational research for diabetes prevention in low and middle‐income countries: The Diabetes Community Lifestyle Improvement Program (D‐CLIP) trial. Primary Care Diabetes2012;6(1):3‐9. [PUBMED: 21616737] ">D‐CLIP</a>; <a href="./references#CD003054-bbs2-0017" title="Study protocol. www.trialregister.nl/trialreg/admin/rctview.asp?TC=1499 (accessed 29 March 2017). VlaarEM , VanValkengoedIG , NierkensV , NicolaouM , MiddelkoopBJ , StronksK . Feasibility and effectiveness of a targeted diabetes prevention program for 18 to 60‐year‐old South Asian migrants: design and methods of the DH!AAN study. BMC Public Health2012;12:371. [PUBMED: 22621376] VlaarEM , VanValkengoedIG , NierkensV , NicolaouM , MiddelkoopBJ , StronksK . Feasibility and effectiveness of a targeted diabetes prevention program for 18 to 60‐year‐old South Asian migrants: design and methods of the DH!AAN study. BMC Public Health2012;12:371. [PUBMED: 22621376] ">DH!AAN</a>; <a href="./references#CD003054-bbs2-0022" title="HesselinkAE , BiloHJ , JonkersR , MartensM , deWeerdtI , RuttenGE . A cluster‐randomized controlled trial to study the effectiveness of a protocol‐based lifestyle program to prevent type 2 diabetes in people with impaired fasting glucose. BMC Family Practice2013;14:184. [PUBMED: 24295397] ">Hesselink 2013</a>; <a href="./references#CD003054-bbs2-0023" title="HuangSH , WengKP , HsiehKS , OuSF , LinCC , ChienKJ , et al. Effects of a classroom‐based weight‐control intervention on cardiovascular disease in elementary‐school obese children. Acta Paediatrica Taiwanica2007;48:201‐6. ">Huang 2007</a>; <a href="./references#CD003054-bbs2-0025" title="Study protocol. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000000798 (accessed 3 April 2017). SakaneN , KotaniK , TakahashiK , SanoY , TsuzakiK , OkazakiK , et al. Japan Diabetes Outcome Intervention Trial‐1 (J‐DOIT1), a nationwide cluster randomized trial of type 2 diabetes prevention by telephone‐delivered lifestyle support for high‐risk subjects detected at health checkups: rationale, design, and recruitment. BMC Public Health2013;13:81. [PUBMED: 23356246] ">J‐DOIT</a>; <a href="./references#CD003054-bbs2-0026" title="KawaharaT , TakahashiK , InazuT , AraoT , KawaharaC , TabataT , et al. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2‐day in‐hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. Diabetes Care2008;31(10):1949‐54. [PUBMED: 18591401] ">Kawahara 2008</a>; <a href="./references#CD003054-bbs2-0027" title="KinmonthAL , WarehamNJ , HardemanW , SuttonS , PrevostAT , FanshaweT , et al. Efficacy of a theory‐based behavioural intervention to increase physical activity in an at‐risk group in primary care (ProActive UK): a randomised trial. Lancet2008;371:41‐8. ">Kinmonth 2008</a>; <a href="./references#CD003054-bbs2-0030" title="LindahlB , NilssonTK , Borch‐JohnsenK , RoderME , SoderbergS , WidmanL , et al. A randomized lifestyle intervention with 5‐year follow‐up in subjects with impaired glucose tolerance: pronounced short‐term impact but long‐term adherence problems. Scandinavian Journal of Public Health2009;37(4):434‐42. [PUBMED: 19181821] LindahlB , NilssonTK , JanssonJH , AsplundK , HallmansG . Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. Journal of Internal Medicine1999;246:105‐12. ">Lindahl 1999</a>; <a href="./references#CD003054-bbs2-0031" title="NCT02000024. clinicaltrials.gov/ct2/show/NCT02000024 (accessed 10 April 2017). MarreroDG , PalmerKN , PhillipsEO , Miller‐KovachK , FosterGD , SahaCK . Comparison of commercial and self‐initiated weight loss programs in people with prediabetes: a randomized control trial. American Journal of Public Health2016;106(5):949‐56. [PUBMED: 26890171] ">Marrero 2016</a>; <a href="./references#CD003054-bbs2-0035" title="PageRC , HarndenKE , WalravensNK , OnslowC , SuttonP , LevyJC , et al. 'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. The Quarterly Journal of Medicine1993;86(3):145‐54. [PUBMED: 8483989] PageRCL , Harnden , CookJTE , TurnerRC . Can life‐styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabetic Medicine1992;9:562‐6. ">Page 1992</a>; <a href="./references#CD003054-bbs2-0037" title="NCT00819455. clinicaltrials.gov/ct2/show/NCT00819455 (accessed 10 April 2017). RamJ , SelvamS , SnehalathaC , NandithaA , SimonM , ShettyAS , et al. Improvement in diet habits, independent of physical activity helps to reduce incident diabetes among prediabetic Asian Indian men. Diabetes Research and Clinical Practice2014;106(3):491‐5. [PUBMED: 25458326] RamachandranA , SnehalathaC , RamJ , SelvamS , SimonM , NandithaA , et al. Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel‐group, randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2013;1(3):191‐8. [PUBMED: 24622367] ">Ramachandran 2013</a>; <a href="./references#CD003054-bbs2-0041" title="Study protocol. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000262909 (assessed 23 March 2017). SathishT , OldenburgB , TappRJ , ShawJE , WolfeR , SajithaB , et al. Baseline characteristics of participants in the Kerala Diabetes Prevention Program: a cluster randomized controlled trial of lifestyle intervention in Asian Indians. Diabetic Medicine2017;34(5):647‐53. [PUBMED: 27279083] ">Sathish 2017</a>; <a href="./references#CD003054-bbs2-0042" title="SavoyeM , ShawM , DziuraJ , TamborlaneWV , RoseP , GuandaliniC , et al. Effects of a weight management program on body composition and metabolic parameters in overweight children. A randomized controlled trial. JAMA2007;297(24):2697‐704. ">Savoye 2007</a>; <a href="./references#CD003054-bbs2-0047" title="ThompsonJL , AllenP , HelitzerDL , QuallsC , WhyteAN , WolfeVK , et al. Reducing diabetes risk in American Indian women. American Journal of Preventive Medicine2008;34(3):192‐201. ">Thompson 2008</a>; <a href="./references#CD003054-bbs2-0048" title="VillarealDT , Miller IIIBV , BanksM , FontanaL , SinacoreDR , KleinS . Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. American Journal of Clinical Nutrition2006;84:1317‐23. ">Villareal 2006</a>; <a href="./references#CD003054-bbs2-0052" title="YatesT , DaviesMJ , SehmiS , GorelyT , KhuntiK . The Pre‐diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years?. Diabetic Medicine : a Journal of the British Diabetic Association2011;28(10):1268‐71. [PUBMED: 21672008] ">Yates 2011</a>). We excluded 11 trials published in 12 references as they did not have intermediate hyperglycaemia as an inclusion criterion or the people with intermediate hyperglycaemia were analysed together with people of another glycaemic status, and separate data were not available (<a href="./references#CD003054-bbs2-0013" title="Study protocol. www.trialregister.nl/trialreg/admin/rctview.asp?TC=1082 (accessed 3 April 2017). VermuntPW , MilderIE , WielaardF , VanOersJA , WestertGP . An active strategy to identify individuals eligible for type 2 diabetes prevention by lifestyle intervention in Dutch primary care: the APHRODITE study. Family Practice2010;27(3):312‐9. [PUBMED: 20089573] ">APHRODITE</a>; <a href="./references#CD003054-bbs2-0014" title="BoS , CicconeG , BaldiC , BeniniL , DusioF , ForastiereG , et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. Journal of General Internal Medicine2007;22(12):1695‐703. ">Bo 2007</a>; <a href="./references#CD003054-bbs2-0018" title="MaJ , KingAC , WilsonSR , XiaoL , StaffordRS . Evaluation of lifestyle interventions to treat elevated cardiometabolic risk in primary care (E‐LITE): a randomized controlled trial. BMC Family Practice2009;10:71. [PUBMED: 19909549] ">E‐LITE</a>; <a href="./references#CD003054-bbs2-0020" title="ErikssonKM , WestborgCJ , EliassonMCE . A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. The Björknäs study. Scandinavian Journal of Public Health2006;34:453‐61. ">Eriksson 2006</a>; <a href="./references#CD003054-bbs2-0034" title="NCT02374788. clinicaltrials.gov/ct2/show/NCT02374788 (accessed 27 March 2017). ">NCT02374788</a>; <a href="./references#CD003054-bbs2-0038" title="RosasLG , LvN , XiaoL , LewisMA , ZavellaP , KramerMK , et al. Evaluation of a culturally‐adapted lifestyle intervention to treat elevated cardiometabolic risk of Latino adults in primary care (Vida Sana): a randomized controlled trial. Contemporary Clinical Trials2016;48:30‐40. [PUBMED: 26995280] ">Rosas 2016</a>; <a href="./references#CD003054-bbs2-0043" title="SchmidtMI , DuncanBB , CastilhosC , WendlandEM , HallalPC , SchaanBD , et al. Lifestyle INtervention for Diabetes prevention After pregnancy (LINDA‐Brasil): study protocol for a multicenter randomized controlled trial. BMC Pregnancy and Childbirth2016;16:68. [PUBMED: 27029489] ">Schmidt 2016</a>; <a href="./references#CD003054-bbs2-0044" title="TriefPM , CibulaD , DelahantyLM , WeinstockRS . Self‐determination theory and weight loss in a Diabetes Prevention Program translation trial. Journal of Behavioral Medicine2016;Epub Dec:Epub. [PUBMED: 28004335] ">SHINE</a>; <a href="./references#CD003054-bbs2-0046" title="DysonPA , HammersleyMS , MorrisRJ , HolmanRR , TurnerRC . The Fasting Hyperglycaemia Study: II. Randomized controlled trial of reinforced healthy‐living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism: Clinical and Experimental1997;46(12 Suppl 1):50‐5. [PUBMED: 9439560] HammersleyMS , MeyerLC , MorrisRJ , ManleySE , TurnerRC , HolmanRR . The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non‐insulin‐dependent diabetes prevention trial. Metabolism: Clinical and Experimental1997;46(12 Suppl 1):44‐9. [PUBMED: 9439559] KarunakaranS , HammersleyMS , MorrisRJ , TurnerRC , HolmanRR . The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose. Metabolism: Clinical and Experimental1997;46(12 Suppl 1):56‐60. [PUBMED: 9439561] ">The Fasting Hyperglycaemia Study 1997a</a>; <a href="./references#CD003054-bbs2-0050" title="WingRR , VendittiE , JakicicJM , PolleyBA , LangW . Lifestyle intervention in overweight individual with a family history of diabetes. Diabetes Care1998;21:350‐9. ">Wing 1998</a>; <a href="./references#CD003054-bbs2-0053" title="YatesT , DaviesMJ , HensonJ , TroughtonJ , EdwardsonC , GrayLJ , et al. Walking away from type 2 diabetes: trial protocol of a cluster randomised controlled trial evaluating a structured education programme in those at high risk of developing type 2 diabetes. BMC Family Practice2012;13:46. [PUBMED: 22642610] ">Yates 2012</a>). We excluded three trials published in three references as they did not allocate the participants to diet, physical activity or both by randomisation (<a href="./references#CD003054-bbs2-0016" title="De laRosaA , FogelfeldL , KolishJ , SanghaniR , PikelnyI , StrongerJH . Detecting and managing metabolic syndrome: preliminary results. Ethnicity and Disease2007;17(S5):24‐5. ">De la Rosa 2007</a>; <a href="./references#CD003054-bbs2-0019" title="ErikssonKF , LindgardeF . Prevention of type 2 (non‐insulin‐dependent) diabetes mellitus by diet and physical exercise. The 6‐year Malmo feasibility study. Diabetologia1991;34:891‐8. ">Eriksson 1991</a>; <a href="./references#CD003054-bbs2-0045" title="TaoLL , DengYB , FanXB , BaoQD . Effect of exercise training in patients with impaired glucose tolerance. Zhongguo Linchuang Kangfu2004;8:2912‐3. ">Tao 2004</a>). We excluded one trial due to inadequate description of the intervention group (<a href="./references#CD003054-bbs2-0040" title="SartorG , ScherstenB , CarlstromS , MelanderA , NordenA , PerssonG . Ten‐year follow‐up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes1980;29(1):41‐9. [PUBMED: 7380107] ">Sartor 1980</a>). We excluded 10 trials in 18 references as they did not compare the interventions of interest for this review (<a href="./references#CD003054-bbs2-0021" title="GreyM , BerryD , DavidsonM , GalassoP , GustafsonE , MelkusGD . Preliminary testing of a program to prevent type 2 diabetes among high risk youth. The Journal of School Health2004;74(1):10‐5. ">Grey 2004</a>; <a href="./references#CD003054-bbs2-0024" title='JarrettRJ , KeenH , FullerJH , McCartneyM . Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia1979;16(1):25‐30. [PUBMED: 761734] '>Jarrett 1979</a>; <a href="./references#CD003054-bbs2-0028" title="ISRCTN80605705. www.isrctn.com/ISRCTN80605705 (accessed 27 March 2017). NCT00677937. clinicaltrials.gov/ct2/show/NCT00677937 (accessed 27 March 2017). DaviesMJ , GrayLJ , AhrabianD , CareyM , FarooqiA , GrayA , et al. A community‐based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. Programme Grants Applied Research2017;5(2):‐. DaviesMJ , GrayLJ , TroughtonJ , GrayA , TuomilehtoJ , FarooqiA , et al. A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine2016;84:48‐56. [PUBMED: 26740346] GrayLJ , KhuntiK , WilliamsS , GoldbyS , TroughtonJ , YatesT , et al. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi‐ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology2012;11:56. [PUBMED: 22607160] GrayLJ , YatesT , TroughtonJ , KhuntiK , DaviesMJ . Engagement, retention, and progression to type 2 diabetes: a retrospective analysis of the cluster‐randomised &quot;Let's Prevent Diabetes&quot; trial. PLoS Medicine2016;13(7):e1002078. [PUBMED: 27404094] LealJ , AhrabianD , DaviesMJ , GrayLJ , KhuntiK , YatesT , et al. Cost‐effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster‐randomised controlled trial. BMJ Open2017;7(1):e013592. [PUBMED: 28069625] ">Let's Prevent</a>; <a href="./references#CD003054-bbs2-0029" title="CarrDB , UtzschneiderKM , BoykoEJ , AsberryPJ , HullRL , KodamaK , et al. A reduced‐fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra‐abdominal fat and improves insulin sensitivity but not beta‐cell function. Diabetes2005;54(2):340‐7. LiaoD , AsberryPJ , ShoferJB , CallahanH , MatthysC , BoykoEJ , et al. Improvement of BMI, body composition, and body fat distribution with lifestyle modification in Japanese Americans with impaired glucose tolerance. Diabetes Care2002;25(9):1504‐10. ">Liao 2002</a>; <a href="./references#CD003054-bbs2-0032" title="NandithaA , RamJ , SnehalathaC , SelvamS , PriscillaS , ShettyAS , et al. Early improvement predicts reduced risk of incident diabetes and improved cardiovascular risk in prediabetic Asian Indian men participating in a 2‐year lifestyle intervention program. Diabetes Care2014;37(11):3009‐15. [PUBMED: 25216506] ">Nanditha 2014</a>; <a href="./references#CD003054-bbs2-0033" title="NCT02250066. clinicaltrials.gov/ct2/show/NCT02250066 (accessed 10 April 2017). ">NCT02250066</a>; <a href="./references#CD003054-bbs2-0036" title="Study protocol. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4149 (accessed 3 April 2017). ">PULSE</a>; <a href="./references#CD003054-bbs2-0039" title="Study protocol. rctportal.niph.go.jp/en/detail?trial_id=UMIN000001959 (accessed 29 March 2017). SaitoT , WatanabeM , NishidaJ , IzumiT , OmuraM , TakagiT , et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Archives of Internal Medicine2011;171(15):1352‐60. [PUBMED: 21824948] ">Saito 2011</a>; <a href="./references#CD003054-bbs2-0049" title="WeinP , BeischerN , HarrisC , PermezelM . A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. The Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1999;39(2):162‐6. [PUBMED: 10755770] ">Wein 1999</a>; <a href="./references#CD003054-bbs2-0051" title="WongCK , FungCS , SiuSC , LoYY , WongKW , FongDY , et al. A short message service (SMS) intervention to prevent diabetes in Chinese professional drivers with pre‐diabetes: a pilot single‐blinded randomized controlled trial. Diabetes Research and Clinical Practice2013;102(3):158‐66. [PUBMED: 24466598] ">Wong 2013</a>). Of these, seven trials in 14 references compared the same intensity of the diet plus physical activity intervention, but applied the advice differently (e.g. one visit per year versus four visits per year) (<a href="./references#CD003054-bbs2-0021" title="GreyM , BerryD , DavidsonM , GalassoP , GustafsonE , MelkusGD . Preliminary testing of a program to prevent type 2 diabetes among high risk youth. The Journal of School Health2004;74(1):10‐5. ">Grey 2004</a>; <a href="./references#CD003054-bbs2-0028" title="ISRCTN80605705. www.isrctn.com/ISRCTN80605705 (accessed 27 March 2017). NCT00677937. clinicaltrials.gov/ct2/show/NCT00677937 (accessed 27 March 2017). DaviesMJ , GrayLJ , AhrabianD , CareyM , FarooqiA , GrayA , et al. A community‐based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. Programme Grants Applied Research2017;5(2):‐. DaviesMJ , GrayLJ , TroughtonJ , GrayA , TuomilehtoJ , FarooqiA , et al. A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let's Prevent Diabetes cluster randomised controlled trial. Preventive Medicine2016;84:48‐56. [PUBMED: 26740346] GrayLJ , KhuntiK , WilliamsS , GoldbyS , TroughtonJ , YatesT , et al. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi‐ethnic UK population with screen detected impaired glucose regulation. Cardiovascular Diabetology2012;11:56. [PUBMED: 22607160] GrayLJ , YatesT , TroughtonJ , KhuntiK , DaviesMJ . Engagement, retention, and progression to type 2 diabetes: a retrospective analysis of the cluster‐randomised &quot;Let's Prevent Diabetes&quot; trial. PLoS Medicine2016;13(7):e1002078. [PUBMED: 27404094] LealJ , AhrabianD , DaviesMJ , GrayLJ , KhuntiK , YatesT , et al. Cost‐effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster‐randomised controlled trial. BMJ Open2017;7(1):e013592. [PUBMED: 28069625] ">Let's Prevent</a>; <a href="./references#CD003054-bbs2-0032" title="NandithaA , RamJ , SnehalathaC , SelvamS , PriscillaS , ShettyAS , et al. Early improvement predicts reduced risk of incident diabetes and improved cardiovascular risk in prediabetic Asian Indian men participating in a 2‐year lifestyle intervention program. Diabetes Care2014;37(11):3009‐15. [PUBMED: 25216506] ">Nanditha 2014</a>; <a href="./references#CD003054-bbs2-0036" title="Study protocol. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4149 (accessed 3 April 2017). ">PULSE</a>; <a href="./references#CD003054-bbs2-0039" title="Study protocol. rctportal.niph.go.jp/en/detail?trial_id=UMIN000001959 (accessed 29 March 2017). SaitoT , WatanabeM , NishidaJ , IzumiT , OmuraM , TakagiT , et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Archives of Internal Medicine2011;171(15):1352‐60. [PUBMED: 21824948] ">Saito 2011</a>; <a href="./references#CD003054-bbs2-0049" title="WeinP , BeischerN , HarrisC , PermezelM . A trial of simple versus intensified dietary modification for prevention of progression to diabetes mellitus in women with impaired glucose tolerance. The Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1999;39(2):162‐6. [PUBMED: 10755770] ">Wein 1999</a>; <a href="./references#CD003054-bbs2-0051" title="WongCK , FungCS , SiuSC , LoYY , WongKW , FongDY , et al. A short message service (SMS) intervention to prevent diabetes in Chinese professional drivers with pre‐diabetes: a pilot single‐blinded randomized controlled trial. Diabetes Research and Clinical Practice2013;102(3):158‐66. [PUBMED: 24466598] ">Wong 2013</a>). We furthermore excluded 16 systematic reviews (<a href="./references#CD003054-bbs2-0070" title="AguiarEJ , MorganPJ , CollinsCE , PlotnikoffRC , CallisterR . Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta‐analysis. The International Journal of Behavioral Nutrition and Physical Activity2014;11:2. [PUBMED: 24423095] ">Aguiar 2014</a>; <a href="./references#CD003054-bbs2-0087" title="GillettM , RoyleP , SnaithA , ScotlandG , PoobalanA , ImamuraM , et al. Non‐pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2012;16(33):1‐236, iii‐iv. [PUBMED: 22935084] ">Gillett 2012</a>; <a href="./references#CD003054-bbs2-0088" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. [MEDLINE: 17237299] ">Gillies 2007</a>; <a href="./references#CD003054-bbs2-0089" title="GlechnerA , HarreiterJ , GartlehnerG , RohlederS , KautzkyA , TuomilehtoJ , et al. Sex‐specific differences in diabetes prevention: a systematic review and meta‐analysis. Diabetologia2015;58(2):242‐54. [PUBMED: 25465437] ">Glechner 2015</a>; <a href="./references#CD003054-bbs2-0090" title="GongQH , KangJF , YingYY , LiH , ZhangXH , WuYH , et al. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta‐analysis of the effects on glycemic control. Internal Medicine (Tokyo, Japan)2015;54(3):303‐10. [PUBMED: 25748739] ">Gong 2015</a>; <a href="./references#CD003054-bbs2-0101" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD003054-bbs2-0103" title="Institute for Clinical and Economic Review. Diabetes prevention programs: effectiveness and value. Final Evidence Report and Meeting SummaryJuly 2016. ">ICER 2016</a>; <a href="./references#CD003054-bbs2-0123" title="SLNorris , XZhang , AAvenell , EGregg , CHSchmid , LauJ . Long‐term non‐pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews2005;Issue 2:CD005270. [DOI: 10.1002/14651858.CD005270] ">Norris 2005</a>; <a href="./references#CD003054-bbs2-0128" title="SantaguidaPL , BalionC , HuntD , MorrisonK , GersteinH , RainaP , et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary)2005;128:1‐11. [PUBMED: 16194123] ">Santaguida 2005</a>; <a href="./references#CD003054-bbs2-0131" title="SelphS , DanaT , BougatsosC , BlazinaI , PatelH , ChouR . Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews2015; Vol. Report no.:13‐05190‐EF‐1. [PUBMED: 25973510] ">Selph 2015</a>; <a href="./references#CD003054-bbs2-0135" title="StevensJW , KhuntiK , HarveyR , JohnsonM , PrestonL , WoodsHB , et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta‐analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice2015;107(3):320‐31. [PUBMED: 25638454] ">Stevens 2015</a>; <a href="./references#CD003054-bbs2-0148" title="YamaokaK , TangoT . Efficacy of lifestyle education to prevent type 2 diabetes. A meta‐analysis of randomized controlled trials. Diabetes Care2005;28:2780‐6. ">Yamaoka 2005</a>; <a href="./references#CD003054-bbs2-0149" title="YatesT , KhuntiK , BullF , GorelyT , DaviesMJ . The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia2007;50(6):1116‐26. [PUBMED: 17415549] ">Yates 2007</a>; <a href="./references#CD003054-bbs2-0150" title="YoonU , KwokLL , MagkidisA . Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism: Clinical and Experimental2013;62(2):303‐14. [PUBMED: 22959500] ">Yoon 2013</a>; <a href="./references#CD003054-bbs2-0152" title="YuenA , SugengY , WeilandTJ , JelinekGA . Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health2010;34(2):172‐8. [PUBMED: 23331362] ">Yuen 2010</a>; <a href="./references#CD003054-bbs2-0154" title="ZhengL , WuJ , WangG , PersuitteG , MaY , ZouL , et al. Comparison of control fasting plasma glucose of exercise‐only versus exercise‐diet among a pre‐diabetic population: a meta‐analysis. European Journal of Clinical Nutrition2016;70(4):424‐30. [PUBMED: 26330149] ">Zheng 2016</a>). </p> </section> </section> <section id="CD003054-sec-0092"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of the included trials see <a href="./references#CD003054-sec-0225" title="">Characteristics of included studies</a>. </p> <p>For an overview of review authors' judgements about each risk of bias item for individual trials and across all trials see <a href="#CD003054-fig-0002">Figure 2</a> and <a href="#CD003054-fig-0003">Figure 3</a>. No trial was free from risk of bias in all 'Risk of bias' domains. </p> <div class="figure" id="CD003054-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not investigated in some studies)." data-id="CD003054-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not investigated in some studies). </p> </div> </div> </div> <div class="figure" id="CD003054-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not report that particular outcome)." data-id="CD003054-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not report that particular outcome). </p> </div> </div> </div> <section id="CD003054-sec-0093"> <h4 class="title">Allocation</h4> <p>We judged eight of the trials to be at low risk of selection bias with regard to the method of randomisation and allocation concealment (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>The remaining trials reported that the participants were randomised but provided no further description (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>We evaluated trial baseline data for our predefined prognostic baseline variables. In one trial a significantly larger proportion of control participants reported engaging in regular physical activity at least once a week compared with intervention participants (53% versus 24%) and there were fewer women (10/32 (32%)) than men (22/32 (69%)) in the control group compared with the diet plus physical activity group (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). Another trial reported that physical activity was significantly higher at baseline in the diet plus physical activity group than in the control group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0094"> <h4 class="title">Blinding</h4> <p>Double‐blinding was not possible or practical in the included trials due to the type of intervention. </p> <p>One trial mentioned that an independent outcome committee evaluated the incidence of T2DM (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). None of the remaining trials reported that a blinded outcome committee was instituted to assess outcomes during the intervention period. </p> <p>Where measured, all primary outcomes of this review were investigator assessed and we judged these to be at low risk of performance and detection bias. All the included trials reported blood glucose measurements performed by the investigators and we judged these outcomes measures to be at low risk of performance and detection bias. Two trials explicitly stated that glycaemic measures were masked for the investigators and participants until diabetes was confirmed (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). Non‐serious adverse events and mild hypoglycaemia were partly or exclusively self‐reported in all trials. Overall, we considered the risk of performance bias and detection bias to be low or unclear for our secondary outcomes. </p> </section> <section id="CD003054-sec-0095"> <h4 class="title">Incomplete outcome data</h4> <p>We considered overall risk of attrition bias to be unclear for most of our outcomes. Ten trials reported the number of participants randomised and finishing the trial for each intervention group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Two trials did not describe how many participants were initially randomised to each intervention group but reported the number analysed (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). Three trials provided details on the participants not completing the trial (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </section> <section id="CD003054-sec-0096"> <h4 class="title">Selective reporting</h4> <p>Six of the trials had a published protocol (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). We judged one trial as low risk of selective outcome reporting bias after the investigators provided additional information (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). We judged eight of the included trials to be at high risk of reporting bias on one or more of the outcomes of relevance for our review (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). Three trials had an unclear risk of selective outcome reporting bias (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Two of the judgments of unclear risk of selective outcome reporting bias were based on lack of trial protocol (<a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>) and one trial because the primary outcome was changed during the trial (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). For more details see <a href="./appendices#CD003054-sec-0202">Appendix 6</a> and <a href="./appendices#CD003054-sec-0203">Appendix 7</a>. One trial had a low risk of selective outcome reporting bias (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> <section id="CD003054-sec-0097"> <h4 class="title">Other potential sources of bias</h4> <p>We judged five trials to be at low risk of other bias (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Three trials had an unclear risk of other bias (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). We judged four trials to be at high risk of other bias, either because the trial was terminated early for benefit (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>) or because trial authors did not report an ICC coefficient in their cluster‐RCT making it necessary to estimate this coefficient (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>Four of the included trials had received grants from a pharmaceutical company and we judged these as unclear risk of other bias (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). One trial did not report funding source (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). It is known that receiving funding or provision of free drugs or devices from a pharmaceutical company leads to more favourable results and conclusions than sponsorship from other sources (<a href="./references#CD003054-bbs2-0113" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. The Cochrane Database of Systematic Reviews2017;2:MR000033. [PUBMED: 28207928] ">Lundh 2017</a>). One trial prolonged the intervention period without any explanation (<a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> </section> </section> <section id="CD003054-sec-0098"> <h3 class="title" id="CD003054-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD003054-tbl-0001"><b>Summary of findings for the main comparison</b> Diet plus physical activity versus standard treatment</a>; <a href="./full#CD003054-tbl-0002"><b>Summary of findings 2</b> Diet versus physical activity or standard treatment</a>; <a href="./full#CD003054-tbl-0003"><b>Summary of findings 3</b> Physical activity versus standard treatment</a> </p> <section id="CD003054-sec-0099"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD003054-sec-0199">Appendix 3</a>; <a href="./appendices#CD003054-sec-0200">Appendix 4</a> and <a href="./appendices#CD003054-sec-0201">Appendix 5</a>. </p> </section> <section id="CD003054-sec-0100"> <h4 class="title">Diet versus comparator</h4> <p>One trial compared diet with one or more comparators (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). This trial had four intervention arms: diet only, physical activity only, diet plus physical activity and standard treatment (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The trial was cluster randomised. The trial had an extended follow‐up period of 17 years. No ICC coefficient was reported. Based on an anticipated ICC coefficient of 0.05 we assumed a design effect of 1.75 (<a href="./references#CD003054-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In the post‐interventional follow‐up period the trialists combined the three intervention groups into one composite intervention group. Data for the extended follow‐up period for the combined intervention groups are described in the section 'Diet plus physical activity versus standard treatment'. </p> </section> <section id="CD003054-sec-0101"> <h4 class="title">Diet versus physical activity</h4> <p>Only one trial compared diet with physical activity in one of its trial arms (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The overall quality of evidence was very low because of risk of reporting and other bias and serious imprecision (very sparse data) </p> <section id="CD003054-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD003054-sec-0103"> <h6 class="title">All‐cause mortality</h6> <p>Three out of 130 participants in the diet‐only trial arm compared with none out of 141 participants in the physical activity‐only trial arm died during the intervention period (when adjusting for cluster‐RCT design: 2/74 versus 0/81). None of the participants died due to cardiovascular disease. None of the participants who died had developed T2DM before death. </p> </section> <section id="CD003054-sec-0104"> <h6 class="title">Incidence of T2DM</h6> <p>The incidence of T2DM was the primary outcome. T2DM was defined according to the WHO 1985 criteria (either a FPG ≥ 140 mg/dL (7.8 mmol/L) or higher or a two‐hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) after 75 g OGTT) and confirmed with a repeated test 7 to 14 days after the first test or from a report of physician‐diagnosed diabetes with evidence in the medical record of high glucose concentrations, or use of glucose‐lowering drugs. Fifty‐seven out of 130 participants in the diet‐only group compared with 58 participants out of 141 in the physical activity only group developed T2DM during the intervention period (when adjusting for cluster‐RCTdesign: 33/74 versus 33/81). The cumulative incidence of T2DM at six years was 43.8% (95% CI 35.3 to 52.3) in the diet only group compared with 41.1% (95% CI 33.4 to 49.4) in the physical activity only group (not adjusted for clustering). In the diet only group the incidence rate of T2DM was 10.0/100 person years (95% CI 7.5 to 12.5) compared with 8.3/100 person years (95% CI 6.4 to 10.3) in the physical activity only group (not adjusted for clustering). When analysing the incidence according to FPG 7.8 mmol/L or above, the rate was 3.7/100 person years (95% CI 2.1 to 5.3) in the diet only group compared with 5.3/100 person years (95% CI 3.6 to 7.0) in the physical activity only group (not adjusted for clustering). </p> <p>Due to the differences in dietary advice according to BMI, <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> evaluated separately the incidence of T2DM in those who had a BMI at baseline less than 25 kg/m<sup>2</sup> or 25 kg/m<sup>2</sup> or higher. Of the lean participants (BMI at baseline &lt; 25 kg/m<sup>2</sup>), 21 (38.2%) out of 55 participants in the diet only compared with 15 (26.5%) out of 57 participants in the physical activity only group developed T2DM during the intervention period (when adjusting for clustering 12/31 versus 9/33). Of the overweight participants (BMI at baseline ≥ 25 kg/m<sup>2</sup>), 36 (48%) out of 75 participants in the diet only compared with 43 (51.2%) out of 84 participants in the physical activity group developed T2DM during the intervention period (when adjusting for clustering 21/43 versus 26/46). </p> <p>Of the 263 diabetes diagnoses made in all the intervention groups during the six years of intervention, 55 (21%) diagnoses were initially made by local physicians and confirmed by the city hospital with an OGTT; 208 (79%) were made as a result of the systematic OGTT during the trial. </p> </section> <section id="CD003054-sec-0105"> <h6 class="title">Serious adverse events</h6> <p>No (serious) adverse events occurred in both groups.</p> </section> </section> <section id="CD003054-sec-0106"> <h5 class="title">Secondary outcomes</h5> <section id="CD003054-sec-0107"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the participants in either group died of cardiovascular reasons.</p> </section> <section id="CD003054-sec-0108"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Not reported, however from a published abstract it was apparent that cardiovascular events were collected during the trial. </p> </section> <section id="CD003054-sec-0109"> <h6 class="title">Non‐fatal stroke</h6> <p>Not reported, however from a published abstract it was apparent that cardiovascular events were collected during the trial. </p> </section> <section id="CD003054-sec-0110"> <h6 class="title">Amputation of lower extremity</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0111"> <h6 class="title">Blindness or severe vision loss</h6> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> reported the incidence of severe retinopathy among the participants originally assigned to diet only (4.5/1000 person years (95% CI 1.8 to 7.1)) compared with physical activity only (5.3/1000 person years (95% CI 2.5 to 8.0)) after 20 years of follow‐up (i.e. 14 years after the end of intervention). This difference was not statistically significant. </p> </section> <section id="CD003054-sec-0112"> <h6 class="title">End‐stage renal disease</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0113"> <h6 class="title">Non‐serious adverse events</h6> <p>No adverse events occurred in either group.</p> </section> <section id="CD003054-sec-0114"> <h6 class="title">Hypoglycaemia</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0115"> <h6 class="title">Health‐related quality of life</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0116"> <h6 class="title">Time to progression to T2DM</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0117"> <h6 class="title">Measures of blood glucose control</h6> <section id="CD003054-sec-0118"> <p><b>Fasting glucose</b></p> <p>At the end of follow‐up after six years of intervention, FPG in the diet only group was 7.0 mmol/L (SD 4.4) based on 130 participants (74 participants when adjusting for clustering) compared with 6.8 mmol/L (SD 2.2) in 141 participants (81 participants when adjusting for clustering) in the physical activity group. </p> </section> <section id="CD003054-sec-0119"> <p><b>Glucose two hours after an oral glucose load</b></p> <p>At the end of follow‐up after six years of intervention, two‐hour glucose after an oral glucose load in the diet only group was 10.5 mmol/L (SD 4.9) based on 130 participants (74 participants when adjusting for clustering) compared with 10.5 mmol/L (SD 3.9) in 141 participants (81 participants when adjusting for clustering) in the physical activity group. </p> </section> <section id="CD003054-sec-0120"> <p><b>HbA1c</b></p> <p>Not reported.</p> </section> </section> <section id="CD003054-sec-0121"> <h6 class="title">Socioeconomic effects</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD003054-sec-0122"> <h4 class="title">Diet versus standard treatment</h4> <p>Only one trial compared diet with standard treatment in one of its trial arms (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The overall quality of evidence was very low because of risk of reporting and other bias and serious imprecision (very sparse data) </p> <section id="CD003054-sec-0123"> <h5 class="title">Primary outcomes</h5> <section id="CD003054-sec-0124"> <h6 class="title">All‐cause mortality</h6> <p>Three out of 130 participants in the diet only group compared with three participants out of 133 in the standard treatment group died during the intervention period (when adjusting for cluster‐design: 2/74 versus 2/76). None of the participants died because of cardiovascular disease. None of the participants who died had developed T2DM before death. The HR (adjusted for age and clustering) when combining diet only, physical activity only and diet plus physical activity compared with standard treatment was 1.33 (95% CI 0.45 to 3.92) at the end of the intervention period. </p> </section> <section id="CD003054-sec-0125"> <h6 class="title">Incidence of T2DM</h6> <p>Fifty‐seven out of 130 participants in the diet only group compared with 90 participants out of 133 in the standard treatment group developed T2DM during the intervention period (when adjusting for cluster design: 33/74 versus 51/76). </p> <p>The cumulative incidence of T2DM at six years was 43.8% (95% CI 35.3 to 52.3) in the diet only group compared with 67.7% (95% CI 59.8 to 75.2) in the standard treatment group (not adjusted for clustering). In the diet only group, the incidence rate of T2DM (defined according to WHO 1985) was 10.0/100 person years (95% CI 7.5 to 12.5) compared with 15.7/100 person years (95% CI 12.7 to 18.7) in the standard treatment group (not adjusted for clustering). When analysing the incidence according to FPG 7.8 mmol/L or higher, the rate was 3.7/100 person years (95% CI 2.1 to 5.3) in the diet only group compared with 9.6/100 person years (95% CI 7.2 to 12.0) in the standard treatment group (not adjusted for clustering). </p> <p>Due to the differences in dietary advice according to BMI, the trialists evaluated separately incidence of T2DM in those who had BMI at baseline less than 25 kg/m<sup>2</sup> or 25 kg/m<sup>2</sup> or higher. Of the lean participants (BMI at baseline &lt; 25 kg/m<sup>2</sup>) 21 (38.2%) out of 55 participants in the diet only group compared with 30 (60%) out of 50 participants in the standard treatment group developed T2DM during the intervention period (when adjusting for clustering 12/31 versus 17/29). Of the obese participants (BMI at baseline ≥ 25 kg/m<sup>2</sup>) 36 (48%) out of 75 participants in the diet only group compared with 60 (72.3%) out of 83 participants in the standard treatment group developed T2DM during the intervention period (when adjusting for clustering 21/43 versus 34/47). </p> <p>After 20 years of follow‐up (i.e. 14 years after the intervention had stopped) the HR (adjusted for age and clustering) for the diet only group versus standard treatment group was 0.58 (95% CI 0.38 to 0.89). </p> </section> <section id="CD003054-sec-0126"> <h6 class="title">Serious adverse events</h6> <p>No (serious) adverse events occurred in either group.</p> </section> </section> <section id="CD003054-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD003054-sec-0128"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the participants in either group died of cardiovascular reasons.</p> </section> <section id="CD003054-sec-0129"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>Not reported, however from a published abstract it was apparent that cardiovascular events were collected during the trial. </p> </section> <section id="CD003054-sec-0130"> <h6 class="title">Non‐fatal stroke</h6> <p>Not reported, however from a published abstract it was apparent that cardiovascular events were collected during the trial. </p> </section> <section id="CD003054-sec-0131"> <h6 class="title">Amputation of lower extremity</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0132"> <h6 class="title">Blindness er severe vision loss</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0133"> <h6 class="title">End‐stage renal disease</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0134"> <h6 class="title">Non‐serious adverse events</h6> <p>No adverse events occurred in either group.</p> </section> <section id="CD003054-sec-0135"> <h6 class="title">Hypoglycaemia</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0136"> <h6 class="title">Health‐related quality of life</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0137"> <h6 class="title">Time to progression to T2DM</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0138"> <h6 class="title">Measures of blood glucose control</h6> <section id="CD003054-sec-0139"> <p><b>Fasting glucose</b></p> <p>FPG at the end of follow‐up after six years of intervention in the diet only group was 7.0 mmol/L (SD 4.4) based on 130 participants (74 participants when adjusting for clustering) compared with 7.6 mmol/L (SD 2.6) in 133 participants (76 participants when adjusting for clustering) in the standard treatment group. </p> </section> <section id="CD003054-sec-0140"> <p><b>Glucose two hours after an oral glucose load</b></p> <p>Glucose two hours after an oral glucose load at the end of follow‐up after six years of intervention in the diet only group was 10.5 mmol/L (SD 4.9) based on 130 participants (74 participants when adjusting for clustering) compared with 12.4 mmol/L (SD 4.2) in 133 participants (76 participants when adjusting for clustering) in the standard treatment group. </p> </section> <section id="CD003054-sec-0141"> <p><b>HbA1c</b></p> <p>Not reported.</p> </section> </section> <section id="CD003054-sec-0142"> <h6 class="title">Socioeconomic effects</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD003054-sec-0143"> <h4 class="title">Physical activity versus standard treatment</h4> <p>Two trials compared physical activity with one or more controls (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> had four intervention arms: diet only, physical activity only, diet plus physical activity and standard treatment (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The trial was cluster randomised. No ICC coefficient was reported. Based on an anticipated ICC coefficient of 0.05 we assumed a design effect of 1.75 (<a href="./references#CD003054-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In the post‐interventional follow‐up period, <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> combined the three intervention groups into one composite intervention group. Data for the extended follow‐up period for the combined intervention group are described in the section 'Diet plus physical activity versus standard treatment'. </p> <p>One trial had two physical activity groups (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>), and initially analysed data from these two groups separately (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). As the outcomes proved to be essentially the same in both groups, they analysed the physical activity groups together and thereafter designated them as the combined physical activity group. Both intervention arms in <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> had a more intense physical activity strategy than the comparator group.The diet advice was identical in the physical activity groups and the standard treatment group. </p> <p>The two trials comparing physical activity with standard treatment varied according to several important prognostic baseline characteristics (e.g. <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> included only Asian Chinese and the average age of the participants was about 45 years compared with <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> including presumably only white people with an average age of participants of 63 years). <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> included people with IGT according to the WHO 1985 criteria. <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> included participants with IGT, IFG or both. <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> had a duration of the intervention of six years compared with three years in <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>. </p> <p>The overall quality of evidence was very low mainly because of risk of bias and imprecision (sparse data) </p> <section id="CD003054-sec-0144"> <h5 class="title">Primary outcomes</h5> <section id="CD003054-sec-0145"> <h6 class="title">All‐cause mortality</h6> <p>One trial reported that none of the 141 participants in the physical activity only group compared with three participants out of 133 in the standard treatment group died during the intervention period (when adjusting for cluster‐RCT design: 0/81 versus 2/76) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). None of the participants who died had developed T2DM before death. The HR (adjusted for age and clustering) when combining diet only, physical activity only and diet plus physical activity compared with standard treatment was 1.33 (95% CI 0.45 to 3.92) at the end of the intervention period (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The other trial reported that four participants died; three out of 84 in the physical activity group and one out of 39 in the standard treatment group. It was not possible to judge to which group the deceased participants had originally been randomised, however, the investigators provided this additional information (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) (<a href="./references#CD003054-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD003054-sec-0146"> <h6 class="title">Incidence of type 2 diabetes</h6> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>'s primary outcome was the incidence of T2DM, which they defined according to the WHO 1985 criteria (either a FPG ≥ 7.8 mmol/L or higher or a two‐hour plasma glucose ≥ 11.1 mmol/L after a 75 gram OGTT) and confirmed with a repeat test 7 to 14 days after the first test or from a report of physician‐diagnosed diabetes with evidence in the medical record of high glucose concentrations, or use of glucose‐lowering drugs. Fifty‐eight out of 141 participants in the physical activity only group compared with 90 participants out of 133 in the standard treatment group developed T2DM during the intervention period (when adjusting for cluster design: 33/84 versus 51/76) ‐ <a href="./references#CD003054-fig-0005" title="">Analysis 1.2</a>. </p> <p>The cumulative incidence of T2DM at six years was 41.1% (95% CI 33.4 to 49.4) in the physical activity only group compared with 67.7% (95% CI 59.8 to 75.2) in the standard treatment group (not adjusted for clustering). In the physical activity only group the incidence of T2DM (defined according to WHO 1985) was 8.3/100 person years (95% CI 6.4 to 10.3) compared with 15.7/100 person years (95% CI 12.7 to 18.7) in the standard treatment group (not adjusted for clustering). When analysing the incidence according to FPG 7.8 mmol/L or higher, the incidence of T2DM was 5.3/100 person years (95% CI 3.6 to 7.0) in the physical activity only group compared with 9.6/100 person years (95% CI 7.2 to 12.0) in the standard treatment group (not adjusted for clustering) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>Of the lean participants (BMI at baseline &lt; 25 kg/m<sup>2</sup>), 15 (26.3%) out of 57 participants in the physical activity only group compared with 30 (60%) out of 50 in the standard treatment group developed T2DM during the intervention period (when adjusting for clustering 9/33 versus 17/29). Of the overweight participants (BMI at baseline ≥ 25 kg/m<sup>2</sup>), 43 (51.2%) out of 84 participants in the physical activity only group compared with 60 (72.3%) out of 83 participants in the standard treatment group developed T2DM during the intervention period (when adjusting for clustering 25/48 versus 34/47) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>For all the 263 diabetes diagnoses made in all the intervention groups during the six years of intervention in <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>, 55 diagnoses (21%) were initially made by local physicians and confirmed by the city hospital with an OGTT; 208 (79%) were made as a result of the systematic OGTT during the trial. </p> <p>The other trial reporting T2DM defined the condition by FPG more than 6.9 mmol/L and/or two‐hour plasma glucose concentration more than 12.1 mmol/L (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). Ten (11.9%) out of 84 participants in the physical activity group compared with seven (17.9%) out of 39 participants in the standard treatment group developed T2DM during the intervention period (<a href="./references#CD003054-fig-0005" title="">Analysis 1.2</a>). </p> <p>In the physical activity group 32 participants had IGT only; 38 had IFG only and 11 had IGT and IFG combined. Of the 32 participants with IGT at baseline in the physical activity group, seven (22%) developed T2DM; of the 38 with IFG at baseline, three (7.8%) developed T2DM; of the 11 with combined IFG and IGT, two (18.2%) developed T2DM. In the standard treatment group 15 participants had IGT only; 21 had IFG only and six had IGT and IFG combined. Of the 15 participants with IGT at baseline in the standard treatment group five (33%) developed T2DM; of the 21 with IFG at baseline, two (7.8%) developed T2DM; of the six with combined IFG and IGT, four (66.7%) developed T2DM (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). The number of the participants included in the subgroups of different glycaemic definitions of intermediate hyperglycaemia did not add up to the total number of participants developing T2DM provided by the investigators of the trial (physical activity 81 versus 84 and standard treatment 32 versus 39) (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). We contacted the investigators about the participants who did not participate in the final follow‐up and asked if these people had developed T2DM (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> <p>One trial had an extended follow‐up period (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The HR for the incidence of T2DM (adjusted for age and clustering) of physical activity versus standard treatment after 20 years of follow‐up was 0.51 (95% CI 0.31 to 0.83) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0147"> <h6 class="title">Serious adverse events</h6> <p>One trial reported that they did not observe any adverse events. However, this seems unlikely, because the publications indicated that serious adverse events were experienced (e.g. cardiovascular events) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The other trial did not publish any data on serious adverse events, but these were provided by the investigators (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). No further definition of the outcome was provided. Three (4.5%) out of 66 participants in the physical activity group versus one (2.6%) out of 39 participants in the standard treatment group experienced a serious adverse event (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) (<a href="./references#CD003054-fig-0006" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD003054-sec-0148"> <h5 class="title">Secondary outcomes</h5> <section id="CD003054-sec-0149"> <h6 class="title">Cardiovascular mortality</h6> <p>None of the participants in the groups died of cardiovascular reasons.</p> </section> <section id="CD003054-sec-0150"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>One trial reported that none of the 66 participants in the physical activity group compared with three (9.7%) of 31 participants in the standard treatment group experienced a non‐fatal myocardial infarction. No further definition of the outcome was provided. These data were provided by the investigators (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> <section id="CD003054-sec-0151"> <h6 class="title">Non‐fatal stroke</h6> <p>One trial reported that one (1.5%) out of 66 participants in the physical activity group compared with one (3.2%) out of 31 participants in the standard treatment group experienced a non‐fatal stroke. No further definition of the outcome was provided. These data were provided by the investigators (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> <section id="CD003054-sec-0152"> <h6 class="title">Amputation of lower extremity</h6> <p>One trial reported that none of the participants in the trial experienced an amputation of the lower extremity. No further definition of the outcome was provided. These data were provided by the investigators (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> <section id="CD003054-sec-0153"> <h6 class="title">Blindness or severe vision loss</h6> <p>Not reported</p> </section> <section id="CD003054-sec-0154"> <h6 class="title">End‐stage renal disease</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0155"> <h6 class="title">Non‐serious adverse events</h6> <p>One trial reported that no adverse event was observed (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0156"> <h6 class="title">Hypoglycaemia</h6> <p>One trial reported that none of the participants in the trial experienced hypoglycaemia. No further definition of the outcome was provided. These data were provided by the investigators (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). </p> </section> <section id="CD003054-sec-0157"> <h6 class="title">Health‐related quality of life</h6> <p>One of the trials comparing physical activity with standard treatment reported health‐related quality of life (HrQoL) (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). Information on this outcome was provided by the investigators. It is unclear whether they assessed HrQoL with a validated instrument. It was measured by two questions, where participants graded their total physical and mental health from 1 to 7. Participants also graded their general health from 1 (best) to 5 (very bad). There were questions about sleep and energy. The investigators reported that 13 participants (27%) in the physical activity group reported that HrQoL from baseline to end of follow‐up worsened, in 21 participants (43%) it was unchanged and in 14 participants (29%) it increased ‐ the total number of participants in the physical activity group included in the analyses was 48 participants. The investigators reported that eight participants (35%) in the standard treatment group rated themselves worsened, 10 participants (43%) remained unchanged and five participants (22%) improved ‐ the total number of participants in the standard treatment group included in the analyses was 23 (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). These data were provided by the investigators. </p> </section> <section id="CD003054-sec-0158"> <h6 class="title">Time to progression to type 2 diabetes</h6> <p>Not reported.</p> </section> <section id="CD003054-sec-0159"> <h6 class="title">Measures of blood glucose control</h6> <section id="CD003054-sec-0160"> <p><b>Fasting glucose</b></p> <p>FPG after six years of intervention in the physical activity group was 6.8 mmol/L (SD 2.2) based on 141 participants (81 participants when adjusting for clustering) compared with 7.6 mmol/L (SD 2.6) in 133 participants (76 participants when adjusting for clustering) in the standard treatment group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The investigators of <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> provided data on change in fasting plasma glucose on request (<a href="./references#CD003054-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD003054-sec-0161"> <p><b>Glucose two hours after an oral glucose load</b></p> <p>One trial reported glycaemic values after six years of intervention. The two‐hour glucose after an oral glucose load in the physical activity group was 10.5 mmol/L (SD 3.9) based on 141 participants (81 participants when adjusting for clustering) compared with 12.4 mmol/L (SD 4.2) in 133 participants (76 participants when adjusting for clustering) in the standard treatment group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The investigators of <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> provided data on change in glucose two hours after an OGTT on request (<a href="./references#CD003054-fig-0008" title="">Analysis 1.5</a>). </p> </section> <section id="CD003054-sec-0162"> <p><b>HbA1c</b></p> <p>Not reported.</p> </section> </section> <section id="CD003054-sec-0163"> <h6 class="title">Socioeconomic effects</h6> <p>Not reported.</p> </section> </section> </section> <section id="CD003054-sec-0164"> <h4 class="title">Diet plus physical activity versus standard treatment</h4> <p>Eleven trials compared the combination of diet plus physical activity with standard treatment or no intervention (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> had four intervention arms: diet only, physical activity only, diet plus physical activity and standard treatment. The trial was cluster randomised. The authors reported that HRs at 20 and 23 years of follow‐up were adjusted for clustering, but no information of adjustment for clustering was provided at the end of intervention. No ICC coefficient was reported (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). Based on an anticipated ICC coefficient of 0.05 we assumed a design effect of 1.75 (<a href="./references#CD003054-bbs2-0099" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). In the post‐intervention follow‐up period <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> combined the three intervention groups (diet only, physical activity only, diet plus physical activity) into one intervention group. Two other trials also reported data with relevance to this review after the intervention had been stopped (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> included people with IGT according to the WHO 1985 criteria (two‐hour plasma glucose ≥ 6.7 mmol/L and &lt; 11.0 mmol/L after an OGTT). </p> <p>Nine trials exclusively included people with IGT (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial included people with IGT, IFG or both (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). One trial included people with FPG levels between 5.3 to 6.9 mmol/L (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). </p> <section id="CD003054-sec-0165"> <h5 class="title">Primary outcomes</h5> <section id="CD003054-sec-0166"> <h6 class="title">All‐cause mortality</h6> <p>Ten trials reported data on all‐cause mortality (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). None of these trials had predefined all‐cause mortality as a primary outcome (see <a href="./appendices#CD003054-sec-0202">Appendix 6</a>). In <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> five out of 126 participants died in the diet plus physical activity group versus three out of 133 participants in the standard treatment group (when adjusted for clustering; diet plus physical activity three out of 72 participants versus standard treatment two out of 76 participants). Most of the trials reporting death were from trials with low risk of selection bias (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>A total of 12 deaths were reported in 2049 participants in the diet plus physical activity group versus 10 out of 2050 participants in the comparator group (RR 1.12, 95% CI 0.50 to 2.50; P = 0.86; 4099 participants, 10 trials; very low‐quality evidence). Funnel plot asymmetry was not present. The 95% prediction interval ranged from 0.44 to 2.88 (<a href="./references#CD003054-fig-0009" title="">Analysis 2.1</a>). </p> <p>Trial sequential analysis (TSA) showed that 0.61% of the diversity‐adjusted information size was accrued so far to detect or reject a 10% relative risk reduction (RRR). Diversity was zero, but we applied a diversity of 20% when calculating the diversity‐required information size, as heterogeneity is likely to increase when future trials are included. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR was accrued, we could not calculate the TSA‐adjusted 95% CIs with diversity at 20%. If a diversity of 0% was applied, then 0.77% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR. Still, we could not calculate the TSA‐adjusted 95% CIs. </p> <p>Subgroup analyses according to the duration of the intervention ((≥ 4 years) versus trials with short duration (&lt; 4 years)), diagnostic criteria (IGT versus other); age (≥ 50 years versus &lt; 50 years); ethnicity (Asian only versus other and mixed ethnicities); morbidity (BMI ≥ 30 kg/m<sup>2</sup> versus &lt; 30 kg/m<sup>2</sup>) showed no statistical significant interactions (<a href="./appendices#CD003054-sec-0214">Appendix 18</a>). We could not perform subgroup analyses according to sex and previous gestational diabetes due to lack of data. </p> <p>Sensitivity analyses including only trials with low risk of selection bias (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>) did not substantially change the effect estimate (RR 1.14, 95% CI 0.42 to 3.12; P = 0.79). </p> <p>One trial reported a HR (adjusted for age and clustering) when combining diet only, physical activity only and diet plus physical activity compared with control at the end of intervention (HR 1.33, 95% CI 0.45 to 3.92) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>Three trials comparing diet plus physical activity had extended follow‐up periods (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). Two of these reported mortality data during the follow‐up period (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> <p>One trial reported that six out of 257 participants originally randomised to diet plus physical activity group died compared with 10 out of 248 participants in the control arm after a median follow‐up of 10.6 years (i.e. 6.6 years after the intervention had stopped) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). Mortality in the former diet plus physical activity group was 2.2/1000 person years (95% CI 1.0 to 0.35) compared with 3.8/1000 person years (95% CI 2.0 to 7.0) in the former control group. The HR was 0.57 (95% CI 0.21 to 1.58) (unknown adjusting) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> <p>One trial reported a HR (adjusted for age and clustering) when combining diet only, physical activity only and diet plus physical activity compared with control to be 0.96 (95% CI 0.65 to 1.41) after 20 years of follow‐up (i.e. 14 years after the intervention had stopped) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The same trial reported 23 years of follow‐up (i.e. 17 years after the intervention had stopped); 121 out of 430 participants (after cluster‐adjustment: 69/246) allocated to the former intervention group (combined diet only, physical activity only and diet plus physical activity) versus 53 out of 138 (after cluster‐adjustment 30/79) in the former control group died (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The cumulative incidence of all‐cause mortality was 28.1% (95% CI 23.9 to 32.4) in the combined former intervention group and 38.4% (95% CI 30.3 to 46.5) in the former comparator group, with a HR (adjusted for cluster‐randomisation) of 0.71 (95% CI 0.51 to 0.99; P = 0.049). Deaths per 1000 person years were 14.3 (95% CI 11.8 to 16.9) in the combined former intervention group compared with 19.9 (95% CI 14.5 to 25.2) in the former comparator group. </p> <p>Post‐hoc subgroup analyses after 23 years of follow‐up showed that, among women, the cumulative incidence of all‐cause mortality in the former comparator group was elevated compared with the combined former intervention group (HR 0.46, 95% CI 0.24 to 0.87; P = 0.02). The number of deaths included in this post‐hoc analysis was 30 deaths in 200 women in the combined former intervention group compared with 17 deaths out of 59 women in the former comparator group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). For men the intervention did not show statistically significant differences (91 deaths among 230 male participants in the combined former intervention group compared with 36 deaths out of 79 participants in the former comparator group; HR 0.97 (95% CI 0.97 to 1.46). We performed multivariable analyses in order to test if different baseline characteristics could explain the differences (e.g. smoking, age), but the difference between men and women persisted. However, when the time to onset of T2DM was included in the multivariable models, then the intervention variable was no longer significant (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0167"> <h6 class="title">Incidence of type 2 diabetes</h6> <p>Eleven trials reported data on the incidence of T2DM. The definition of T2DM varied among the included trials. Three trials applied the WHO 1985 diagnostic criteria (either FPG ≥ 7.8 mmol/L or higher or a two‐hour plasma glucose ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>); four trials applied the WHO 1999 criteria to establish the diagnosis of T2DM (either FPG ≥ 7.0 mmol/L and/or a two‐hour plasma glucose concentration ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial established the diagnosis of T2DM based on the ADA 1997 diagnostic criteria (FPG ≥ 7.0 mmol/L or a two‐hour plasma glucose ≥ 11.1 mmol/L after a 75 g OGTT (i.e. identical to WHO 1999 criteria)) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). One trial applied FPG levels above 7.0 mmol/L to establish the diagnosis of T2DM (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). One trial applied FPG levels above 7.8 mmol/L to establish the diagnosis of T2DM (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>). One trial established the diagnosis of T2DM based on two‐hour plasma glucose of 11.1 mmol/L or higher after a 75 g OGTT (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Furthermore, four trials also defined the diagnosis of T2DM as reported by a physician or the use of glucose‐lowering drugs (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>A total of 315 out of 2122 participants developed T2DM in the diet plus physical activity group versus 614 out of 2389 participants in the comparator group (RR 0.57, 95% CI 0.50 to 0.64; P &lt; 0.00001; 4511 participants, 11 trials; moderate quality evidence). The 95% prediction interval ranged from 0.50 to 0.65. TSA showed firm evidence for a 10% RRR in favour of diet plus physical activity. Funnel plot asymmetry was not present (<a href="./references#CD003054-fig-0016" title="">Analysis 2.8</a>). </p> <p>Of the 12 participants in <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a> diagnosed with T2DM in the diet plus physical activity group, only two participants were diagnosed with OGTT at the third year of the trial. The remaining 10 participants who developed T2DM in the diet plus physical activity group during the trial were diagnosed by a physician. In the control group 10 participants were diagnosed with T2DM, based on a physicians' diagnosis and seven participants were diagnosed with the OGTT at the third year of the trial (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>The incidence rate of T2DM in the Japan Diabetes Prevention Program (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>) trial was 2.7/100 person years in the diet plus physical activity group compared with 5.1/100 person years in the control group. The JDPP trial included both lean and obese participants with a BMI ranging from 16.8 to 39.6 kg/m<sup>2</sup>. Additional analyses were made according to BMI at baseline. T2DM developed in five out of 52 participants in the lowest quartile (two from the control group and three from the intervention group) during the three years. An effect of the behaviour‐changing intervention was therefore not apparent in this lowest BMI quartile. However, the cut‐off point for the lower quartile was not available from the publication (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). Subgroup analysis for the participants with BMI more than 22.5 kg/m<sup>2</sup> revealed a significant decrease in the cumulative incidence of T2DM with the intervention (P = 0.027). The cumulative incidence of T2DM was significantly lower in the diet plus physical activity group compared with controls among participants with baseline HbA1c levels of 5.7% or higher, while this was not found among participants with baseline HbA1c levels less than 5.7% (<a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). </p> <p>The Indian Diabetes Prevention Programmes (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>) trial reported a cumulative incidence of T2DM at 39.3% (95% CI 30.4 to 48.5) in the diet plus physical activity group compared with 55.0% (95% CI 46 to 63.5) in the control group (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). The number of participants needed to be treated to prevent one T2DM case was 6.4. The HR for developing T2DM (adjusted for sex, age, family history of diabetes, BMI, waist circumference, baseline fasting and two‐hour glucose and corresponding insulin values, hypertension and smoking) for the diet plus physical activity group compared with the control group was 0.62 (95% CI 0.23 to 1.02; P = 0.018) (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). Plasma glucose two‐hour after an OGTT, fasting and two‐hour insulin showed independent influence on the development of T2DM (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). </p> <p>In <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> the incidence rate of T2DM in the diet plus physical activity group was 9.6/100 person years (95% CI 7.2 to 12.0) compared with 15.7/100 person years (95% CI 12.7 to 18.7) in the control group (not adjusted for clustering). When analysing the incidence rate of T2DM according to fasting plasma glucose of 7.8 mmol/L or higher, the incidence rate of T2DM was 5.5/100 person years (95% CI 3.7 to 7.3) in the diet plus physical activity group compared with 9.6/100 person years (95% CI 7.2 to 12.0) in the control group (not adjusted for clustering) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The HR (adjusted for age and clustering) when combining diet only, physical activity only and diet plus physical activity compared with control was 0.49 (95% CI 0.33 to 0.73). </p> <p>Of the lean participants (BMI at baseline &lt; 25 kg/m<sup>2</sup>), 16 (34.8%) out of 46 participants in the diet plus physical activity group compared with 30 (60%) out of 50 in the control group developed T2DM during the intervention period (when adjusting for clustering 9/26 versus 17/29). Of the obese participants (BMI at baseline ≥ 25 kg/m<sup>2</sup>), 42 (52.5%) out of 80 participants in the diet plus physical activity group compared with 60 (72.3%) out of 83 in the control group developed T2DM during the intervention period (when adjusting for clustering 24/46 versus 34/47) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>A total of 263 participants were diagnosed with T2DM during the six years of intervention; 55 diagnoses (21%) were initially made by local physicians and confirmed by the city hospital with an OGTT; 208 (79%) were made as a result of the systematic OGTTs during the trial (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>In <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a> the incidence rate of T2DM after a median of four years' intervention was 4.2/100 person years in the diet plus physical activity group compared with 7.4/100 person years in the control group. The HR (adjusted for sex, age, BMI, waist circumference, fasting and two‐hour glucose, insulin, homeostatic model assessment ‐ insulin resistance (HOMA‐IR), estimated risk with The Finnish Diabetes Risk Score (FINDRISC)) was 0.54 (95% CI 0.37 to 0.78) in favour of the diet plus physical activity group. Incidence and HRs were present for several baseline variables (sex, age, BMI, waist circumference; fasting plasma glucose; two‐hour glucose; fasting insulin; HOMA‐IR and FINDRISC) (<a href="./appendices#CD003054-sec-0215">Appendix 19</a>). The interaction between age at baseline as a continuous variable and intervention effect was statistically significant (P = 0.0130) (<a href="./appendices#CD003054-sec-0215">Appendix 19</a>). Baseline glycaemic (fasting and two‐hour glucose) status was directly associated with diabetes incidence in the diet plus physical activity group and the control group. However, the effect of intervention was independent of glycaemic status (<a href="./appendices#CD003054-sec-0215">Appendix 19</a>). </p> <p>The trial authors performed several subgroup analyses according to different prognostic baseline variables in <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> (<a href="./appendices#CD003054-sec-0215">Appendix 19</a>). Subgroup analyses found that treatment effects did not differ substantially according to sex, race or ethnic group; however, the effect of the behaviour‐changing intervention was greater among participants with lower baseline glucose concentrations two hours after a glucose load. </p> <p>One publication presented a composite analysis including three of the included trials (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). A total of 749 participants were included in the analyses with a mean follow‐up of 3.1 years (<a href="./references#CD003054-bbs2-0124" title="PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] ">Penn 2013</a>). The HR for the incidence of T2DM was 0.42, (95% CI 0.29 to 0.60; P &lt; 0.001) in favour of diet plus physical activity. On average 7.4 people had to undergo diet plus physical activity for a mean of 3.1 years to prevent one case of T2DM (number needed to treat for an additional beneficial outcome 22.9 for one year). </p> <p><b>Subgroup analysis</b>: analysing trials according to the duration of the intervention and diagnostic criteria showed no interaction between the subgroups (P = 0.88 and P = 0.42) (<a href="./references#CD003054-fig-0017" title="">Analysis 2.9</a>; <a href="./references#CD003054-fig-0018" title="">Analysis 2.10</a>) (<a href="./appendices#CD003054-sec-0214">Appendix 18</a>). Subgroup analyses stratifying the included trials according to age, ethnicity and obesity showed statistically significant interactions (<a href="./appendices#CD003054-sec-0214">Appendix 18</a>) (<a href="./references#CD003054-fig-0019" title="">Analysis 2.11</a>; <a href="./references#CD003054-fig-0020" title="">Analysis 2.12</a>; <a href="./references#CD003054-fig-0021" title="">Analysis 2.13</a>). However, the CIs in these analyses overlap to a small degree. As a caveat, these observations should be regarded as hypothesis‐generating only. We could not perform subgroup analyses according to sex and previous gestational diabetes due to lack of data. </p> <p><b>Sensitivity analysis</b>: we could not perform sensitivity analysis according to publication status (all included trials were published) and language of publication (all included trials were published in English). Sensitivity analysis restricted to only trials with low risk of selection bias showed a RR of 0.50 (95% CI 0.44 to 0.58; P &lt; 0.00001) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>), that is, it did not show substantial differences to including all trials. Analysing trials performed in Asia showed a RR of 0.67 (95% CI 0.56 to 0.82; P &lt;0.0001) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>); for trials performed in Europe, the RR was 0.54 (95% CI 0.41 to 0.72; P &lt; 0.0001) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>Three trials reported the incidence of T2DM after an extended follow‐up period (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). One trial reported the incidence of T2DM after nine years (i.e. five years after the end of the intervention period). A total of 106 in the diet plus physical activity group out of 265 participants versus 140 out of 257 participants in the control group were diagnosed with T2DM (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). The incidence of T2DM per 100 person years was 4.5 (95% CI 3.8 to 5.5) in the diet plus physical activity group versus 7.2 (95% CI 6.1 to 8.5) in the control group; the HR (adjusted for sex, age, BMI and two‐hour glucose) was 0.61 (95% CI 0.48 to 0.79; P &lt; 0.001) and the absolute risk reduction was 19%. The number needed to treat to prevent one case of T2DM was 5.2. In the post‐intervention follow‐up (median seven years), 62 out of 200 participants in the former diet plus physical activity group, compared with 68 out of 166 participants in the former control group were newly diagnosed with T2DM. The incidence of T2DM in the former diet plus physical activity group was 4.9 (95% CI 3.8 to 6.3) compared with 7.0 (95% CI 5.5 to 8.9) in the control group (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>); the HR (adjusted for sex, age, BMI and two‐hour glucose) was 0.67 (95% CI 0.48 to 0.95; P = 0.023). There was a 32% relative risk reduction and a 15% absolute risk reduction during the post‐intervention follow‐up period in favour of the former diet plus physical activity group (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> reported the incidence of T2DM after 20 and 23 years of follow‐up. The HR (adjusted for age and clustering) of the former diet plus physical activity group (diet only, physical activity only, diet plus physical activity) versus control after 20 years of follow‐up was 0.57 (95% CI 0.41 to 0.81). After 23 years of follow‐up 312 out of 430 participants of the combined former intervention group versus 124 out of 138 participants in the former control group developed T2DM. The HR (adjusted for clustering) was 0.55 (95% CI 0.40 to 0.76; P = 0.001). The median delay to the onset of T2DM was 3.6 years after 20 years of follow‐up. </p> <p>During the first seven years the incidence of T2DM in the Diabetes Prevention Program Outcomes Study (DPPOS) compared with the incidence of T2DM in the Diabetes Prevention Program (DPP) decreased in the control group (‐42%) (HR 0.58, 95% CI 0.48 to 0.69) compared with the incidence in the former diet plus physical activity group (31%) group (HR 1.31, 95% CI 1.07 to 1.61) (see <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). After 15 years of follow‐up in the DPPOS the incidence of T2DM was reduced by 27% in the former diet plus physical activity group (HR 0.73, 95% CI 0.65 to 0.83; P &lt; 0.0001) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). Over the 15 years of follow‐up the average annual T2DM incidence rate was 5.2% in the former diet plus physical activity group and 7.0% in the former control group. At year 15, the cumulative incidence of T2DM was 562 participants (62%) in the former control group versus 480 participants (55%) in the former diet plus physical activity group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The median delay to onset of T2DM after 10 years was about four years by diet plus physical activity compared with control. After 10 years of follow‐up (i.e. about seven years after the intervention period had stopped) 23% in the former diet plus physical activity group compared with 19% in the former control group had become normoglycaemic (fasting glucose &lt; 6.1 mmol/L, two‐hour glucose &lt; 7.8 mmol/L, and no previous diagnosis of T2DM) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The annual incidence of T2DM in the diet plus physical activity group rose slowly through year 4 after randomisation, then declined to steady levels at year 7. The control group had the highest incidence of T2DM early in the DPP, with a relatively steady decline through the end of the DPP and into the DPPOS, and levelling late in the DPPOS. Post hoc analysis defining T2DM by HbA1c at 6.5% or higher showed that the incidence rate was reduced with diet plus physical activity compared with control during the DPP (4.6 cases/100 person years versus 8.8 cases/100 person years) and at 10 years of follow‐up (3.5 cases/100 person years versus 5.0 cases/100 person years) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). Only participants with HbA1c less than 6.5% at baseline were included in this post hoc analysis (diet plus physical activity N = 932 at baseline; control N = 922 at baseline) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). During the total follow‐up period there were differences among ethnic groups in the incidence of diabetes defined as HbA1c 6.5% or higher or FPG 7.0 mmol/L or higher and/or two‐hour plasma glucose 11.1 mmol/L or higher (<a href="./appendices#CD003054-sec-0215">Appendix 19</a>). Only 26% of the participants diagnosed with T2DM according to FPG or glucose values after an OGTT had previous or simultaneous HbA1 6.5% or higher. On the other hand, 55% of those first attaining an HbA1c 6.5% or higher had current or previous diagnosis of T2DM defined according to FPG 7.0 mmol/L or higher and/or two‐hour plasma glucose 11.1 mmol/L or higher (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </section> <section id="CD003054-sec-0168"> <h6 class="title">Serious adverse events</h6> <p>Two trials reported serious adverse events (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). In one trial the investigators provided information that one out of 51 participants in the diet plus physical activity group compared with none out of 51 participants in the control group experienced a serious adverse event (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). The other trial reported that no adverse events were experienced in the intervention arms (low‐quality evidence) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>) (<a href="./references#CD003054-fig-0037" title="">Analysis 2.29</a>)). Four other trials clearly described recording serious adverse events but they did not present any data (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). In <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> only serious adverse events related to metformin were reported for each trial arm. We could not perform any meta‐analysis or subgroup analysis due to lack of data. </p> </section> </section> <section id="CD003054-sec-0169"> <h5 class="title">Secondary outcomes</h5> <section id="CD003054-sec-0170"> <h6 class="title">Cardiovascular mortality</h6> <p>Seven trials reported data on cardiovascular mortality (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). Four of the trials reported that none of the participants died due to cardiovascular disease (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). The number of participants who died due to cardiovascular disease was low (four out of 1626 participants in the diet plus physical activity group compared with four out of 1637 participants in the control group) (RR 0.94, 95% CI 0.24 to 3.65; P = 0.93; 3263 participants, 7 trials; very low‐quality evidence). The 95% prediction interval was not meaningful (<a href="./references#CD003054-fig-0022" title="">Analysis 2.14</a>). </p> <p>TSA showed that 0.13% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR. Diversity was zero, but we applied a diversity of 20% when calculating the diversity‐required information size as heterogeneity is likely to increase when future trials are included. As only a minor fraction of the diversity‐adjusted required information size to detect or reject a 10% RRR was accrued, we could not calculate the TSA‐adjusted 95% CIs with a diversity at 20%. Applying diversity at 0%, 0.16% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR. Still, we could not calculate the TSA‐adjusted 95% CIs. </p> <p>We did not perform subgroup or sensitivity analyses due to lack of data.</p> <p>One trial reported cardiovascular mortality after the intervention period had stopped (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The trial reported the HR (adjusted for age and clustering) after a total follow‐up period of 20 years (i.e. 14 years after the intervention had stopped) for the combined former diet only, physical activity only and diet plus physical activity group versus former control to be 0.83 (95% CI 0.48 to 1.05). After 23 years of follow‐up 78 participants died as a result of cardiovascular disease; 51 in the combined former intervention groups versus 27 in the former control group (when adjusting for clustering 29 versus 15). Cumulative incidences were 11.9% (95% CI 8.8 to 15.0) versus 19.6% (95% CI 12.9 to 26.3; the HR (adjusted for age and clustering) was 0.59 (95% CI 0.36 to 0.96; P = 0.03). Post hoc analyses comparing women with men after 23 years of follow‐up showed a HR of 0.28 (95% CI to 0.11 to 0.71; P = 0.01) and 0.91 (95% CI 0.50 to 1.65), respectively (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0171"> <h6 class="title">Non‐fatal myocardial infarction</h6> <p>None of the trials reported non‐fatal myocardial infarction at the end of the intervention period. However, the investigators of one of the included trials reported that none of the participants in the diet plus physical activity group or the standard treatment group (51 participants in each intervention group) had a non‐fatal myocardial infarction (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) ‐ low quality evidence. </p> <p>The DPP reported the total number of non‐fatal cardiovascular events at the end of the intervention. Non‐fatal cardiovascular events occurred in 24 out of 1079 participants (2.2%) (incidence rate 9.7 events per 1000 patient‐years) in the diet plus physical activity group compared with 18 out of 1082 participants (1.7%) with an incidence rate of 7.3 events per 1000 patient‐years in the control group. No substantial differences were seen in the diet plus physical activity group compared with standard treatment (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The excess of events in the diet plus physical activity group was due to hospitalisations because of cardiovascular disease and revascularisation procedures (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> <p>The IDPP also only reported the total number of cardiovascular events with four (3.3%) out of 120 participants in the diet plus physical activity group compared with two (1.5%) out of 133 participants in the control group (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). </p> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> reported a cumulative incidence of any first cardiovascular event to be 5.2 (95% CI 3.0 to 7.3) in the combined intervention group (diet only, physical activity only, diet plus physical activity) compared with 5.4 (95% CI 1.5 to 9.2) in the control group during the intervention period. The incidence rate per 100 person years was 0.9 (95% CI 0.2 to 1.6) in the intervention group compared with 0.9 (95% CI 0.5 to 1.3) in the control group during the intervention period. The HR adjusted for age and clustering was 0.96 (95% CI 0.76 to 1.44). </p> <p>From one trial it was apparent that cardiovascular event data were collected during the intervention period, but no data were reported (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> <p>Two trials reported cardiovascular complications after the intervention period had stopped (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). One trial reported composite cardiovascular morbidity after a total follow‐up of 10.6 years (i.e. about 6.6 years after the end of intervention); 57 cardiovascular events were reported in 257 participants of the former diet plus physical activity group compared with 54 events in 248 participants in the former control group (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). The incidence rate of cardiovascular morbidity was 22.9 in the former diet plus physical activity group versus 22.0 per 1000 person years in the former control group; the HR was 1.04( 95% CI 0.72 to 1.51). Men and women had the same incidence in the two intervention groups (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> reported the cumulative incidence of any first cardiovascular event to be 40.9 (95% CI 36.0 to 45.9) in the combined former intervention group (diet only, physical activity only, diet plus physical activity) compared with 44.1 (95% CI 35.3 to 53.0) in the former control group after a total follow‐up period of 20 years (i.e. 14 years after the intervention had stopped). The incidence rate per 100 person years was 2.3 (95% CI 1.9 to 2.7) in the intervention group compared with 2.5 (95% CI 1.9 to 3.2) in the control group after 20 years of follow‐up. The HR adjusted for age and clustering was 0.98 (95% CI 0.71 to 1.37) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0172"> <h6 class="title">Non‐fatal stroke</h6> <p>None of the trials reported non‐fatal stroke at the end of the intervention period. However, the investigators of one of the included trials reported that none of the participants in the diet plus physical activity or the control group (51 participants in each intervention group) had a non‐fatal stroke (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) ‐ low quality evidence. </p> <p>Several trials reported data on composite cardiovascular events (see above) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). </p> </section> <section id="CD003054-sec-0173"> <h6 class="title">Amputation of lower extremity</h6> <p>None of the trials reported amputation of the lower extremity at the end of the intervention period. However, the investigators of one of the included trials reported that none of the participants in the diet plus physical activity or the control group (51 participants in each intervention group) had an amputation of the lower extremity (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). </p> <p>Several trials reported data on composite cardiovascular events (see above) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). </p> </section> <section id="CD003054-sec-0174"> <h6 class="title">Blindness or severe vision loss</h6> <p>We did not identify trials with data on blindness or severe vision loss for this comparison.</p> <p>One trial reported severe retinopathy after 20 years of follow‐up. Severe retinopathy occurred in 31 participants out of 238 in the intervention group (cumulative incidence 9.2%) compared with 17 out of 93 in the control group (cumulative incidence 16.2%) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The HR (adjusted for clustering and age) was 0.53 (95% CI 0.29 to 0.99; P = 0.048) in favour of the intervention (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). All participants with severe retinopathy had developed T2DM by the time the retinopathy was recognised (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>One trial reported an aggregate outcome of microvascular disease (nephropathy, retinopathy and neuropathy) after 15 years of follow‐up (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The prevalence of microvascular outcomes after 15 years did not differ substantially between the intervention and control group despite group differences in the incidence of T2DM (former diet plus physical activity group 11.3% (95% CI 10.1 to 12.7) compared with former control 12.4% (95% CI 11.1 to 13.8)). The women but not the men in the former diet plus physical activity group experienced a reduction in microvascular disease (RR 0.79, 95% CI 0.64 to 0.98) compared with the former control group. There were no substantial differences in the treatment effects on aggregate microvascular complications in subgroups defined by age or ethnicity, except that Hispanic Americans had a lower microvascular disease prevalence in the former diet plus physical activity group than in the former control group (RR 0.43, 95% CI 0.20 to 0.91) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </section> <section id="CD003054-sec-0175"> <h6 class="title">End‐stage renal disease</h6> <p>None of the trials reported end‐stage renal disease at the end of the intervention period. </p> <p>One trial reported renal replacement therapy or death due to kidney failure after 20 years of follow‐up (i.e. 14 years after the intervention had stopped) . Seven out of 441 participants (when adjusting for clustering: 4 out of 252 participants) of the combined former intervention group compared with two out of 136 participants (when adjusting for clustering 1 out of 78 participants) in the former control group developed end‐stage renal disease (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0176"> <h6 class="title">Non‐serious adverse events</h6> <p>One trial reported that no non‐serious adverse events were reported (diet plus physical activity 0/126 (adjusted for clustering 0/72 versus control 0/76)) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). Another trial reported three (3.6%) out of 84 participants in the diet plus physical activity group compared with four (4.8%) out of 83 participants in the control group experienced a non‐serious adverse event (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </section> <section id="CD003054-sec-0177"> <h6 class="title">Hypoglycaemia</h6> <p>Two trials reported that none of the participants experienced hypoglycaemia (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>: diet plus physical activity 0/133 compared with control 0/136; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>: diet plus physical activity 0/51 compared with control 0/51). </p> </section> <section id="CD003054-sec-0178"> <h6 class="title">Health‐related quality of life</h6> <p>The DPP trial applied the 36‐item Short‐Form (SF‐36) to evaluate the health utility index (SF‐6D), physical component summaries (PCS) and mental component summaries (MCS). Minimal important difference (MID) was defined as a difference in scores between groups of at least 3% (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). A total of 1070 participants from the diet plus physical activity group and 1074 participants from the standard treatment group were included (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). In both the diet plus physical activity arm as well as the control arm HrQoL summary scores worsened during the trial, but the decline for SF‐6D (P &lt; 0.05) and PCS (P &lt; 0.01) was slower in diet plus physical activity participants compared to the changes in the control group; however, none reached the MID of 3%. After a mean of 3.2 years of follow‐up there were improvements in the SF‐6D (0.008; P = 0.04) in the diet plus physical activity group compared with control, however, the MID of 3% between the intervention groups was not achieved. The PCS (1.57; P &lt; 0.0001) also improved in the diet plus physical activity group compared with control (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). Again, the MID between the intervention groups was not achieved. MCS improved in the placebo group compared with the diet plus physical activity group during the intervention period with 0.28 (SD 0.32). No exact P‐value was provided, the value was more than 5%. The MID was not achieved (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). The overall quality of evidence for this outcome measure was very low. </p> <p>The investigators from the <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a> reported that the participants were asked how healthy they were during the trial. The replies were not analysed at the end of the intervention. </p> <p>One trial stated in the design article that HrQoL measured with the SF‐36 would be assessed. However, no data were available (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). One publication stated that HrQoL was measured, but no data were reported (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). According to the investigators HrQoL was not analysed (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). </p> </section> <section id="CD003054-sec-0179"> <h6 class="title">Time to progression to type 2 diabetes</h6> <p>One trial reported data on the time to progression to T2DM in the post‐interventional follow‐up period (median of seven years). Among the participants who developed T2DM the median time to the onset of T2DM was 15 years (95% CI 13 to 17) in the former intervention group compared with 10 years (95% CI 8 to 12 years) in the former control group (95% CI 8 to 12 years) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). </p> </section> <section id="CD003054-sec-0180"> <h6 class="title">Measures of blood glucose control</h6> <section id="CD003054-sec-0181"> <p><b>Fasting glucose</b></p> <p>Ten trials reported FPG (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Effect‐estimates in both random‐effects and fixed‐effect models showed differences (random MD ‐0.17 mmol/L, 95% CI ‐0.27 to ‐0.06; P = 0.003; fixed MD ‐0.21 mmol/L, 95% CI ‐0.27 to ‐0.15; P &lt; 0.00001; 10 trials; 3530 participants; <a href="./references#CD003054-fig-0026" title="">Analysis 2.18</a>). The 95% prediction interval ranged between ‐0.43 mmol/L to 0.09 mmol/L. </p> <p>TSA showed that diversity‐adjusted information size was accrued to detect or reject a difference in fasting plasma glucose at ‐0.17 mmol/L in favour of the diet plus physical activity group. Diversity was 70%. </p> <p><b>Subgroup analyses</b>: according to duration of the intervention ((≥ 4 years) versus trials with short duration (&lt; 4 years)), diagnostic criteria of participants with IGT versus other; age (included participants ≥ 50 years versus &lt; 50 years); ethnicity (Asian versus predominantly White); morbidity (BMI ≥ 30 kg/m<sup>2</sup> versus &lt; 30 kg/m<sup>2</sup>); showed no statistically significant interactions (<a href="./appendices#CD003054-sec-0214">Appendix 18</a>). We could not perform subgroup analyses according to sex and previous gestational diabetes due to lack of data. </p> <p><b>Sensitivity analysis</b>: we could not perform sensitivity analyses according to publication status and language of publication as all included trials were published in English. Sensitivity analysis restricted to trials with low risk of selection bias showed a MD of ‐0.14 mmol/L (95% CI ‐0.26 to ‐0.01; P = 0.03) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>;<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Analysing trials according to geographies for trials performed in Asia showed a MD of ‐0.18 mmol/L (95% CI ‐0.49 to 0.13; P = 0.15) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). Trials performed in Europe showed a MD of ‐0.08 mmol/L (95% CI ‐0.80 to 0.08; P = 0.15) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). One trial reported FPG after 20 years of follow‐up (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The mean FPG was 7.9 (SD 3.2) in 260 participants (149 participants when adjusting for clustering) in the combined former intervention groups compared with 8.7 (SD 3.1) in 80 participants (46 participants when adjusting for clustering) in the former control group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). Another trial reported FPG after 15 years of follow‐up. FPG was 6.8 mmol/L (SD 2.0) in 751 participants in the former diet plus physical activity group compared with 6.8 mmol/L (SD 1.9) in 780 participants in the former control group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </section> <section id="CD003054-sec-0182"> <p><b><i>Glucose two hours after an oral glucose load</i> </b></p> <p>Nine trials reported glucose values two hours after an oral glucose load (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Two hours after an oral glucose load glucose values were higher in the control group compared with the diet plus physical activity group (random MD ‐0.46 mmol/L, 95% CI ‐0.79 to ‐0.12; P = 0.008; fixed MD ‐0.29 mmol/L, 95% CI ‐0.44 to ‐0.15; P &lt; 0.00001; 9 trials; 3261 participants; <a href="./references#CD003054-fig-0032" title="">Analysis 2.24</a>). The 95% prediction interval ranged between ‐1.41 mmol/L to 0.49 mmol/L. </p> <p>TSA showed that diversity‐adjusted information size was accrued to detect or reject a difference in two‐hour plasma glucose at ‐0.46 mmol/L in favour of the diet plus physical activity group. Diversity was 82%. </p> <p><b>Subgroup analyses</b>: according to duration of the intervention ((≥ 4 years) versus trials with short duration (&lt; 4 years)), ethnicity (Asian versus predominantly white); morbidity (BMI ≥ 30 kg/m<sup>2</sup> versus &lt; 30 kg/m<sup>2</sup>); showed no statistically significant interactions (<a href="./appendices#CD003054-sec-0214">Appendix 18</a>). The subgroups of trials according to age (≥ 50 years versus &lt; 50 years) showed significant interaction between subgroups (P = 0.003). However, the CIs in these analyses overlap to a small degree. As a caveat, these observations should be regarded as hypothesis‐generating only. We could not perform subgroup analyses according to sex, diagnostic criteria of participants with IGT versus other and previous gestational diabetes due to lack of data. </p> <p><b>Sensitivity analysis</b>: we could not perform sensitivity analysis according to publication status (all included trials were published) and language of publication (all included trials were published in English). Sensitivity analysis restricted to trials with low risk of selection bias showed a MD of ‐0.14 mmol/L (95% CI ‐0.26 to ‐0.01; P = 0.03) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). Analysing trials performed in Asia showed a MD of ‐1.10 mmol/L (95% CI ‐2.3 to 0.11; P = 0.07) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). Trials performed in Europe showed a MD of ‐0.35 mmol/L (95% CI ‐0.78 to 0.08; P = 0.11) (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>One trial reported glucose values two hours after an OGTT after 20 years of follow‐up (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The mean two‐hour glucose value was 11.5 mmol/L (SD 5.0) in 100 participants (57 participants when adjusting for clustering) in the combined former intervention groups compared with 13.8 mmol/L (SD 5.8) in 28 participants (16 participants when adjusting for clustering) in the former control group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </section> <section id="CD003054-sec-0183"> <p><b>HbA1c</b></p> <p>Four trials reported data on HbA1c (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>In the random‐effects model the MD was ‐0.11% (95% CI ‐0.23 to 0.02; P = 0.09; 4 trials; 2453 participants) (<a href="./references#CD003054-fig-0039" title="">Analysis 2.31</a>), in the fixed‐effect model the MD was ‐0.18%, 95% CI ‐0.23 to ‐0.13; P &lt; 0.00001). The 95% prediction interval ranged between ‐1.64% and 1.42%. </p> <p>TSA showed that 36.5% diversity‐adjusted information size was accrued to detect or reject a HbA1c difference of ‐0.11% between the intervention groups. Alfa‐spending‐adjusted 95% CI was ‐0.34 to 0.12. Diversity was 86%. </p> <p><b>Subgroup analysis</b>: analysing trials according to the duration of the intervention (≥ 4 years) versus trials with short duration (&lt; 4 years) showed no interaction between subgroups (P = 0.99) (<a href="./references#CD003054-fig-0042" title="">Analysis 2.34</a>; <a href="./appendices#CD003054-sec-0214">Appendix 18</a>). Analysing trials according to the BMI ≥ 30 kg/m<sup>2</sup> versus &lt; 30 kg/m<sup>2</sup> showed no interaction between subgroups (P = 0.10) (<a href="./references#CD003054-fig-0043" title="">Analysis 2.35</a>). All trials reporting HbA1c included people with IGT, all included participants aged 50 years or more, and all included only white or mainly white people (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p><b>Sensitivity analysis</b>: we could not perform sensitivity analysis according to publication status (all included trials were published) and language of publication (all included trials were published in English). Sensitivity analysis restricted to only trials with low risk of selection bias showed MD ‐0.15%, 95% CI ‐0.27 to ‐0.04; P = 0.009 (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>). Analysing trials according to geographies in trials performed in Europe showed a MD of ‐0.02%, 95% CI ‐0.26 to 0.21; P = 0.84 (<a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). </p> <p>One trial reported the HbA1c after 20 years of follow‐up (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The mean HbA1c was 7.34% (SD 1.7) in 271 participants (155 participants when adjusting for clustering) in the combined former intervention group compared with 7.83% (SD 2.0) in 81 participants (46 participants when adjusting for clustering) in the former control group (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). Another trial reported the HbA1c after 15 years of follow‐up. The mean HbA1c was 6.2% (SD 1.2) in 751 participants in the former diet plus physical activity group compared with 6.3% (SD 1.2) in 780 participants in the former control group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </section> </section> <section id="CD003054-sec-0184"> <h6 class="title">Socioeconomic effects</h6> <p>During <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>, the diet plus physical activity groups were substantially more expensive than the standard treatment intervention. Direct medical costs of the interventions during the DPP were estimated to be USD 3628 for the diet plus physical activity group versus USD 184 for the control group. Direct medical costs (hospital days, emergency room visits, urgent care visits, outpatient visits, calls to providers, supplies, laboratory tests, and prescription medications within the intervention groups) outside the DPP were estimated to be USD 5182 for the diet plus physical activity group compared with USD 5680 for the control group. However, due to the high direct medical costs of T2DM, the diet plus physical activity intervention was estimated to be cost‐effective. The quality of evidence was low. From the perspective of the health system (direct medical costs of the interventions plus direct medical costs of care outside the trial) the cost was USD 31,500 per quality‐adjusted life years (QALY) gained with diet plus physical activity compared with control. From the perspective of society (direct medical costs plus non medical costs (expenditure on medical treatment but not involving purchase of medical services or products) plus indirect costs (costs to society due to morbidity and mortality, e.g. absent from work due to medical treatment)) the cost was USD 51,600 per QALY gained with diet plus physical activity compared with control. </p> <p><a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a> reported that the extra mean cost for the diet plus physical activity group was GBP 1126 (95% CI –2414 to 4666) after three years, with GBP 615 of the difference being dietitian costs. Primary‐care visits and costs did not differ between groups, but there were more outpatient visits in the intervention group (costing GBP 327 more than in the control group). </p> <p><a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a> estimated direct medical costs of interventions over the three‐year trial period to be USD 61 per participant in the control group compared with USD 225 in the diet plus physical activity group. The cost‐effectiveness to prevent one case of diabetes with diet plus physical activity was USD 1052. </p> <p>In <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>, direct medical costs for each participant in the diet plus physical activity group were USD 850 compared with USD 142 in the control group. Direct costs of care outside the trial were USD 5177 for the diet plus physical activity group compared with USD 7454 for the control group. </p> <p>The overall quality of evidence was low for this outcome measure.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003054-sec-0185" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003054-sec-0185"></div> <section id="CD003054-sec-0186"> <h3 class="title" id="CD003054-sec-0186">Summary of main results</h3> <p>This Cochrane Review investigated the effects of diet or physical activity, or both in people at increased risk of developingT2DM. We included 12 trials with a total of 5238 participants. We judged all trials as at unclear or high risk of bias in one or more 'Risk of bias' domains. The amount of evidence on patient‐important outcomes was limited. The meta‐analysis comparing diet plus physical activity with standard or no treatment showed moderate‐quality evidence of a reduced incidence of T2DM after the end of the intervention. The diversity‐adjusted required information size of TSA to confirm a 10% RRR was reached. The reporting on mortality and macrovascular as well as microvascular diabetes complications was insufficient and we judged the quality of evidence for these outcome measures as low or very low. </p> </section> <section id="CD003054-sec-0187"> <h3 class="title" id="CD003054-sec-0187">Overall completeness and applicability of evidence</h3> <p>The diagnosis of intermediate hyperglycaemia varied among trials and some trials used a definition that may have included participants judged to be euglycaemic or having T2DM. However, all trials except one had IGT as an inclusion criterion (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>). The results of this review might therefore not be applicable to people defined by other glycaemic categories of intermediate hyperglycaemia. </p> <p>Detailed information about the participants was lacking in most trials. The included trials applied different intensities of diet and physical activity. In our review, all programmes were conducted in adults. Therefore, our results may not apply to children and adolescents. A potential selection bias exists as more healthy and motivated people may participate in a clinical trial. However, a Cochrane Review observed that clinical outcomes in people participating in RCTs are comparable to similar individuals outside trials (<a href="./references#CD003054-bbs2-0138" title="VistGE , BryantD , SomervilleL , BirminghemT , OxmanAD . Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews (Online)2008;3:MR000009. [PUBMED: 18677782] ">Vist 2008</a>). However, the implementation of diet and physical activity programmes outside a clinical trial often shows less pronounced effects in surrogate markers (e.g. glycaemic measures) (<a href="./references#CD003054-bbs2-0072" title="AshraNB , SpongR , CarterP , DaviesMJ , DunkleyA , GilliesC , et al. A systematic review and meta‐analysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. www.gov.uk/government/uploads/system/uploads/attachment_data/file/456147/PHE_Evidence_Review_of_diabetes_prevention_programmes‐_FINAL.pdf (accessed 17 March 2017). ">Ashra 2015</a>). </p> <p>Three of the included trials contributed about 70% of all data (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). Reporting of complications associated with T2DM during the intervention period was lacking. However, after 23 years of follow‐up, all‐cause mortality and cardiovascular mortality were reduced in one study (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). This effect was only found in women. However, the trial found a delay in the onset of T2DM of 3.6 years (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). The only data on microvascular complications were available after an extended follow‐up period. There was discrepancy in the long‐term effects of the diet plus physical activity intervention in the <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> and the <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> follow‐up. <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a> reported a reduction of severe retinopathy after 20 years of follow‐up in the former intervention group (HR 0.53, 95% CI 0.29 to 0.99; P = 0.048). In <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> there was no influence on microvascular outcomes after 15 years of follow‐up. </p> <p>The three major trials all included people with IGT. Unfortunately, similar trials have not been performed in people with IFG or moderately elevated HbA1c. One of the excluded trials included 379 overweight Japanese people with IFG only. However, the intervention group and the control group received similar diet and physical activity advice, but with less frequent visits in the control group, and was consequently not included in this review (<a href="./references#CD003054-bbs2-0039" title="Study protocol. rctportal.niph.go.jp/en/detail?trial_id=UMIN000001959 (accessed 29 March 2017). SaitoT , WatanabeM , NishidaJ , IzumiT , OmuraM , TakagiT , et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Archives of Internal Medicine2011;171(15):1352‐60. [PUBMED: 21824948] ">Saito 2011</a>). The trial did not find an impact on the risk of T2DM in participants with isolated IFG after 36 months of intervention (HR 1.17, 95% CI 0.50 to 2.74) (<a href="./references#CD003054-bbs2-0039" title="Study protocol. rctportal.niph.go.jp/en/detail?trial_id=UMIN000001959 (accessed 29 March 2017). SaitoT , WatanabeM , NishidaJ , IzumiT , OmuraM , TakagiT , et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Archives of Internal Medicine2011;171(15):1352‐60. [PUBMED: 21824948] ">Saito 2011</a>). However, because of the technical complexities of performing an OGTT compared with measuring fasting glucose or HbA1c, most people with intermediate hyperglycaemia are expected to be diagnosed with these modalities (International Expert Committee 2009). It is therefore unclear whether similar effects in reducing or delaying T2DM incidence will be found in the majority of people with intermediate hyperglycaemia. </p> <p>The number of participants diagnosed with T2DM in the control groups in the included trials was higher than that estimated from observational studies (<a href="./references#CD003054-bbs2-0080" title="ChengC , KushnerH , FalknerBE . The utility of fasting glucose for detection of prediabetes. Metabolism: Clinical and Experimental2006;55(4):434‐8. [PUBMED: 16546472] ">Cheng 2006</a>; <a href="./references#CD003054-bbs2-0121" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>). This might be explained by the regular glycaemic testing of people participating in a RCT. Therefore, many of those diagnosed with T2DM in a RCT may not be diagnosed in a 'real‐world' setting. </p> <p>Most trials included participants aged above 50 years. In both <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> and <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>, diet plus physical activity was most effective in reducing T2DM incidence in people aged 60 years or more. A person aged 65 years or more with newly diagnosed T2DM with a HbA1c of 7% has a theoretical life‐time risk of blindness or end‐stage renal disease of less than 0.5% (<a href="./references#CD003054-bbs2-0137" title="VijanS , HoferTP , HaywardRA . Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Annals of Internal Medicine1997;127(9):788‐95. [PUBMED: 9382399] ">Vijan 1997</a>). The reason for the lack of reliable data on diabetic complications T2DM in our review might be explained by the low rate of these complications in the people with the largest intervention effect and the time it takes to develop these complications (<a href="./references#CD003054-bbs2-0137" title="VijanS , HoferTP , HaywardRA . Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Annals of Internal Medicine1997;127(9):788‐95. [PUBMED: 9382399] ">Vijan 1997</a>). </p> <p>In all trials reporting the direct costs of the diet and physical activity programmes, the intervention was significantly more expensive than control (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>). However, the diet plus physical activity intervention programmes were estimated to be cost‐effective due to the reduction of T2DM with these programmes (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). On the other hand, the interventions in the included trials would be challenging and costly to implement in daily life. In general, the adherence to diet and lifestyle advice was low in the included trials, and might even be lower in a non‐trial setting. A more cost‐effective and long‐lasting solution could be to enable people to undertake physical activity as part of their everyday life, and regulation of food costs. </p> <p>Not only people with intermediate hyperglycaemia but also people with manifest T2DM are recommended to increase physical activity and lower calorie intake (<a href="./references#CD003054-bbs2-0069" title="American Diabetes Association. Standards of medical care in diabetes ‐ 2017. Diabetes Care2017;40:(Suppl 1). ">ADA 2017</a>). However, the only long‐term RCT assessing the effects of diet plus physical activity in people with T2DM was stopped early due to futility after a median follow‐up of 9.6 years (<a href="./references#CD003054-bbs2-0111" title="Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine2013;369(2):145‐54. [DOI: 10.1056/NEJMoa1212914] ">Look AHEAD 2013</a>). In addition, long‐term follow‐up data for <a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a> have not shown any substantial effect on mortality or diabetes‐related complications after 15 years of follow‐up, even though the incidence of T2DM was reduced with the diet plus physical activity intervention. </p> </section> <section id="CD003054-sec-0188"> <h3 class="title" id="CD003054-sec-0188">Quality of the evidence</h3> <p>For all trials, we contacted one or more trial authors to obtain supplemental information on baseline data, bias domains and outcomes. In addition, we asked investigators to confirm our extracted outcomes. Unfortunately only four investigators (33%) of the included trials either just confirmed a question or provided additional data that could be implemented for the 'Risk of bias' assessment or the meta‐analyses of outcomes (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>We included trials with an intervention duration of two years or more. Trials with shorter duration could have been included, but as we were focusing on patient‐important outcomes we did not include such short‐term studies (<a href="./references#CD003054-bbs2-0015" title="Study protocol. clinicaltrials.gov/show/NCT01283308 (accessed 17 September 2017). WeberMB , RanjaniH , MeyersGC , MohanV , NarayanKM . A model of translational research for diabetes prevention in low and middle‐income countries: The Diabetes Community Lifestyle Improvement Program (D‐CLIP) trial. Primary Care Diabetes2012;6(1):3‐9. [PUBMED: 21616737] ">D‐CLIP</a>; <a href="./references#CD003054-bbs2-0017" title="Study protocol. www.trialregister.nl/trialreg/admin/rctview.asp?TC=1499 (accessed 29 March 2017). VlaarEM , VanValkengoedIG , NierkensV , NicolaouM , MiddelkoopBJ , StronksK . Feasibility and effectiveness of a targeted diabetes prevention program for 18 to 60‐year‐old South Asian migrants: design and methods of the DH!AAN study. BMC Public Health2012;12:371. [PUBMED: 22621376] VlaarEM , VanValkengoedIG , NierkensV , NicolaouM , MiddelkoopBJ , StronksK . Feasibility and effectiveness of a targeted diabetes prevention program for 18 to 60‐year‐old South Asian migrants: design and methods of the DH!AAN study. BMC Public Health2012;12:371. [PUBMED: 22621376] ">DH!AAN</a>; <a href="./references#CD003054-bbs2-0022" title="HesselinkAE , BiloHJ , JonkersR , MartensM , deWeerdtI , RuttenGE . A cluster‐randomized controlled trial to study the effectiveness of a protocol‐based lifestyle program to prevent type 2 diabetes in people with impaired fasting glucose. BMC Family Practice2013;14:184. [PUBMED: 24295397] ">Hesselink 2013</a>; <a href="./references#CD003054-bbs2-0023" title="HuangSH , WengKP , HsiehKS , OuSF , LinCC , ChienKJ , et al. Effects of a classroom‐based weight‐control intervention on cardiovascular disease in elementary‐school obese children. Acta Paediatrica Taiwanica2007;48:201‐6. ">Huang 2007</a>; <a href="./references#CD003054-bbs2-0025" title="Study protocol. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000000798 (accessed 3 April 2017). SakaneN , KotaniK , TakahashiK , SanoY , TsuzakiK , OkazakiK , et al. Japan Diabetes Outcome Intervention Trial‐1 (J‐DOIT1), a nationwide cluster randomized trial of type 2 diabetes prevention by telephone‐delivered lifestyle support for high‐risk subjects detected at health checkups: rationale, design, and recruitment. BMC Public Health2013;13:81. [PUBMED: 23356246] ">J‐DOIT</a>; <a href="./references#CD003054-bbs2-0026" title="KawaharaT , TakahashiK , InazuT , AraoT , KawaharaC , TabataT , et al. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2‐day in‐hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. Diabetes Care2008;31(10):1949‐54. [PUBMED: 18591401] ">Kawahara 2008</a>; <a href="./references#CD003054-bbs2-0027" title="KinmonthAL , WarehamNJ , HardemanW , SuttonS , PrevostAT , FanshaweT , et al. Efficacy of a theory‐based behavioural intervention to increase physical activity in an at‐risk group in primary care (ProActive UK): a randomised trial. Lancet2008;371:41‐8. ">Kinmonth 2008</a>; <a href="./references#CD003054-bbs2-0030" title="LindahlB , NilssonTK , Borch‐JohnsenK , RoderME , SoderbergS , WidmanL , et al. A randomized lifestyle intervention with 5‐year follow‐up in subjects with impaired glucose tolerance: pronounced short‐term impact but long‐term adherence problems. Scandinavian Journal of Public Health2009;37(4):434‐42. [PUBMED: 19181821] LindahlB , NilssonTK , JanssonJH , AsplundK , HallmansG . Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. Journal of Internal Medicine1999;246:105‐12. ">Lindahl 1999</a>; <a href="./references#CD003054-bbs2-0031" title="NCT02000024. clinicaltrials.gov/ct2/show/NCT02000024 (accessed 10 April 2017). MarreroDG , PalmerKN , PhillipsEO , Miller‐KovachK , FosterGD , SahaCK . Comparison of commercial and self‐initiated weight loss programs in people with prediabetes: a randomized control trial. American Journal of Public Health2016;106(5):949‐56. [PUBMED: 26890171] ">Marrero 2016</a>; <a href="./references#CD003054-bbs2-0035" title="PageRC , HarndenKE , WalravensNK , OnslowC , SuttonP , LevyJC , et al. 'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. The Quarterly Journal of Medicine1993;86(3):145‐54. [PUBMED: 8483989] PageRCL , Harnden , CookJTE , TurnerRC . Can life‐styles of subjects with impaired glucose tolerance be changed? A feasibility study. Diabetic Medicine1992;9:562‐6. ">Page 1992</a>; <a href="./references#CD003054-bbs2-0037" title="NCT00819455. clinicaltrials.gov/ct2/show/NCT00819455 (accessed 10 April 2017). RamJ , SelvamS , SnehalathaC , NandithaA , SimonM , ShettyAS , et al. Improvement in diet habits, independent of physical activity helps to reduce incident diabetes among prediabetic Asian Indian men. Diabetes Research and Clinical Practice2014;106(3):491‐5. [PUBMED: 25458326] RamachandranA , SnehalathaC , RamJ , SelvamS , SimonM , NandithaA , et al. Effectiveness of mobile phone messaging in prevention of type 2 diabetes by lifestyle modification in men in India: a prospective, parallel‐group, randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2013;1(3):191‐8. [PUBMED: 24622367] ">Ramachandran 2013</a>; <a href="./references#CD003054-bbs2-0041" title="Study protocol. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611000262909 (assessed 23 March 2017). SathishT , OldenburgB , TappRJ , ShawJE , WolfeR , SajithaB , et al. Baseline characteristics of participants in the Kerala Diabetes Prevention Program: a cluster randomized controlled trial of lifestyle intervention in Asian Indians. Diabetic Medicine2017;34(5):647‐53. [PUBMED: 27279083] ">Sathish 2017</a>; <a href="./references#CD003054-bbs2-0042" title="SavoyeM , ShawM , DziuraJ , TamborlaneWV , RoseP , GuandaliniC , et al. Effects of a weight management program on body composition and metabolic parameters in overweight children. A randomized controlled trial. JAMA2007;297(24):2697‐704. ">Savoye 2007</a>; <a href="./references#CD003054-bbs2-0047" title="ThompsonJL , AllenP , HelitzerDL , QuallsC , WhyteAN , WolfeVK , et al. Reducing diabetes risk in American Indian women. American Journal of Preventive Medicine2008;34(3):192‐201. ">Thompson 2008</a>; <a href="./references#CD003054-bbs2-0048" title="VillarealDT , Miller IIIBV , BanksM , FontanaL , SinacoreDR , KleinS . Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. American Journal of Clinical Nutrition2006;84:1317‐23. ">Villareal 2006</a>; <a href="./references#CD003054-bbs2-0052" title="YatesT , DaviesMJ , SehmiS , GorelyT , KhuntiK . The Pre‐diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years?. Diabetic Medicine : a Journal of the British Diabetic Association2011;28(10):1268‐71. [PUBMED: 21672008] ">Yates 2011</a>). </p> <p>None of the 11 included trials in our review was classified as having low risk of bias in all 'Risk of bias' domains. The description of randomisation and allocation was insufficient in 33% of the included trials (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>; <a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] ">SLIM 2003</a>). Only one trial was classified as having low risk of bias for selective outcome reporting (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>). The remaining trials had insufficient reporting of one or more outcomes of relevance to our review. However, we were able to assess one or more of our predefined outcomes in all of the included trials. </p> <p>For the comparisons 'diet only versus comparator' and 'physical activity only versus comparator', we judged the quality of evidence to be very low because of sparse data and various risks of bias. For the comparison 'diet plus physical activity' more data were available. However, again most outcome measures were associated with low‐ or very low‐quality evidence. </p> </section> <section id="CD003054-sec-0189"> <h3 class="title" id="CD003054-sec-0189">Potential biases in the review process</h3> <p>We were unable to draw funnel plots to assess small‐study bias due to lack of data for most outcomes. However, for one of our primary outcomes ‐ the incidence of T2DM ‐ we were able to draw a funnel plot, which did not indicate publication bias. If more data had been available on the patient‐important outcomes of our review, we would have performed more meta‐analyses. Many of the included trials were not designed or powered to detect our predefined patient‐important outcomes. For the performed meta‐analyses we investigated heterogeneity and the potential reasons for it through subgroup and sensitivity analyses. We were dealing with a substantially heterogeneous group of trials. Our meta‐analyses were limited by the inability to use individual participant data to assess whether distinct clinical characteristics may have influenced the effect estimates of the interventions. To reduce the risk of random errors, we conducted TSA on all predefined outcomes and calculated prediction intervals, whenever possible. We contacted all trial authors for clarification if one of the bias domains was not adequately reported. Several trials were published in more than one publication, which for some trials made it difficult to separate the primary publication from companion papers. We excluded trials including participants with IGT due to other conditions (e.g. cystic fibrosis or glucocorticoid treatment). We included trials with a minimum duration of two years in order to detect clinically relevant differences for the predefined outcomes. Even though we focused on long‐term trials, the reporting of clinical outcomes in the included trials was poor. Two review authors carried out data extraction. However, the review authors extracting the data were not blinded as to which trial they were extracting data from. </p> </section> <section id="CD003054-sec-0190"> <h3 class="title" id="CD003054-sec-0190">Agreements and disagreements with other studies or reviews</h3> <p>We conducted an extensive search for trials, including publications in all languages and tried to obtain additional data on all trials. Investigators of three trials provided additional information (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). We looked for additional trials and cross‐checked our data with other meta‐analyses and Cochrane Reviews of relevance (<a href="./references#CD003054-bbs2-0070" title="AguiarEJ , MorganPJ , CollinsCE , PlotnikoffRC , CallisterR . Efficacy of interventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta‐analysis. The International Journal of Behavioral Nutrition and Physical Activity2014;11:2. [PUBMED: 24423095] ">Aguiar 2014</a>; <a href="./references#CD003054-bbs2-0071" title="AliMK , Echouffo‐TcheuguiJ , WilliamsonDF . How effective were lifestyle interventions in real‐world settings that were modelled on the Diabetes Prevention Program?. Health Affairs (Project Hope)2012;31(1):67‐75. [PUBMED: 22232096] ">Ali 2012</a>; <a href="./references#CD003054-bbs2-0072" title="AshraNB , SpongR , CarterP , DaviesMJ , DunkleyA , GilliesC , et al. A systematic review and meta‐analysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. www.gov.uk/government/uploads/system/uploads/attachment_data/file/456147/PHE_Evidence_Review_of_diabetes_prevention_programmes‐_FINAL.pdf (accessed 17 March 2017). ">Ashra 2015</a>; <a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>; <a href="./references#CD003054-bbs2-0078" title="Cardona‐MorrellM , RychetnikL , MorrellSL , EspinelPT , BaumanA . Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta‐analysis. BMC Public Health2010;10:653. [PUBMED: 21029469] ">Cardona‐Morrell 2010</a>; <a href="./references#CD003054-bbs2-0085" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>; <a href="./references#CD003054-bbs2-0087" title="GillettM , RoyleP , SnaithA , ScotlandG , PoobalanA , ImamuraM , et al. Non‐pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England)2012;16(33):1‐236, iii‐iv. [PUBMED: 22935084] ">Gillett 2012</a>; <a href="./references#CD003054-bbs2-0088" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. [MEDLINE: 17237299] ">Gillies 2007</a>; <a href="./references#CD003054-bbs2-0089" title="GlechnerA , HarreiterJ , GartlehnerG , RohlederS , KautzkyA , TuomilehtoJ , et al. Sex‐specific differences in diabetes prevention: a systematic review and meta‐analysis. Diabetologia2015;58(2):242‐54. [PUBMED: 25465437] ">Glechner 2015</a>; <a href="./references#CD003054-bbs2-0090" title="GongQH , KangJF , YingYY , LiH , ZhangXH , WuYH , et al. Lifestyle interventions for adults with impaired glucose tolerance: a systematic review and meta‐analysis of the effects on glycemic control. Internal Medicine (Tokyo, Japan)2015;54(3):303‐10. [PUBMED: 25748739] ">Gong 2015</a>; <a href="./references#CD003054-bbs2-0101" title="HopperI , BillahB , SkibaM , KrumH . Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta‐analysis of randomised controlled clinical trials. European Journal of Cardiovascular Prevention and Rehabilitation2011;18(6):813‐23. [PUBMED: 21878448] ">Hopper 2011</a>; <a href="./references#CD003054-bbs2-0103" title="Institute for Clinical and Economic Review. Diabetes prevention programs: effectiveness and value. Final Evidence Report and Meeting SummaryJuly 2016. ">ICER 2016</a>; <a href="./references#CD003054-bbs2-0118" title="MerlottiC , MorabitoA , CerianiV , PontiroliAE . Prevention of type 2 diabetes in obese at‐risk subjects: a systematic review and meta‐analysis. Acta Diabetologica2014;51(5):853‐63. [PUBMED: 25085464] ">Merlotti 2014a</a>; <a href="./references#CD003054-bbs2-0119" title="MerlottiC , MorabitoA , PontiroliAE . Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies. Diabetes, Obesity &amp; Metabolism2014;16(8):719‐27. [PUBMED: 24476122] ">Merlotti 2014b</a>; <a href="./references#CD003054-bbs2-0120" title="ModestiPA , GalantiG , Cala'P , CalabreseM . Lifestyle interventions in preventing new type 2 diabetes in Asian populations. Internal and Emergency Medicine2016;11(3):375‐84. [PUBMED: 26475162] ">Modesti 2016</a>; <a href="./references#CD003054-bbs2-0123" title="SLNorris , XZhang , AAvenell , EGregg , CHSchmid , LauJ . Long‐term non‐pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews2005;Issue 2:CD005270. [DOI: 10.1002/14651858.CD005270] ">Norris 2005</a>; <a href="./references#CD003054-bbs2-0128" title="SantaguidaPL , BalionC , HuntD , MorrisonK , GersteinH , RainaP , et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence Report/Technology Assessment (Summary)2005;128:1‐11. [PUBMED: 16194123] ">Santaguida 2005</a>; <a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>; <a href="./references#CD003054-bbs2-0131" title="SelphS , DanaT , BougatsosC , BlazinaI , PatelH , ChouR . Screening for abnormal glucose and type 2 diabetes mellitus: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews2015; Vol. Report no.:13‐05190‐EF‐1. [PUBMED: 25973510] ">Selph 2015</a>; <a href="./references#CD003054-bbs2-0135" title="StevensJW , KhuntiK , HarveyR , JohnsonM , PrestonL , WoodsHB , et al. Preventing the progression to type 2 diabetes mellitus in adults at high risk: a systematic review and network meta‐analysis of lifestyle, pharmacological and surgical interventions. Diabetes Research and Clinical Practice2015;107(3):320‐31. [PUBMED: 25638454] ">Stevens 2015</a>; <a href="./references#CD003054-bbs2-0148" title="YamaokaK , TangoT . Efficacy of lifestyle education to prevent type 2 diabetes. A meta‐analysis of randomized controlled trials. Diabetes Care2005;28:2780‐6. ">Yamaoka 2005</a>; <a href="./references#CD003054-bbs2-0149" title="YatesT , KhuntiK , BullF , GorelyT , DaviesMJ . The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia2007;50(6):1116‐26. [PUBMED: 17415549] ">Yates 2007</a>; <a href="./references#CD003054-bbs2-0150" title="YoonU , KwokLL , MagkidisA . Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism: Clinical and Experimental2013;62(2):303‐14. [PUBMED: 22959500] ">Yoon 2013</a>; <a href="./references#CD003054-bbs2-0152" title="YuenA , SugengY , WeilandTJ , JelinekGA . Lifestyle and medication interventions for the prevention or delay of type 2 diabetes mellitus in prediabetes: a systematic review of randomised controlled trials. Australian and New Zealand Journal of Public Health2010;34(2):172‐8. [PUBMED: 23331362] ">Yuen 2010</a>; <a href="./references#CD003054-bbs2-0153" title="ZhangX , ImperatoreG , ThomasW , ChengYJ , LobeloF , NorrisK , et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2017;123:149‐64. [PUBMED: 28024276] ">Zhang 2017</a>; <a href="./references#CD003054-bbs2-0154" title="ZhengL , WuJ , WangG , PersuitteG , MaY , ZouL , et al. Comparison of control fasting plasma glucose of exercise‐only versus exercise‐diet among a pre‐diabetic population: a meta‐analysis. European Journal of Clinical Nutrition2016;70(4):424‐30. [PUBMED: 26330149] ">Zheng 2016</a>). However, several publications defined the increased risk of T2DM development to be associated with additional covariates, with intermediate hyperglycaemia being only one risk factor (e.g. obesity, metabolic risk factors, family history of diabetes ‐ <a href="./references#CD003054-bbs2-0071" title="AliMK , Echouffo‐TcheuguiJ , WilliamsonDF . How effective were lifestyle interventions in real‐world settings that were modelled on the Diabetes Prevention Program?. Health Affairs (Project Hope)2012;31(1):67‐75. [PUBMED: 22232096] ">Ali 2012</a>; <a href="./references#CD003054-bbs2-0072" title="AshraNB , SpongR , CarterP , DaviesMJ , DunkleyA , GilliesC , et al. A systematic review and meta‐analysis assessing the effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes mellitus in routine practice. www.gov.uk/government/uploads/system/uploads/attachment_data/file/456147/PHE_Evidence_Review_of_diabetes_prevention_programmes‐_FINAL.pdf (accessed 17 March 2017). ">Ashra 2015</a>; <a href="./references#CD003054-bbs2-0073" title="BalkEM , EarleyA , RamanG , AvendanoEA , PittasAG , RemingtonPL . Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Annals of Internal Medicine2015;163(6):437‐51. [PUBMED: 26167912] ">Balk 2015</a>; <a href="./references#CD003054-bbs2-0078" title="Cardona‐MorrellM , RychetnikL , MorrellSL , EspinelPT , BaumanA . Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta‐analysis. BMC Public Health2010;10:653. [PUBMED: 21029469] ">Cardona‐Morrell 2010</a>; <a href="./references#CD003054-bbs2-0085" title="DunkleyAJ , BodicoatDH , GreavesCJ , RussellC , YatesT , DaviesMJ , et al. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta‐analysis. Diabetes Care2014;37(4):922‐33. [PUBMED: 24652723] ">Dunkley 2014</a>; <a href="./references#CD003054-bbs2-0118" title="MerlottiC , MorabitoA , CerianiV , PontiroliAE . Prevention of type 2 diabetes in obese at‐risk subjects: a systematic review and meta‐analysis. Acta Diabetologica2014;51(5):853‐63. [PUBMED: 25085464] ">Merlotti 2014a</a>; <a href="./references#CD003054-bbs2-0119" title="MerlottiC , MorabitoA , PontiroliAE . Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies. Diabetes, Obesity &amp; Metabolism2014;16(8):719‐27. [PUBMED: 24476122] ">Merlotti 2014b</a>; <a href="./references#CD003054-bbs2-0120" title="ModestiPA , GalantiG , Cala'P , CalabreseM . Lifestyle interventions in preventing new type 2 diabetes in Asian populations. Internal and Emergency Medicine2016;11(3):375‐84. [PUBMED: 26475162] ">Modesti 2016</a>; <a href="./references#CD003054-bbs2-0129" title="SchellenbergES , DrydenDM , VandermeerB , HaC , KorownykC . Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta‐analysis. Annals of Internal Medicine2013;159(8):543‐51. [PUBMED: 24126648] ">Schellenberg 2013</a>; <a href="./references#CD003054-bbs2-0153" title="ZhangX , ImperatoreG , ThomasW , ChengYJ , LobeloF , NorrisK , et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: a systematic review and meta‐analysis. Diabetes Research and Clinical Practice2017;123:149‐64. [PUBMED: 28024276] ">Zhang 2017</a>). Furthermore, these systematic reviews excluded trials with the same intensity in diet and physical activity, where the only difference between the intervention arms was the approach on how to motivate the participants. We excluded these trials (e.g. evaluating mobile text messages versus individual sessions, or one visit a year versus four visits a year) because this setting addresses another research question, and it is important to clarify whether the interventions work as such. Also, our review is the first focusing on patient‐important outcomes. Therefore, we only included trials with an intervention duration of two years or more. Even though we focused on longer‐term trials, the reporting on patient‐important outcomes was still lacking. Observational data of trials with extended follow‐up periods could also not prove long‐term beneficial effects regarding patient‐important outcomes (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>). The only trial reporting long‐term benefits was <a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>, however, few participants were included in the analyses. In addition, these observational extension periods of interventional trials need to be interpreted with caution because the long‐term cohort may not be comparable with the originally randomised participants. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003054-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram" data-id="CD003054-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not investigated in some studies)." data-id="CD003054-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not investigated in some studies). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not report that particular outcome)." data-id="CD003054-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not report that particular outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Physical activity versus comparator, Outcome 1 All‐cause mortality." data-id="CD003054-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Physical activity versus comparator, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Physical activity versus comparator, Outcome 2 Incidence of type 2 diabetes." data-id="CD003054-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Physical activity versus comparator, Outcome 2 Incidence of type 2 diabetes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Physical activity versus comparator, Outcome 3 Serious adverse events." data-id="CD003054-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Physical activity versus comparator, Outcome 3 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Physical activity versus comparator, Outcome 4 Fasting plasma glucose." data-id="CD003054-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Physical activity versus comparator, Outcome 4 Fasting plasma glucose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Physical activity versus comparator, Outcome 5 2 hour glucose values." data-id="CD003054-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Physical activity versus comparator, Outcome 5 2 hour glucose values.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 1 All‐cause mortality." data-id="CD003054-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 1 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 2 All‐cause mortality: duration of intervention." data-id="CD003054-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 2 All‐cause mortality: duration of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 3 All‐cause mortality: diagnostic criteria." data-id="CD003054-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 3 All‐cause mortality: diagnostic criteria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 4 All‐cause mortality: age." data-id="CD003054-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 4 All‐cause mortality: age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 5 All‐cause mortality: sex." data-id="CD003054-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 5 All‐cause mortality: sex. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 6 All‐cause mortality: ethnicity." data-id="CD003054-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 6 All‐cause mortality: ethnicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 7 All‐cause mortality: obesity." data-id="CD003054-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 7 All‐cause mortality: obesity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 8 Incidence of type 2 diabetes." data-id="CD003054-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 8 Incidence of type 2 diabetes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 9 Incidence of type 2 diabetes: duration of the intervention." data-id="CD003054-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 9 Incidence of type 2 diabetes: duration of the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 10 Incidence of type 2 diabetes: diagnostic criteria." data-id="CD003054-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 10 Incidence of type 2 diabetes: diagnostic criteria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 11 Incidence of type 2 diabetes: age." data-id="CD003054-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 11 Incidence of type 2 diabetes: age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 12 Incidence of type 2 diabetes: ethnicity." data-id="CD003054-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 12 Incidence of type 2 diabetes: ethnicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 13 Incidence of type 2 diabetes: obesity." data-id="CD003054-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 13 Incidence of type 2 diabetes: obesity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 14 Cardiovascular mortality." data-id="CD003054-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 14 Cardiovascular mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 15 Non‐fatal stroke." data-id="CD003054-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 15 Non‐fatal stroke.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 16 Non‐serious adverse events." data-id="CD003054-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 16 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 17 Amputation of lower extremity." data-id="CD003054-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 17 Amputation of lower extremity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 18 Fasting plasma glucose." data-id="CD003054-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 18 Fasting plasma glucose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 19 Fasting plasma glucose: duration of intervention." data-id="CD003054-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 19 Fasting plasma glucose: duration of intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 20 Fasting plasma glucose: diagnostic criteria." data-id="CD003054-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 20 Fasting plasma glucose: diagnostic criteria. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 21 Fasting plasma glucose: age." data-id="CD003054-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 21 Fasting plasma glucose: age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 22 Fasting plasma glucose: ethnicity." data-id="CD003054-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 22 Fasting plasma glucose: ethnicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 23 Fasting plasma glucose: obesity." data-id="CD003054-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 23 Fasting plasma glucose: obesity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 24 2h plasma glucose." data-id="CD003054-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 24 2h plasma glucose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 25 2 hour plasma glucose: duration of the intervention." data-id="CD003054-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 25 2 hour plasma glucose: duration of the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 26 2 hour plasma glucose: age." data-id="CD003054-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 26 2 hour plasma glucose: age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 27 2 hour plasma glucose: ethnicity." data-id="CD003054-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 27 2 hour plasma glucose: ethnicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 28 2 hour plasma glucose: obesity." data-id="CD003054-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 28 2 hour plasma glucose: obesity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 29 Serious adverse events." data-id="CD003054-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 29 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 30 Hypoglycaemia." data-id="CD003054-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 30 Hypoglycaemia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 31 HbA1c." data-id="CD003054-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 31 HbA1c.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 32 Non‐fatal myocardial infarction." data-id="CD003054-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 32 Non‐fatal myocardial infarction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 33 End‐stage renal disease." data-id="CD003054-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 33 End‐stage renal disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 34 HbA1c: duration of the intervention." data-id="CD003054-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 34 HbA1c: duration of the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003054-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/urn:x-wiley:14651858:media:CD003054:CD003054-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_t/tCD003054-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Diet plus physical activity versus comparator, Outcome 35 HbA1c: obesity." data-id="CD003054-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 Diet plus physical activity versus comparator, Outcome 35 HbA1c: obesity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/media/CDSR/CD003054/image_n/nCD003054-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003054-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Diet plus physical activity versus standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diet plus physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> diet plus physical activity </p> <p><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diet plus physical activity</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: up to 6 years (mean duration 3.6 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> (2 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> (0.50 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4099 (10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged from 0.44 to 2.88</p> <p>TSA showed that 0.61% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Diagnostic criteria:</p> <p> <ul id="CD003054-list-0001"> <li> <p>3 trials applied the WHO 1985 criteria (FPG ≥ 7.8 mmol/L or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a>; <a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. ">Oldroyd 2005</a>). </p> </li> <li> <p>3 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>). </p> </li> <li> <p>1 trial with ADA 1997 criteria (FPG ≥ 7.0 mmol/L or 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT (i.e. identical to WHO 1999 criteria) (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>). </p> </li> <li> <p>1 trial with FPG &gt; 7.0 mmol/L (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>), 1 trial with FGP &gt; 7.8 mmol/L (<a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. ">Kosaka 2005</a>), 1 trial with 2‐hour PG ≥ 11.1 mmol/L after a 75 g OGTT (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </li> <li> <p>4 trials also relied on T2DM reported by physicians or the use of glucose‐lowering drugs (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>; <a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> </li> </ul> </p> <p>Follow‐up: up to 6 years (mean duration 3.8 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>257 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> (129 to 164) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.57</b> (0.50 to 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4511 (11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged from 0.50 to 0.65</p> <p>TSA showed firm evidence for a 10% RRR in favour of diet plus physical activity</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events (SAE)</b> </p> <p>Follow‐up: up to 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In 1 trial 1/51 participants in the diet plus physical activity group compared with 0/51 participants in the standard treatment group experienced a SAE (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) </p> <p>1 trial reported that no adverse occurred (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>In 4 other trials it was clearly described that SAE data had been collected but data were not presented (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>; <a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>; <a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>; <a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] ">JDPP 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: up to 6 years (mean duration 3.1 years)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> (1 to 9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b> (0.24 to 3.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3263 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TSA showed that 0.13% of the diversity‐adjusted information size was accrued to detect or reject a 10% RRR </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b><br/> Follow‐up: 3.11 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that none of the participants experienced a non‐fatal myocardial infarction or non‐fatal stroke (<a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] ">EDIPS 2009</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Description: SF‐36 to evaluate the SF‐6D, PCS and MCS</p> <p>MID was defined as difference in scores between groups of at least 3%</p> <p>Follow‐up: 3.2 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SF‐6D and PCS improved in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>), MID was not achieved </p> <p>MCS improved in the placebo group (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>), MID was not achieved </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b><br/> Description: direct medical costs of the interventions </p> <p>Follow‐up: up to 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean direct medical costs of the intervention ranged across control groups from<br/> USD 61 to USD 184 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean direct medical costs in the intervention groups ranged across diet plus physical activity group from USD 225 to USD 3625 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2775 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported on the health system/society perspective: USD 31,500/USD 51,600 per QALY with diet plus physical activity (<a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] ">DPP 2002</a>) </p> <p>1 trial reported total extra 3‐year mean costs for the diet plus physical activity group of GBP 1126, with GBP 615 being dietitian costs, and more outpatient visits in the intervention group than in the control group costing GBP 327 more (<a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] ">PODOSA 2014</a>). </p> <p>1 trial reported direct medical costs for each participant in the diet plus physical activity group of USD 850 compared with USD 142 in the control group; direct costs of care outside the trial were USD 5177 for the diet plus physical activity group compared with USD 7454 for the control group (<a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] ">HELP PD 2011</a>) </p> <p>1 trial reported direct medical costs of interventions over the 3‐year trial period of USD 61 per participant in the control group compared with USD 225 in the diet plus physical activity group (<a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] ">IDPP 2006</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ADA:</b> American Diabetes Association; <b>CI:</b> confidence interval; <b>DPP:</b> Diabetes Prevention Program; <b>FGL:</b> fasting glucose levels; <b>FPG:</b> fasting plasma glucose; <b>MCS:</b> mental component summaries; <b>MID:</b> minimal important difference; <b>OGTT:</b> oral glucose tolerance test; <b>PCS:</b> physical component summaries;<b>PG:</b> plasma glucose; <b>QUALY:</b> quality‐adjusted life years; <b>RR:</b> risk ratio; <b>RRR:</b> relative risk reduction; <b>SAE:</b> serious adverse event; <b>SF‐36:</b> 36‐Item Short‐Form; <b>SF‐6D:</b> health utility index (SF‐6D); <b>T2DM:</b> type 2 diabetes mellitus; <b>TSA:</b> trial sequential analysis; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of bias including possible publication and other bias, inconsistency and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>b</sup>Downgraded by one level because of other bias (early termination of three trials due to benefit providing the majority of data) ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>c</sup>Downgraded by two levels because of reporting bias and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>d</sup>Downgraded by two levels because of serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>e</sup>Downgraded by three levels because of serious risk of bias (performance bias, detection bias, other bias) and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>.<br/> <sup>f</sup>Downgraded by two levels because of risk of bias (trial stopped early for benefit providing the majority of data) and imprecision ‐ see <a href="./appendices#CD003054-sec-0210">Appendix 14</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Diet plus physical activity versus standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003054-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diet versus physical activity or standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Diet versus physical activity or standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> dietary intervention </p> <p><b>Comparison:</b> physical activity or standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Physical activity</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Diet or standard treatment</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/130 participants died in the diet group vs 0/141 participants in the physical activity group </p> <p>3/133 participants died in the standard treatment group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Definition: WHO 1985 criteria</p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/130 participants developed T2DM in the diet group vs 58/141 participants in the physical activity group </p> <p>90/133 participants developed T2DM in the standard treatment group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No (serious) adverse events occurred in any group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants in any group died of cardiovascular reasons</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus; <b>WHO:</b> World Health Organization </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of reporting and other bias and serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0211">Appendix 15</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Diet versus physical activity or standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003054-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Physical activity versus standard treatment</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Physical activity versus standard treatment for prevention or delay of type 2 diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population:</b> people at increased risk of developing type 2 diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> physical activity </p> <p><b>Comparison:</b> standard treatment </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Standard treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Physical activity</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 0/141 participants in the physical activity group compared with 3/133 participants in the standard treatment group died (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>) </p> <p>1 trial reported that 3/84 participants in the physical activity group and 1/39 participants in the standard treatment group died (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of type 2 diabetes mellitus</b> </p> <p>Definition:</p> <p> <ul id="CD003054-list-0002"> <li> <p>1 trial: FPG ≥ 7.8 mmol/L or a 2‐hour plasma glucose ≥ 11.1 mmol/L after a 75 g OGTT (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> </li> <li> <p>1 trial FPG &gt; 6.9 mmol/L and/or 2‐hour plasma glucose concentration &gt; 12.1 mmol/L (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) </p> </li> </ul> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 58/141 participants in the physical activity group compared with 90/133 participants in the standard treatment group developed T2DM (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>) </p> <p>1 trial reported that 10/84 participants in the physical activity group compared with 7/39 participants in the standard treatment group developed T2DM (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 3 and 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>397 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported no (serious) adverse events occurred (<a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a>). </p> <p>1 trial reported that 3/66 participants in the physical activity group compared with 1/39 participants in the standard treatment group experienced a serious adverse event (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: 6 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>274 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants in any group died of cardiovascular reasons</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal myocardial infarction/stroke</b><br/> Description: non‐fatal myocardial infarction/stroke </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 trial reported that 0/66 participants in the physical activity group compared with 3/31 participants in the standard treatment group experienced a non‐fatal myocardial infarction (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> <p>1 trial reported that 1/66 participants in the physical activity group compared with 1/31 participants in the standard treatment group experienced a non‐fatal stroke (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Health‐related quality of life</b> </p> <p>Definition: measured by two questions (grading total physical and mental health from 1 to 7; grading general health from 1 (best) to 5 (very bad)) </p> <p>Follow‐up: 3 years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27%, 43% and 29% of participants in the physical activity group experienced worse, unchanged and better health‐related quality of life, respectively (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> <p>35%, 43% and 22% in the standard treatment group experienced worse, unchanged and better health‐related quality of life, respectively (<a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] ">Hellgren 2016</a> ‐ data provided by trial authors) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Socioeconomic effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FPG:</b> fasting plasma glucose; <b>OGTT:</b> oral glucose tolerance test; <b>RR:</b> risk ratio; <b>T2DM:</b> type 2 diabetes mellitus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>Assumed risk was derived from the event rates in the comparator groups </p> <p><sup>a</sup>Downgraded by three levels because of risk of reporting and other bias and serious imprecision (very sparse data) ‐ see <a href="./appendices#CD003054-sec-0212">Appendix 16</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Physical activity versus standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003054-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial (design)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Screened/eligible<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ITT<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysed<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Finishing trial<br/> (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Randomised finishing trial<br/> (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up<br/> (extended follow‐up)<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD003054-bbs2-0001" title="ChenY , WangJ , AnY , GongQ , HeY , ZhangB , et al. Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre‐diabetic patients:long‐term follow‐up of Da Qing Diabetes Prevention Study. Zhonghua Nei Ke Za Zhi2015;54(1):13‐7. [PUBMED: 25877139] GongQ . Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. app.core‐apps.com/tristar_ada14/abstract/e3048dedfd3d5fbcc516bc86387992ec (accessed 24 April 2017). GongQ , GreggEW , WangJ , AnY , ZhangP , YangW , et al. Long‐term effects of a randomised trial of a 6‐year lifestyle intervention in impaired glucose tolerance on diabetes‐related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia2011;54(2):300‐7. [PUBMED: 21046360] GongQ , ZhangP , WangJ , AnY , GreggEW , LiH , et al. Changes in mortality in people with IGT before and after the onset of diabetes during the 23‐year follow‐up of the Da Qing diabetes prevention study. Diabetes Care2016;39(9):1550‐5. [PUBMED: 27411697] LiG , ZhangP , WangJ , AnY , GongQ , GreggEW , et al. Cardiovascular mortality, all‐cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23‐year follow‐up study. The Lancet Diabetes &amp; Endocrinology2014;2(6):474‐80. [PUBMED: 24731674] LiG , ZhangP , WangJ , GreggEW , YangW , GongQ , et al. The long‐term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20‐year follow‐up study. Lancet2008;371(9626):1783‐9. [PUBMED: 18502303] LiGW , HuYH , YangWY , JiangYY , WangJP , XiaoJZ , et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the Da Qing IGT and Diabetes Study. Diabetes Research and Clinical Practice2002;58:193‐200. LiH , WangJ , HuY , ChenY , AnY , ZhangP , et al. Both fasting and 2‐hour post load glycemic progression predicts subsequent cardiovascular events in persons with impaired glucose tolerance: long‐term follow‐up of the Da Qing Diabetes Prevention Study. Diabetes2014; Vol. 63, issue 0:A350. PanXR , LiGW , HuYH , WangJX , YangWY , AnZX , et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance.The Da Qing IGT and diabetes study. Diabetes Care1997;20:537‐44. ">Da Qing 1997</a><b><sup>a</sup> </b> </p> <p><b>(cluster‐RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 1: diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>"Power calculations were done for the original 6‐year intervention trial. For the present study we estimated minimal detectable differences. With an α of 0·05, we estimated that there was an 80% chance of detecting a 43% reduction in all‐cause mortality and a 63% reduction in cardiovascular disease mortality when comparing the control group with the combined lifestyle intervention groups" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>110,660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>6 years (23 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 2: physical activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention 3: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91.9<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0002" title="Diabetes Prevention Program. clinicaltrials.gov/ct2/show/NCT00004992 (accessed 23 January 2017). Diabetes Prevention Program Outcomes Study (DPPOS). clinicaltrials.gov/ct2/show/NCT00038727 (accessed 23 January 2017). CrandallJ , SchadeD , MaY , FujimotoWY , Barrett‐ConnorE , FowlerS , et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2006;61(10):1075‐81. [MEDLINE: 17077202] Diabetes Prevention Program. The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care2012;35(4):723‐30. [PUBMED: 22442395] Diabetes Prevention Program (DPP) Group. Impact of lifestyle intervention and metformin on health‐related quality of life: the diabetes prevention program randomized trial. Journal of General Internal Medicine2012;27(12):1594‐601. [PUBMED: 22692637] Diabetes Prevention Program (DPP) Group. Long‐term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. International Journal of Urology2015;22(2):206‐12. [PUBMED: 25352018] Diabetes Prevention Program (DPP) Group. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance. Diabetes, Obesity &amp; Metabolism2014;16(4):326‐33. [PUBMED: 24118860] Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes Prevention Program (DPP). dppos.bsc.gwu.edu/documents/1124073/1127212/DPPPROTOCOL.PDF/807eddd1‐d9bf‐497d‐89f0‐5de15fc43d79 (accessed 23 January 2017). Diabetes Prevention Program (DPP) Group. Protocol for the Diabetes prevention Program Outcomes Study (DPPOS). dppos.bsc.gwu.edu/documents/1124073/1127212/Version+4.2+May+1%2C+2016/14e782f2‐2da9‐47d1‐a501‐6004bcaee74e (accessed 31 January 2017). Diabetes Prevention Program (DPP) Group. The cost‐effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of Internal Medicine2005;142(5):323‐32. Diabetes Prevention Program (DPP) Research Group. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet2009;374(9707):2054. [DOI: 10.1016] Diabetes Prevention Program (DPP) Research Group. Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes2015;64(3):989‐98. [DOI: 10] Diabetes Prevention Program (DPP) Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: a randomized clinical trial. Diabetes Care2015;38(1):51‐8. [PUBMED: 25336746] Diabetes Prevention Program (DPP) Research Group. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care2014;37(8):2253‐60. [PUBMED: 24824548] Diabetes Prevention Program (DPP) Research Group. Long‐term changes in dietary and food intake behaviour in the Diabetes Prevention Program Outcomes Study. Diabetic Medicine2014;31(12):1631‐42. [PUBMED: 24824893] Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care2002;25(12):2165‐71. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care2000;23:1619‐29. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care1999;22:623‐34. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program: recruitment methods and results. Controlled Clinical Trials2002;23:157‐71. Diabetes Prevention Program (DPP) Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10‐year follow‐up. Journal Clinical Endocrinology and Metabolism2015;100(4):1646‐53. Diabetes Prevention Program (DPP) Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26(9):2518‐23. [PUBMED: 12941712] Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes2016;65(2):520‐6. [PUBMED: 26525880] Diabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes &amp; Endocrinology2015;3(11):866‐75. [PUBMED: 26377054] HermanWH . The cost‐effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study. Clinical Diabetes and Endocrinology2015; Vol. 1, issue 9:pp. HermanWH , EdelsteinSL , RatnerRE , MontezMG , AckermannRT , OrchardTJ , et al. Effectiveness and cost‐effectiveness of diabetes prevention among adherent participants. The American Journal of Managed Care2013;19(3):194‐202. [PUBMED: 23544761] KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346(6):393‐403. MaY , KriskaAM , GoldenSH , BrayGA , LuchsingerJA , CrandallJ , et al. Physical function decline in the diabetes prevention program outcome study. Diabetes2014;63(0):A344. MarreroD , PanQ , Barrett‐ConnorE , DeGrootM , ZhangP , PercyC , et al. DPPOS Research Group. Impact of diagnosis of diabetes on health‐related quality of life among high risk individuals: the Diabetes Prevention Program Outcomes Study. Quality of Life Research2014;23(1):75‐88. O'BrienMJ , WhitakerRC , YuD , AckermannRT . The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program. Preventive Medicine2015;77:125‐30. [DOI: 10] PerreaultL , MaY , Dagogo‐JackS , HortonE , MarreroD , CrandallJ , et al. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care2008;31(7):1416‐21. [PUBMED: 18356403] The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care2003;26:36‐47. The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care2005;28:888‐94. The Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes2005;54:1566‐72. The Diabetes Prevention Program Research Group. Long‐term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care2012;35(4):731‐7. [PUBMED: 22442396] The Diabetes Prevention Program Research Group. Within‐trial cost‐effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care2003;26:2518‐23. WestDS , Elaine PrewittT , BursacZ , FelixHC . Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity (Silver Spring, Md.)2008;16(6):1413‐20. [PUBMED: 18421273] WingRR , HammanRF , BrayGA , DelahantyL , EdelsteinSL , HillJO , et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obesity Research2004;12(9):1426‐34. [PUBMED: 15483207] "><b>DPP 2002</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The principal analyses of primary and secondary outcomes will employ the "intent‐to‐treat" approach ... The intent‐to‐treat analyses will include all randomized participants with all participants included in their randomly assigned treatment group; treatment group assignment will not be altered based on the participant’s adherence to the assigned treatment regimen. All statistical tests will be two‐sided. The overall significance level of the primary outcome will be α = 0.05. However, because interim analyses will be conducted throughout the DPP, the significance levels used in the interim and final analyses of the primary outcome will be adjusted to account for the multiplicity of interim analyses" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>153,183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2.8 years (15 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: placebo + standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.3</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0003" title="NCT00518167. clinicaltrials.gov/ct2/show/NCT00518167 (accessed 12 January 2017). ErikssonJ , LindströmJ , ValleT , AunolaS , HämäläinenH , Ilsnne‐ParikkaP , et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1‐year interim report on the feasibility of the lifestyle intervention programme. Diabetologia1999;42:793‐801. HamalainenH , RonnemaaT , VirtanenA , LindstromJ , ErikssonJG , ValleTT , et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia2005;48(11):2248‐53. [PUBMED: 16205886] HerderC , PeltonenM , KoenigW , KraftI , Muller‐ScholzeS , MartinS , et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes2006;55(8):2340‐6. [PUBMED: 16873699] Ilanne‐ParikkaP , ErikssonJG , LindstromJ , PeltonenM , AunolaS , HamalainenH , et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(4):805‐7. [PUBMED: 18184907] LaaksonenDE , LindstromJ , LakkaTA , ErikssonJG , NiskanenL , WikstromK , et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes2005;54(1):158‐65. [PUBMED: 15616024] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Association of long‐term dietary fat intake, exercise, and weight with later cognitive function in the Finnish Diabetes Prevention Study. The Journal of Nutrition, Health &amp; Aging2016;20(2):146‐54. [PUBMED: 26812510] LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , Ilanne‐ParikkaP , et al. Diabetes, glycaemia, and cognition‐a secondary analysis of the Finnish Diabetes Prevention Study. Diabetes/Metabolism Research and Reviews2016;32(1):102‐10. [PUBMED: 26172529] LindströmJ , ErikssonJG , ValleTT , AunolaS , CepaitisZ , HakumakiM , et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial. Journal of the American Society of Nephrology : JASN2003;14(7 Suppl 2):S108‐13. [PUBMED: 12819313] LindströmJ , Ilanne‐ParikkaP , PeltonenM , AunolaS , ErikssonJG , HemiöK , et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow‐up of the Finnish Diabetes Prevention Study. Lancet2006;368:1673‐9. LindströmJ , LouherantaA , MannelinM , RastasM , SalminenV , ErikssonG , et al. The Finnish Diabetes Prevention Study (DPS). Diabetes Care2003;26:3230‐6. LindströmJ , PeltonenM , ErikssonJG , AunolaS , HamalainenH , Ilanne‐ParikkaP , et al. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care2008;31(5):857‐62. [PUBMED: 18252900] LindströmJ , PeltonenM , ErikssonJG , Ilanne‐ParikkaP , AunolaS , Keinanen‐KiukaanniemiS , et al. Improved lifestyle and decreased diabetes risk over 13 years: long‐term follow‐up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia2013;56(2):284‐93. [PUBMED: 23093136] LindströmJ , PeltonenM , ErikssonJG , LouherantaA , FogelholmM , UusitupaM , et al. High‐fibre, low‐fat diet predicts long‐term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia2006;49(5):912‐20. [PUBMED: 16541277] LuchsingerJA , LehtisaloJ , LindstromJ , NganduT , KivipeltoM , AhtiluotoS , et al. Cognition in the Finnish diabetes prevention study. Diabetes Research and Clinical Practice2015;108(3):e63‐6. [PUBMED: 25799080] OttelinAM , LindstromJ , PeltonenM , MartikainenJ , UusitupaM , GyllingH , et al. Costs of a self‐selected, health‐promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care2007;30(5):1275‐7. [PUBMED: 17325262] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] TuomilehtoJ , LindströmJ , ErikssonJG , ValleTT , HämäläinenH , Ilanne‐ParikkaP , et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine2001;344(18):1343‐50. UusitupaM , LindiV , LouherantaA , SalopuroT , LindströmJ , TuomilehtoJ . Long term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance; 4‐year results from the Finnish Diabetes Prevention Study. Diabetes2003;52:2532‐8. UusitupaM , LouherantaA , LindströmJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83(Suppl 1):S137‐52. UusitupaM , PeltonenM , LindstromJ , AunolaS , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , et al. Ten‐year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study‐‐secondary analysis of the randomized trial. PloS One2009;4(5):e5656. [PUBMED: 19479072] deMelloVD , LindstromJ , ErikssonJG , Ilanne‐ParikkaP , Keinanen‐KiukaanniemiS , PihlajamakiJ , et al. Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD2015;25(7):635‐42. [PUBMED: 25921846] ">DPS 2001</a><b><sup>d</sup> </b> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"The DPS is designed to be large enough to detect a 35% reduction in diabetes incidence with an intensive diet and exercise intervention with 80% power (beta = 20%) at the two‐tailed 5% significance level (alpha = 5%) ..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Median 4 years (10.6 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0004" title="ISRCTN15670600. www.isrctn.com/ISRCTN15670600 (accessed 22 March 2017). PennL , MoffattSM , WhiteM . Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. BMC Public Health2008;8:235. [PUBMED: 18616797] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] PennL , WhiteM , OldroydJ , WalkerM , AlbertiKG , MathersJC . Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health2009;9:342. [PUBMED: 19758428] "><b>EDIPS 2009</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"EDIPS‐Newcastle was designed to contribute to the European study. We aimed for a sample size of 100 participants (50 in each arm), contributing to a planned total of 750 participants across Europe" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3.11 years (3.11 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0005" title="HellgrenMI , JanssonPA , WedelH , LindbladU . A lifestyle intervention in primary care prevents deterioration of insulin resistance in patients with impaired glucose tolerance: a randomised controlled trial. Scandinavian Journal of Public Health2016;‐:‐. [PUBMED: 27550085] HellgrenMI , PetzoldM , Beteus‐ForslundH , WedelH , JanssonPA , LindbladU . Feasibility of a randomized controlled intervention with physical activity in participants with impaired glucose tolerance recruited by FINDRISC: a pilot study. Scandinavian Journal of Public Health2014;42(5):463‐70. [PUBMED: 24867622] "><b>Hellgren 2016</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>9734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0006" title="BlackwellCS , FosterKA , IsomS , KatulaJA , VitolinsMZ , RosenbergerEL , et al. Healthy Living Partnerships to Prevent Diabetes: recruitment and baseline characteristics. Contemporary Clinical Trials2011;32(1):40‐9. [PUBMED: 20974289] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellC , EspelandMA , LawlorMS , et al. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. Contemporary Clinical Trials2010;31(1):71‐81. [PUBMED: 19758580] KatulaJA , VitolinsMZ , RosenbergerEL , BlackwellCS , MorganTM , LawlorMS , et al. One‐year results of a community‐based translation of the Diabetes Prevention Program: Healthy‐Living Partnerships to Prevent Diabetes (HELP PD) Project. Diabetes Care2011;34(7):1451‐7. [PUBMED: 21593290] LawlorMS , BlackwellCS , IsomSP , KatulaJA , VitolinsMZ , MorganTM , et al. Cost of a group translation of the Diabetes Prevention Program: healthy living partnerships to prevent diabetes. American Journal of Preventive Medicine2013;44(4 Suppl 4):S381‐9. [PUBMED: 23498303] NCT00631345 . Healthy living partnership to prevent diabetes (HELPPD). clinicaltrials.gov/ct2/show/NCT00631345 (accessed 17 March 2017). VitolinsMZ , IsomSP , BlackwellCS , KernodleD , SydellJM , PedleyCF , et al. The healthy living partnerships to prevent diabetes and the diabetes prevention program: a comparison of year 1 and 2 intervention results. Translational Behavioral Medicine2016 [Epub ahead of print]. [PUBMED: 27796775] "><b>HELP PD 2011</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"Based on a longitudinal correlation of r = 0.20, this sample was projected to provide 94% power to detect a net intervention effect of 3.5 mg/dL (two‐sided alpha of 0.05) and 86% power to detect an effect size of 3 mg/dL. These estimates include allowance for a 5% loss to follow‐up rate every 6 months" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0007" title="NCT00279240. clinicaltrials.gov/show/NCT00279240 (accessed 3 April 2017). RamachandranA , ArunN , ShettyAS , SnehalathaC . Efficacy of primary prevention interventions when fasting and postglucose dysglycemia coexist: analysis of the Indian Diabetes Prevention Programmes (IDPP‐1 and IDPP‐2). Diabetes Care2010;33(10):2164‐8. [PUBMED: 20519663] RamachandranA , SnehalathaC , MaryS , MukeshB , BhaskarAD , VijayV . The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP‐1). Diabetologia2006;49:289‐97. RamachandranA , SnehalathaC , SatyavaniK , SivasankariS , VijayV . Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indians‐‐Result of Indian diabetes prevention programme. Diabetes Research and Clinical Practice2007;76(2):215‐8. [PUBMED: 16982107] RamachandranA , SnehalathaC , YamunaA , MaryS , PingZ . Cost‐effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Within‐trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care2007;30:2548‐52. SnehalathaC , MaryS , JoshiVV , RamachandranA . Beneficial effects of strategies for primary prevention of diabetes on cardiovascular risk factors: results of the Indian Diabetes Prevention Programme. Diabetes &amp; Vascular Disease Research2008;5(1):25‐9. [PUBMED: 18398809] SnehalathaC , MaryS , SelvamS , Sathish KumarCK , ShettySB , NandithaA , et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme‐1 (IDPP‐1). Diabetes Care2009;32(10):1796‐801. [PUBMED: 19587369] "><b>IDPP 2006</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"It was assumed that the cumulative incidence of diabetes in 3 years would be approximately 30% in the control group and that there would be a 50% reduction with the intervention methods. The sample size required in each of the four subgroups was 134 with a type 1 error of 5%, 80% power, and allowing for a dropout rate of 10%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,839</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0008" title="Japan Diabetes Prevention Program. Lifestyle intervention using existing human resources on the development of type 2 diabetes. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;type=summary&amp;recptno=R000003799&amp;language=E (accessed 27 January 2017). SakaneN . Japan Diabetes Prevention Program. Nippon Rinsho2005;63(Suppl 2):488‐92. SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effect of baseline HbA1c level on the development of diabetes by lifestyle intervention in primary healthcare settings: insights from subanalysis of the Japan Diabetes Prevention Program. BMJ Open Diabetes Research &amp; Care2014;2(1):e000003. [PUBMED: 25452854] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TominagaM , et al. Effects of lifestyle intervention on weight and metabolic parameters in patients with impaired glucose tolerance related to beta‐3 adrenergic receptor gene polymorphism Trp64Arg(C/T): results from the Japan Diabetes Prevention Program. Journal of Diabetes Investigation2016;7(3):338‐42. [PUBMED: 27330719] SakaneN , SatoJ , TsushitaK , TsujiiS , KotaniK , TsuzakiK , et al. Prevention of type 2 diabetes in a primary healthcare setting: three‐year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health2011;11(1):40. [PUBMED: 21235825] "><b>JDPP 2013</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"According to prospective studies on the Japanese population, the yearly incidence of diabetes among subjects with IGT varies between 1 and 5% ... Therefore, it was assumed that the 6‐year cumulative incidence of diabetes would be 30% in the control group. The present study was designed to detect a 50% reduction in the incidence by the intervention. Thus the sample size required was 313 with a type 1 error of 5%, with 80% power (beta = 20%) at the two‐tailed 5% significance level, and allowing for a withdrawal rate of 30%" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0009" title="KosakaK , NodaM , KuzuyaT . Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Research and Clinical Practice2005;67:152‐62. "><b>Kosaka 2005</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>‐</p> <p>(Number of randomised participants was calculated based on the following information: "The rate of drop‐out during the 1‐year observation was 5.6% in the control group and 4.7% in the intensive intervention group, respectively") </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0010" title="OldroydJC , UnwinNC , WhiteM , ImrieK , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months. Diabetes Research and Clinical Practice2001;52:29‐43. OldroydJC , UnwinNC , WhiteM , MathersJC , AlbertiKGMM . Randomised controlled trial evaluating lifestyle interventions in people with impaired glucose tolerance. Diabetes Research and Clinical Practice2006;72:117‐27. "><b>Oldroyd 2005</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"We calculated that a sample size of 100 individuals (50 in each arm) was necessary to detect a 0.6 mmol/l difference in mean fasting plasma glucose and a 20% difference in the proportion with glucose intolerance, both with 90% power at the 5% significance level" </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: no intervention</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0011" title="ISRCTN25729565. www.isrctn.com/ISRCTN25729565 (accessed 20 March 2017). BhopalRS , DouglasA , WalliaS , ForbesJF , LeanME , GillJM , et al. Effect of a lifestyle intervention on weight change in South Asian individuals in the UK at high risk of type 2 diabetes: a family‐cluster randomised controlled trial. Lancet. Diabetes &amp; Endocrinology2014;2(3):218‐27. [PUBMED: 24622752] DouglasA , BhopalRS , BhopalR , ForbesJF , GillJM , McKnightJ , et al. Design and baseline characteristics of the PODOSA (Prevention of Diabetes &amp; Obesity in South Asians) trial: a cluster, randomised lifestyle intervention in Indian and Pakistani adults with impaired glycaemia at high risk of developing type 2 diabetes. BMJ Open2013;3(2):e002226. [PUBMED: 23435795] WelshP , CezardG , GillJM , WalliaS , DouglasA , SheikhA , et al. Associations between weight change and biomarkers of cardiometabolic risk in South Asians: secondary analyses of the PODOSA trial. International Journal of Obesity2016;40(6):1005‐11. [PUBMED: 26927315] "><b>PODOSA 2014</b> </a> </p> <p><b>(cluster‐RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"When the protocol was amended in 2009, we knew that the number of families with more than one person recruited with impaired fasting glucose or impaired glucose tolerance was small, so the new power calculation did not take clustering into account. A sample of 150 people assessed at 3 years gave 86% power to detect a mean difference in weight of 2.5 kg between the two groups, assuming an SD of 5 kg with a two‐sided 5% significance level." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD003054-bbs2-0012" title="CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , BlaakEE . Lifestyle intervention and adipokine levels in subjects at high risk for type 2 diabetes: the Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetes Care2007;30(12):3125‐7. [PUBMED: 17890316] CorpeleijnE , FeskensEJ , JansenEH , MensinkM , SarisWH , DeBruinTW , et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia2006;49(10):2392‐401. [PUBMED: 16896932] MensinkM , BlaakEE , CorpeleijnE , SarisWH , DeBruinTW , FeskensEJ . Lifestyle intervention according to general recommendation improves glucose tolerance. Obesity Research2003;11(12):1588‐96. MensinkM , CorpeleijnE , FeskensEJM , KruijshoopM , SarisWHM , DeBruinTWA , et al. Study on lifestyle‐intervention and impaired glucose tolerance Maastricht (SLIM): design and screening results. Diabetes Research and Clinical Practice2003;61:49‐58. MensinkM , FeskensEJ , KruijshoopM , DeBruinTW , SarisWH , BlaakEE . Subscapular skinfold thickness distinguishes between transient and persistent impaired glucose tolerance: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht (SLIM). Diabetic medicine : a Journal of the British Diabetic Association2003;20(7):552‐7. [PUBMED: 12823236] MensinkM , FeskensEJ , SarisWH , DeBruinTW , BlaakEE . Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. International Journal of Obesity and Related Metabolic Disorders2003;27(3):377‐84. [PUBMED: 12629566] PennL , WhiteM , LindstromJ , DenBoerAT , BlaakE , ErikssonJG , et al. Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT. PloS One2013;8(2):e57143. [PUBMED: 23451166] RoumenC , CorpeleijnE , FeskensEJ , MensinkM , SarisWH , BlaakEE . Impact of 3‐year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabetic Medicine : a Journal of the British Diabetic Association2008;25(5):597‐605. [PUBMED: 18445174] RoumenC , FeskensEJ , CorpeleijnE , MensinkM , SarisWH , BlaakEE . Predictors of lifestyle intervention outcome and dropout: the SLIM study. European Journal of Clinical Nutrition2011;65(10):1141‐7. [PUBMED: 21587283] "><b>SLIM 2003</b> </a> </p> <p><b>(parallel RCT)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention: physical activity + diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>"It was calculated that, based on the results of the Finnish Diabetes Prevention Study (DPS), 50–60 subjects per group would be sufficient to detect a 1.0 mmol/l difference in 2‐h glucose concentration between groups ..." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4.1 years (range 3 to 6 years)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Comparator: standard treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.9</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>total:</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b><i>Grand total</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>2136</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>3091</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>All interventions and c</i> <i>omparators</i> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>5238<sup>l</sup> </i> </b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>"‐" denotes not reported</p> <p><sup>a</sup>Randomised numbers in each group not specified.<br/> <sup>b</sup>After 6 years of intervention, during the subsequent 17‐year follow‐up period after the intervention had stopped 6 participants were lost to follow‐up.<br/> <sup>c</sup>Of the 1082 participants assigned to placebo, 1052 were available for the DPPOS (see DPP 2002); of these 935 were enrolled in the DPPOS. Of the 1079 assigned to the behaviour changing intervention 1042 were available for the DPPOS; of these 915 were enrolled in the DPPOS.<br/> <sup>d</sup>Trial authors state that ITT analysis was performed but data are presented as a per‐protocol analysis.<br/> <sup>e</sup>Data for the end of intervention. Participants included in the extension period were 200 in the intervention group and 166 in the control group.<br/> <sup>f</sup>Number of analysed participants varied during the trial (intervention group: 39 at 1 year; 35 at 2 years; 27 at 3 years; 28 at 4 years; 21 at 5 years; control group: 43 at 1 year; 37 at 2 years; 33 at 3 years; 28 at 4 years; 21 at 5 years).<br/> <sup>g</sup>123 participants were eligible for the trial, 4 died and 10 developed T2DM and did not complete the final examination. One received a gastric bypass; 17 refused follow‐up. Not specified to which intervention groups these people were randomised.<br/> <sup>h</sup>Number of analysed participants varied during the trial (intervention group: 139 at 6 months, 135 at 12 months, 125 at 18 months and 127 at 24 months; control group: 141 at 6 months, 138 at 12 months, 132 at 18 months and 134 at 24 months).<br/> <sup>i</sup>Number of analysed participants varied during the trial (intervention group: 37 at 6 months, 32 at 12 months and 30 at 24 months; control group: 32 at 6 months, 30 at 12 months and 24 at 24 months).<br/> <sup>j</sup>78 families with 85 participants and 55 family volunteers were allocated to the intervention, 78 families with 86 participants and 69 family volunteers were allocated to the control.<br/> <sup>k</sup>Number of analysed participants varied during the trial (intervention group: 52 at 3 years, 51 at 4 years, 34 at 5 years and 35 (one that was missing at 6 years attended 6‐year follow‐up) at 6 years; control group: 54 at 3 years, 43 at 4 years, 29 at 5 years and 35 (6 that were missing at five years attended 6‐year follow‐up) at 6 years.<br/> <sup>l</sup>2 trials did not report the number of randomised participants per intervention group. Therefore, numbers do not add up accurately. </p> <p>DPP: Diabetes Prevention Program; DPPOS: Diabetes Prevention Program Outcome Study; EDIPS: European Diabetes Prevention Study; HELP PD: Healthy Living Partnerships to Prevent Diabetes; IDPP: Indian Diabetes Prevention Programmes; ITT: intention‐to‐treat; JDPP: Japan Diabetes Prevention Program; PODOSA: Prevention of Diabetes and Obesity in South Asians; RCT: randomised controlled trial; SLIM: Study on Lifestyle‐intervention and Impaired glucose tolerance Maastricht </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/full#CD003054-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003054-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Physical activity versus comparator</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of type 2 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Fasting plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 2 hour glucose values <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Physical activity versus comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003054-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Diet plus physical activity versus comparator</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ≥ 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.33, 5.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 &lt; 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.38, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 IGT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Age ≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.39, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Age &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.32, 6.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality: sex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality: ethnicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.37, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 (Predominantly)White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.36, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality: obesity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.50, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BMI ≥ 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.36, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 BMI &lt; 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.37, 4.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Incidence of type 2 diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Incidence of type 2 diabetes: duration of the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Long duration (≥ 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Short duration (&lt; 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.48, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Incidence of type 2 diabetes: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 IGT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.12, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Incidence of type 2 diabetes: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 age ≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.44, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 age &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.57, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Incidence of type 2 diabetes: ethnicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 (Predominantly)White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.43, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Incidence of type 2 diabetes: obesity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.50, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.43, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.55, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.24, 3.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Non‐fatal stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Amputation of lower extremity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Fasting plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Fasting plasma glucose: duration of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Long duration (≥ 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.24, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Short duration (&lt; 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.30, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Fasting plasma glucose: diagnostic criteria <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 IGT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.26, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Other criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.46, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Fasting plasma glucose: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Age ≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.26, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Age &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.78, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Fasting plasma glucose: ethnicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.30, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 (Predominantly) White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.30, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Fasting plasma glucose: obesity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3530</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.27, ‐0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.30, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.34, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 2h plasma glucose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.79, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 2 hour plasma glucose: duration of the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.79, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Long duration (≥ 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>697</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.77, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Short duration (&lt; 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.70, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 2 hour plasma glucose: age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.79, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Age ≥ 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.49, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Age &lt; 50 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.62 [‐2.49, ‐0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 2 hour plasma glucose: ethnicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.79, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Asian</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.72, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 (Predominantly) White</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.55, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 2 hour plasma glucose: obesity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.79, ‐0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.55, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.77, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Hypoglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 HbA1c <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.23, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Non‐fatal myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 End‐stage renal disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 HbA1c: duration of the intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.23, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 ≥ 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.37, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 &lt; 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.36, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 HbA1c: obesity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.23, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.27, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.17, 0.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Diet plus physical activity versus comparator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003054.pub4/references#CD003054-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003054.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003054-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003054-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003054-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003054-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD003054-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003054-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003054-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003054-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003054-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003054-note-0018">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003054\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003054\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003054\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003054\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003054\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Oy81c7tH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003054.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003054.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003054.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003054.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003054.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716244071"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003054.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716244075"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003054.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9abd0ae21bf6',t:'MTc0MDcxNjI0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 